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Abstract 
In the field of nanotechnology, research is nowadays deeply focusing on the translational 
application of nanomaterials in medicine. Whereas findings from physics, genetics and 
immunology have already changed the everyday clinical practice in different fields. 
Nanotechnology is expanding its legacy by implementing approaches aimed to delivering 
therapeutics and developing new diagnostic and imaging tools. One of the most fascinating 
frontiers of nanotechnology is the development of nanomaterials for diagnostic and therapeutic 
purposes possibly at the same time. However, before any effective application of in medicine, 
a critical step to be done is represented by the assessment of their impact on the immune system, 
independently of their specific purpose. Following parenteral administration (e.g. intravenous, 
intramuscular, subcutaneous, etc.), nanomaterials immediately enter in contact with peripheral 
immune cells either in the blood or in the peripheral tissues. In this context, during my thesis, I 
focused on the immunological impact of some of the main promising nanomaterials for 
biomedical applications: Carbon based materials such as carbon nanotubes (CNTs) and 
graphene, lipid nanocapsules (NCs) and super paramagnetic iron oxide nanoparticles (SPIONs), 
in order to study their potential to be applied in therapy and diagnostic applications taking 
advantage from their intrinsic properties. Initially, thanks to the evidences suggested by the 
literature and previous works of my advisor, the potential immunostimulatory properties of 
functionalized-CNTs to restore the dysregulation of immune functions found in absence of 
gravity was evaluated. Furtherly I focused my attention on graphene, particularly on its oxidized 
form [called graphene oxide (GO)] investigating the effects of several types of thoroughly 
characterized GO sheets, different in their lateral dimension and functionalization, on human 
primary lymphomonocytes from healthy donors.  Wide range of assays looking at cell viability, 
cell activation, and molecular interaction were done. Moreover, to better dissect the 
immunological effects of these nanomaterials on individual cells, we applied single-cell mass 
cytometry to evaluate the effect of functionalized GOs on 15 cellular populations corresponding 
to 200 nodes of distinct but logically interconnected cell sub-populations. We used whole-
transcriptomic analysis (Illumina BeadArray) for functional and molecular characterization of 
graphenes on human T-cells and monocytes. Following part of the findings got during the 
immune characterization of different graphenes, we were able to apply a new few-layer 
graphene (FLG) dispersions prepared by a mechano-chemical approach employing melamine 
as the exfoliating agent of graphite. We found, indeed, an intrinsic specific impact of FLG on 
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cells belonging to the monocytic lineage (CD14 positive) showing neither toxic nor activation 
effects on the other immune cells. Thanks to this intrinsic biological property, we further 
explored the possible therapeutic application of FLG on neoplastic monocytes ex vivo, from 
acute myeloid leukemia and chronic myelomonocytic leukemia patients. We also performed 
related experiment on other nanomaterials, such as NCs and SPIONs, looking at their impact 
on immune cells and exploiting the possible ultrasound contrast properties of SPIONs. The 
different studies presented in this thesis explicitly demonstrate that the interactions between 
nanomaterials and the immune cells depend on many factors correlated to their 
physicochemical characteristics. A positive impact of nanomaterials on the immune system, 
able to trigger both immune suppression and immune activation, is a concept helpful in the 
development of new nanoscale platforms in medicine. These analyzed platforms can be 
investigated as immunotherapy tools, vaccine carriers, adjuvants, and drug delivery systems to 
target pathology or inflammatory and inflammation-associated disorders. 
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The term “Nanotechnology” refers to the design, characterization and application of structures, 
devices and systems by controlling shape and size at atomic, molecular and supramolecular 
level [1]. Advances in nanotechnology have led to the development of new nanomaterials 
whose physico-chemical properties differ from those of their larger counterparts due to their 
higher surface-to-volume ratio. These novel properties make them excellent candidates for 
biomedical applications. Nanotechnology is a new discipline of science and engineering that 
has led to innovative approaches in many areas of medicine. Its applications in the screening, 
diagnosis, and treatment of diseases are collectively referred to as “nanomedicine”, an emerging 
field that has the potential to revolutionize individual and population-based health of this 
century [2]. In contrast to conventional therapies, where the basic approach is to remove 
diseased cells faster than healthy cells, nanomedicine attempts to use sophisticated approaches 
to either kill specific cells or repair them, one cell at a time [3]. It is now possible to provide 
therapy at a molecular level with the help of different nanomaterials, treating diseases and 
adding light to our understanding of their pathogenesis. Nanomedicine can be considered a 
refinement of molecular medicine, integrating innovations in genomics and proteomics on the 
road to a more personalized medicine, so as to allow improved treatment efficacies for many 
diseases.  
1.1 Nanomedicine 
The advent of nanomaterials was forecast as long ago as 1959 by Richard P. Feynman, “the 
man who dared to think small” [1]. Feynman proposed using new materials to make smaller 
machine tools and so on until the atomic level [4]. Nowadays, nearly sixty years later, 
nanomedicine is playing a growing part in pharmaceutical research and development, primarily 
in the form of nanomaterials/nanoparticle-based delivery systems for drugs, genes and imaging 
agents, connecting a broad range of disciplines form biology to engineering.  This field is 
characterized by continuous increasing interest given by the scientific community and the 
public in this domain [5]. Leading specialists suggest that nanomedicine will revolutionize 
almost all the branches of medicine, starting from basic medical check-ups and early diagnosis 
to personalized therapies [6]. 
Chapter 1| Introduction 
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1.2 Nanomaterials and the immune system  
 
For any translational applications of nanomaterials into medical tools, a critical step is 
represented by the assessment of nanomaterial impact on the immune system, independently of 
their specific purpose [7].  
It is well known that the immune system is the guardian of our body with the aim to protects it 
from any foreign element. It senses and reacts to external and internal aggressions, from 
pathogens to malignancies through different types of materials it may be in contact with. 
Immune reactions bring into play different types of cells and soluble factors that, together, will 
induce the most adapted response in order to try to eliminate intruders. They are classically 
divided in two arms called respectively innate and adaptive immunity. Innate immunity is the 
first line of defense and is rapidly set up upon any threat encounter. It mainly relies on the 
activation of the complement system, a complex system of plasma proteins, as well as of 
phagocytic cells (e.g. macrophages, neutrophils) present in tissues and body fluids. The final 
purpose of innate immune reactions is to eliminate the detected foreign element but it also helps 
triggering specific long-lasting mechanisms, namely adaptive immune reactions. Adaptive 
immunity takes more time to proceed but it leads to highly specific immune responses thanks 
to T and B lymphocytes, which express antigen-specific receptors. Antigen recognition together 
with co-stimulatory signals leads to lymphocyte activation and differentiation into effector 
cells. CD8+ T cells become cytotoxic (CTL) while CD4+ T cells become helper T cells, (Th) 
harbor varied cytokine secretion profiles allowing to define several subsets: some of them are 
pro-inflammatory (Th1 and Th17 subsets) while others are rather anti-inflammatory (Th2 
subset). This system is also specialized in supporting B cell differentiation into antibody-
secreting cells (called plasma cells). Although usually protective, immune reactions can also 
become harmful when they are directed towards self-components, leading to autoimmune 
disorders, or when they are over-stimulated by persistent intruders, leading to chronic 
inflammation for example [8]. Some researchers have shown that nanomaterials can stimulate 
and/or suppress the immune responses, and that their compatibility with the immune system is 
largely determined by their surface chemistry and dimension [9-11]. Indeed, modifications of 
the surface chemistry can significantly reduce the immunotoxicity and change the immune 
impact of nanomaterials making them useful platforms for many applications in biomedicine 
[12]. Following this statement, any type of nanomaterials could be designed modulating its 
physicochemical characteristics, to target or to avoid specific interactions with the immune 
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system. A contact between a nanoparticle and the immune system is considered desirable when 
it may lead to various beneficial medical applications, such as vaccines or therapeutics for 
inflammatory and autoimmune disorders [13]. However, the proper design of nanomaterials 
able to specifically modulate the immune system is still not well understood and needs to be 
clarified. 
 
1.3 Nanomaterials for medical applications and interaction with the immune 
system 
 
In this part of the thesis, examples are provided for some of the most interesting nanomaterials 
platforms exploited in the last years for therapeutic purpose i.e. Carbon Based Nanomaterials 
(CBMs), Nanoemulsions such as lipid nanocapsuels and Super paramagnetic Iron Oxide 
Nanoparticles, currently developed for several kind applications. A brief discussion is provided 
for each nanomaterial highlighting also the knowledge already present regarding their 
interaction with the immune system. 
 
1.3.1 Carbon Based Materials 
Carbon exists in nature in three different allotropic forms: amorphous carbon, graphite and 
diamond. With the discovery of fullerene (C60) in 1985, a large family of others carbon based 
materials have been discovered and these new carbon nanostructures obtained great interest in 
the field of nanotechnology and nanomedicine. The most investigated new forms of carbon that 




Figure 1: Nanostructured allotropic forms of carbon. 
Chapter 1| Introduction 
 
Dr. Marco Orecchioni. Titolo “Biomedical applications of different nanomaterials: 
Characterization and interaction with the immune system”  
Tesi di dottorato in Life Sciences and Biotechnologies, Università degli Studi di Sassari. 
11
 
a) Carbon Nanotubes 
Carbon nanotubes (CNTs) have been described for the first time at the atomic level in 1991 by 
Iijima, but the first evidence of their existence appeared already in the ‘50-‘60, when they have 
been reported as carbon filament or carbon whiskers . CNTs are structures of 2D sheets of 
carbon (graphene) rolled up to form a 3D cylindrical structure with varying degrees of twist 
along their length, obtaining in this way a material with a variety of chiralities (Figure 1). The 
electronic properties of CNTs depend on the way to wrap the graphene layer. Depending to the 
number of wrap if they consist by a single shell of graphene or by multiple concentrical 
graphene sheets coaxially arranged around a central hollow core, CNTs can be classified in 
single-walled carbon nanotubes (SWCNTs) and multi-walled carbon nanotubes (MWCNTs). 
SWCNTs have a diameter from 0.7 to 3.0 nm and a length ranging between few nanometers to 
few micrometers. On the other hand, MWCNTs are larger and they can have a diameter up to 
100 nm, with a length that could reach several millimetres.  
CNTs, with their unique and extraordinary physicochemical properties, are currently being 
explored for biomedical and tissue engineering [14], imaging [9], biosensors [15] and drug 
delivery systems [16]. Interfacing CNTs with living systems has raised concerns about the 
toxicity of this material. This is an important issue that should render attentive the researchers 
when thinking about the potential use of CNTs in nanomedicine. It has been reported that 
pristine, (non-functionalized CNTs) are toxic. However, different in vitro and in vivo studies 
demonstrated that chemical functionalization of the surface of CNTs reduces their toxicity [7, 
17, 18]. The effects of CNTs seem to depend on both the type of functionalization and the type 
of cells and/or organs analyzed [8, 19].  
For example, Delogu LG et al discovered that functionalized water soluble CNTs increased the 
biocompatibility on primary cells isolated from human blood [20].  
 
b) Graphene 
Graphene is a single layer of carbon atoms arranged in a honeycomb lattice as shown in figure 
1 It is the building block for other carbon-based materials where the rolling up graphene 
produces carbon nanotubes and buckyballs while stacking graphene produces graphite. The in-
plane strength of the carbon bonds is much stronger than the c-axis bonds of graphite causing 
it to shear easily. It is this ability for graphite to cleave easily that lead to the first isolation of a 
single graphene by simply using adhesive tape in a technique known as mechanical exfoliation 
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[21].  Following the discovery of graphene in 2004 by Gaim and Novoselov at the University 
of Manchester came a huge wave of scientific research [21]. 
Graphene, is among other CBMs (fullerenes and CNTs) characterized by the most promising 
physicochemical properties [22]. The biological applications of graphene-based materials 
(GBMs) have significantly grown in the last years also in the field of medicine [23]. Graphene 
is a two-dimensional structure composed of carbon atoms with sp2 hybridization connected to 
form hexagons. It has impressive mechanical and physical properties such as over 100 times 
stronger than steel, and extremely high elasticity [24]. In addition, graphene presents high 
thermal durability and chemical resistance against water and organic solvents. Its extraordinary 
surface has the largest absorption capacity of chemical compounds including drugs, antibodies, 
proteins and nucleic acids. The last property is fundamental for medical applications ranging 
from drug delivery to biosensing. Its importance is given by the ability of graphene to be 
multifunctionalized, with drugs and also specific targeting molecules that can improve the 
specific delivery to the desired site [25].  
 
1.3.2 Nanoemulsion the example of Lipid Nanocapsules 
 
Nowadays, different colloidal systems such as nanoparticles and nanocapsules have been 
reported as potential carriers for drug delivery and also for different biomedical applications 
[26, 27]. Structured nanocapsules are generally described as colloidal systems with a core-shell 
structure, where the core acts as a liquid reservoir for several molecules or drugs, and the shell 
as a protective membrane. These nanosystems present promising applications as carriers of 
drugs, proteins, DNA chains and small interference RNA or in diagnosis applications as 
contrast agents [28, 29]. In particular, lipid nanocapsules (NCs), consisting of an oil-filled core 
with a surrounding polymer shell have special use for encapsulating and delivering hydrophobic 
drugs. The versatility of these NC for an efficient encapsulation in their oily core of several 
anti-cancer drugs has been demonstrated by several repots [30, 31]. Moreover, their useful 
properties include biocompatibility, biodegradability, low toxicity, controlled release of drugs 
and the ability to target specific tissues [32]. Current used drugs in pharmacotherapy, due to 
their hydrophobic character must use solubilizer agents for their intravenous administration [33, 
34]. These agents being foreign substance has to be added in the blood stream and can interact 
with the immune system. This is why NCs offer a promising system and an excellent alternative 
to emulsions or microemulsions for pharmaceutical application of hydrophobic drugs [35]. 
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Thanks to the drug protection and their controlled release on cancer cells, these kinds of 
nanoparticles provide an ideal solution, leading to selective cytotoxicity, minimizing the serious 
and unpleasant side effects of cancer drugs and preventing damage to healthy tissues [36, 37]. 
The shell of NCs can be formed by a wide variety of polymers/surfactants with hydrophilic 
segments such as polyethylene glycol (PEG), polyethylene oxide, poloxamers, poloxamines, 
polysorbates, chitosan, Pluronic and so on. [38-40]. These types of polymers, together with the 
enhancing of  the intrinsic colloidal stability of the system, may help to avoid their recognition 
by the mononuclear phagocyte system, a major drawback that often arises after intravenous 
injection of drug carriers, causing a decrease in circulating NCs as well as undesirable 
accumulation of these colloids in different organs such as liver or spleen [28]. Therefore, the 
nature of the polymeric shell is crucial to minimize this action by repelling plasma proteins and 
achieving the so-called Stealth nanosystems [41]. This would increase the in vivo long-term 
stability of the nanoparticles, and it would also facilitate their ability to cross certain biological 
barriers. For example, nanoparticles coated with polysorbates or poloxamers have been 
reported to successfully pass the blood-brain-barrier and other physiological barriers [42]. 
 
1.3.3 Super Paramagnetic Iron Oxide Nanoparticles 
Magnetic nanoparticles have attracted increasing interest as advanced nanomaterials for several 
types of applications, as well as for drug and gene delivery and/or imaging agents [43, 44]. In 
this context superparamagnetic iron oxide nanoparticles (SPIONs) have been investigated for 
biomedical applications such as tissue repair, immunoassays, detoxification of biological fluids, 
hyperthermia, drug delivery, probes, in vitro cell separation and to produce antibiotic-resistant 
biofilms. They are, indeed important candidate materials for new perspectives in nanomedicine 
[45]. SPIONs belong to the class of inorganic based particles having an iron oxide core coated 
by either inorganic materials (silica, gold) and organic materials (phospholipids, fatty acids, 
polysaccharides, peptides or other surfactants and polymers) [46, 47]. In contrast to other 
nanoparticles, their magnetic properties, based on their inducible magnetization, allow them to 
be directed to a defined location or heated in the presence of an externally applied magnetic 
field. These characteristics makes them attractive for many applications, ranging from various 
separation techniques and contrast enhancing agents for MRI to drug delivery systems, 
magnetic hyperthermia (local heat source in the case of tumor therapy), and magnetically 
assisted transfection of cells [45]. Research with SPIONs has already demonstrated that these 
particles have the potential to become an important tool for enhancing magnetic resonance 
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contrast. SPIONs coated with organic molecules showing an overall median diameter of less 
than 50 - 160 nm were available on the market as MRI contrast agents for detecting liver tumors 
or to differentiate metastatic from inflammatory lymph nodes. SPION functionalized with 
targeting peptides exhibit an additional potential for providing important information for a 
number of diseases for example due to the increased expression of cellular markers. 
Furthermore, they could help physicians to identify dangerous arteriosclerotic plaques by MRI 
[48]. The ongoing research is directed towards monitoring events on the physiological and 
molecular level, so that inflammatory diseases or tumors can be detected via the accumulation 
of SPIONs or markers expressed on the cell surface [49].   
 
 
1.4 Nanomaterials biocompatibility and impact on immune cells 
 
1.4.1 Carbon nanotubes 
Carbon nanotubes have been investigated with great expectation by several research groups in 
many contexts, ranging from electronics to medicine. Through the years, however, their 
cytotoxic effects and their interaction with the immune system raised major concerns regarding 
the real possibility to apply carbon nanotubes in medicine as diagnostic or therapeutic 
applications. Pristine nanotubes in fact tend to form agglomerate, induce cellular 
necrosis/apoptosis and oxidative stress when ingested by phagocytes. In mice, they determine 
formation of granulomas, resembling in part the effect of asbestos [50, 51]. Moreover, carbon 
nanotubes can directly bind some plasma protein as fibrinogen and apolipoproteins and trigger 
activation of complement cascade [52]. Concerning the cytotoxicity, in general, higher is the 
dose higher is the toxic effect. The functionalization of pristine nanotubes is also the key for 
improving their biocompatibility [53]. Several studies have demonstrated that some f-CNTs 
bear immunostimulatory properties in absence of cytotoxicity [10, 20]. Importantly, most of 
the studies have shown lack of relevant toxicity of f-CNTs at relatively high concentrations 
both in vitro and in vivo [53, 54]. Following these aspects, several parameters as the number of 
walls, the diameter, the length, and, importantly, the type of functionalization of CNTs can 
influence the uptake, biocompatibility and/or activation also on the immune cells.  
An example of the interaction of CNTs with immune cells is given by Dutta et al. that 
investigated the importance of plasma protein adsorption by oxidized SWCNTs in murine 
macrophages [55]. Intriguingly, the authors noticed that the complex between SWCNTs and 
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albumin inhibited the induction of cox-2 and suggested that the proteins adsorbed onto 
nanotubes may alter their immune modulatory and toxicity properties. Furthermore, other 
modifications (e.g. non anionic surfactant coating) could reduce albumin adsorption and 
decrease their anti-inflammatory properties. In a similar way also the uptake could be affected, 
indeed, Pantarotto et al. [56] had shown that f-CNTs were able to cross the cell membrane and 
accumulate into the cytoplasm or reach the nucleus of living cell, similarly Porter et al. observed 
that SWCNT can cross the membrane of macrophage and localize mostly into the lysosomes. 
It should be mentioned that different nanomaterial coating and functionalization are finalized 
not only to reach a good biocompatibility but also to elude phagocytic-mediated clearance. In 
this context a good example is given by the work performed by the group of Tasciotti [57], in 
which the authors showed how nanoporous silicon particles coated with cellular membranes 
can avoid opsonization, delay uptake by mononuclear phagocytes and elude lysosomal 
pathway. However, the elicitation of phagocytic cells (Monocytes/Macrophage) functions is 
desirable when the purpose is to enhance the immunogenicity of a certain molecule.  Thus, 
monocytes and their differentiated progeny (macrophages and dendritic cells) play an important 
role in both the innate and adaptive immunity, by exerting immune-regulatory proprieties to the 
production of several modulatory cytokines [58]. During a potential injection of nanomaterials 
for diagnostic or therapeutic purposes, these cells will be the responsible population for a 
possible innate and thanks to a cross talk with lymphocytes, adaptive response of the immune 
system. Meunier et al. for example assessed the effect of pristine double-walled CNTs on 
monocytes, the authors observed an induced IL-1β secretion linked to caspase-1 and to Nlrp3 
inflammasome activation in human monocytes, while no induction of the corresponding mRNA 
was observed. The authors also showed that similar increase of IL-1β was observed using 
oxidized Double walled CNTs. However, the researchers did not assess whether the IL-1β 
release mediated by oxidized CNTs was dissociated from the induction of caspase- mediated 
apoptotic stimuli. In absence of functionalization, in fact, CNTs are highly cytotoxic and can 
mediate the induction of several inflammatory cytokines through the activation of pathways 
associated to oxidative stress and caspase cascade [50]. As stated above during a normal 
immune response, Innate and adaptive immune systems often work together to induce an 
efficient protection against foreign intrusions and only ex vivo on different immune 
subpopulations and in vivo experiments allow to consider the complex molecular and cellular 
network that link the different immune response. A large number of studies took advantage of 
the easiness of in vitro culturing cell lines. The clear advantages in using these cell models 
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(highly reproducible experiments, low cost and favorable culture conditions) are somehow in 
contrast with its neoplastic characteristics that may not always reflect the physiological 
condition of immune cell behavior. To avoid this concern, Delogu LG et al explored the impact 
of different functionalized MWCNTs on PBMCs from healthy donors [20]. MWCNTs oxidized 
and functionalized with ammonium group by 1,3-dipolar cycloaddition were found to not 
induce T cell expansion or activation (evaluated by CD25, and CD69 markers), while all of 
them were able to activate NK cells, which upregulated CD69, and CD161 activation markers 
following f-CNTs treatment. Moreover, f-MWCNTs induce the expression of the CD25 
activation markers and release of IL-1β, IL-6, TNF, and IL-10 by mostly in human monocytes 
not accompanied by the activation of cytotoxic mechanisms [10, 20]. Following this aspect, 
through a genome-wide analysis on T cells and monocyte cells, Pescatori M et al showed that 
ammino-functionalized as well as oxidized MWCNTs with larger diameter provoke a profound 
modulation of immune-regulatory pathways not accompanied by the induction of apoptotic 
pathways. They demonstrated that these f-CNTs induce profound modulation of inflammatory 
molecules at the transcriptomic level. Molecular pathways activated by these nanotubes 
included toll-like receptor (TLR), IL-6, dendritic cell maturation, TNF, NFKB, and T helper 1 
chemokine pathways (CXCR3 and CCR5 ligand pathways) [10]. Because of the critical role of 
these inflammatory pathways (especially the Th1 chemokine pathways) in controlling immune-
mediated tumor rejection, their findings suggested the highly promising application of this type 
of f-CNTs as adjuvant molecules in the contest of cancer immunotherapy or other adjuvant 
applications [59]. These intrinsic CNT immunostimulatory properties, if well-controlled, could 
be exploited for vaccination or any therapeutic protocol that requires activation of the immune 
system. Following this way undesirable effects might become desirable. 
 
1.4.2 Graphene 
Graphene based materials seem to retrace the same road of scientific expectation of CNTs. Even 
for this materials a careful assessment of toxicity in vitro and in vivo in appropriate models is 
necessary before starting its testing in clinical trials [60]. The precise structure of graphene has 
been the subject of debate over the years since it varies greatly with the preparation methods 
and extent of oxidation [61]. Nevertheless, graphene can be rich in functional groups such as 
carboxylic and hydroxyl groups which facilitate its surface modifications increasing its 
biocompatibility. Very recently, graphene and graphene oxide (GO) have been investigated in 
a growing number of medical applications, such as drug delivery, diagnostics, tissue 
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engineering and gene transfection all with the final aim to use it as a therapy material [62, 63]. 
However, one of the main concerns of using graphene in nanomedicine is its biocompatibility. 
Similarly, to many other nanomaterials, it is necessary to carefully address its biodegradability 
in aqueous solutions. In addition, the dimensions of the flakes of graphene could be responsible 
of different impacts on cell viability [11]. On the other hand, specific toxic effects of graphene 
on cancer cells could represent a positive point. Indeed, many reports have shown that this 
function of graphene could be useful in possible future therapeutic applications [64, 65], for 
example as an inhibitor of cancer cell metastasis [66].  
Risk to benefit ratio needs to be accurately evaluated before any medical application i.e. as 
delivery tool, immunotheraphy and for biomarker detection. 
As discussed above graphene and its derivatives have been proposed for several attractive 
biomedical applications. Most of these applications demand intravenous injection of graphene, 
and hence the evaluation of its immune impact is an essential prerequisite. The majority of 
papers since now for immune interaction are performed with GO [25]. This is explained by the 
better immune compatibility of the oxidized form compared to pristine graphene. As shown by 
Sasidharan et al. the oxidation of graphene significantly reduces the toxicity in a macrophage 
cell line compared to pristine form with no reactive oxygen species (ROS)-mediated apoptosis 
[67]. Similarly Zhou et al. confirmed the effect of pristine graphene on macrophages, 
highlighting also that sub-cytotoxic concentrations of pristine graphene on both primary murine 
macrophages and immortalized macrophages significantly stimulates the secretion of Th1/Th2 
cytokines including IL-1, IL-6, IL-10, TNF- and GM-CSF as well as chemokines such as 
MCP-1, MIP-1, MIP-1 and RANTES, evidencing a clear activation of macrophages [68]. 
Also the different size dimensions of GO are still under discussion in the context of the immune 
impact. Recent studies have shown that a lateral dimensions lower than 1 μm seems to trigger 
a higher activation of immune cells instead the higher lateral dimensions do not affect the 
immune activation or biocompatibility [11]. However, in other studies in macrophage cell lines 
GOs with an average dimension between 1 and 2 μm led to a Toll-like receptor 4 (TLR4)-
dependent necrosis [69]. These contrasting findings highlight the need of new studies about the 
correlation of dimension and molecular immune interaction of graphene.  In a similar way the 
chemical modifications of graphene can significantly affect their impact on the immune system. 
Indeed, is already illustrated by many reports how the functionalization can reduce the toxicity 
changing the ability of graphene to modulate the immune response. In this sense, the 
functionalization of graphene with biocompatible polymers such as polyethylene glycol (PEG) 
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was found to increase its stability in physiological conditions, minimizing the interactions with 
other biomolecules and reducing the risk of immunological response [70]. Feito et al. 
demonstrated a reduced activation of T- and B-lymphocytes and macrophages in the presence 
of GO-PEG in a dose-dependent manner. Moreover, no significant changes in cytokine 
secretion were found after treatment with different GO-PEGs [70]. On the other hand, 
alternative functionalizations of GO could improve the immune activation. Wu et al. for 
example demonstrated that both carboxylated and PEGylated GO was able to reduce the IgE 
production but at the same time modulate the humoral immunity and antigen-specific T-cell 
responses with no systemic toxicity [72]. With another functionalization strategy for the 
development of highly effective GO-based vaccine nano-adjuvants, Xu et al. proved the ability 
of GO functionalized with PEG and various types of polyethylenimine (PEI) to act as a positive 
modulator of the immune response promoting the maturation of dendritic cells (DCs) and 
enhancing their cytokine secretion through activation of multiple toll-like receptor (TLR) 
pathways while showing low toxicity [73]. The effects of different physicochemical parameters 
of graphene on immune cells are an open chapter and need to be fully understood. To date, 
understand how to control the different physicochemical parameters of graphene based on its 
biological action is mandatory to reduce possible immune toxicity effects and to take advantage 
of the intrinsic immune properties of this nanomaterial for possible biological applications.
  
1.4.3 Lipid nanocapsules  
The appropriate carrier design and functionalization, particularly the composition and the 
surface properties, are essential to ensure high biocompatibility and to protect molecules of 
interest from degradation and premature elimination [41]. Biodegradable polymers and 
molecules have been extensively studied as loading molecules for NCs to improve their 
hydrophilicity in biological media, for new possible treatments of many diseases.  
However, increasing the long term stability of NCs i.e. into the blood stream, could lead to 
augmented interactions with the immune system. It is already well known that emulsions and 
nanoemulsion are used in vaccines development. It has been reported that the nanoscale-sized 
emulsions such as NCs are able to permeate the nasal mucosa and carry the antigen to the 
antigen-presenting cells more efficiently than larger-sized emulsions. Nanoscale emulsion-
based intranasal vaccines have been investigated for hepatitis B, HIV, influenza, and anthrax 
[13].   
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However, before any pre-clinical application in drug delivery, it is of fundamental importance 
to choose the most suitable coating for NCs able to avoid or to boost the interaction with the 
immune system. Indeed, the NCs immunocompatibility assessment is critical for any translation 
into clinical practice. As a matter of fact, the possible interactions between NCs with different 
coatings and the immune system, could result into an immunostimulation or an 
immunosuppression, which might either be applied in immunotherapy or may promote 
treatment in anti-inflammatory/autoimmune disorders [12, 13].  
1.4.4 Super Paramagnetic Iron Oxide Nanoparticles  
Regarding the SPION interaction with the immune cells there are still many question to be 
addressed to understand the mechanisms of their immune recognition. The composition of 
SPION comprise multiple magnetite-maghemite (Fe3O4 and -Fe2O3) crystals. The surface of 
the crystals is anionic. Biopolymer coating (dextran, carboxydextran, chitosan, etc.) is 
necessary to impart water solubility and colloidal stability to the particles. The main 
translational disadvantages of these nanoparticles are immune-related adverse effects and high 
nonspecific uptake by following injection. SPIONs show rapid clearance and uptake by liver 
and spleen macrophages [74] and leukocytes [75]. Several dextran-coated SPION formulations 
showed severe anaphylactic-like reactions in patients (this is the example of Feridex and 
Combidex recently withdrown from the market). Indeed, the SPION structure made by iron 
oxide crystal lattice exhibits a molecular pattern of periodical anionic charges, whereas dextran 
is the biopolymer composed of periodic sugar groups. Dextran maintains aqueous solubility of 
nanoparticles, but it does not cover the crystal surface and the anionic crystals are significantly 
exposed and can come in contact with the immune cells giving undesirable reactions [76]. 
This unsuccessful use of SPIONs can be further addressed to improve knowledge about 
mechanisms of interactions between these nanoparticles and the immune system, increasing 
and exploiting also new types of functionalizations that could overcame the undesired effect 
found with dextran-coated SPIONs.  
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Chapter 2 
2.1 Aim of the thesis 
Despite the everyday progresses of medicine solutions for human health, the development of 
new technologies to cure and prevent diseases such as cancer is still one of the biggest 
challenges for humanity. As presented in the introduction section nanotechnology is one of the 
best promises to develop new therapies in medicine. In the recent years, numerous 
nanomaterials have been explored for potential medical applications thanks to their properties. 
Compared to traditional diagnostic agents or drugs, nanomaterials can be engineered to improve 
and integrate multiple functions in a single system also to give the control of drugs release, 
being of hope for the building of a next generation therapy and imaging tools. However, still 
limited amounts of results are available on the biological responses and the possible toxic 
effects of nanomaterials. Moreover, independently from any specific purpose, a critical step for 
any translational application in medicine is represented by the assessment of nanomaterials 
safety and impact on the immune system. Following any type of exposures, nanomaterials 
immediately contact the organism immune cells. Hence the investigation of the immune cell 
reactions induced by nanomaterials is a milestone for the safe exploitation of these materials 
for therapeutic and diagnostic applications.  
The present thesis (as summarized in Scheme 1) aim to provide new insights on the safety and 
immune impact of several types of nanomaterials, such as carbon based materials (carbon 
nanotubes and graphene), lipid nanocapsules and super paramagnetic iron oxide nanoparticles, 
analyzing their molecular impact into the heterogeneity of the immune cells exploiting also 
their possible biological applications in cancer therapy and imaging.  
 
The summarized main objectives are: 
1. The assessment of the immuno-activity of the above mentioned nanomaterials on several 
immune cell subpopulations such as: T and B Lymphocytes, Natural Killer cells, Monocytes 
and Dendritic Cells.  
2. The classification of nanomaterials by the immune cell response with their physico-
chemical correlation using also OMICS technology, to characterize by high-throughput 
methods the immunological impact of the different nanomaterials analyzed.   
3. The assessment of new therapy and diagnostic applications of characterized nanomaterials, 
applying their intrinsic immune modulatory properties. 
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Brief summary of the presented results 
In this thesis, the results are presented in six different papers according to the different 
nanomaterials used. A brief summary of the main results for each paper is presented below.  
Paper I: In space, living organisms are confronted with two important factors: microgravity 
and cosmic radiation. A microgravity environment imparts to an object a lower acceleration 
compared to that produced by the Earth on its surface. It is well known that the constant 
influence of microgravity leads to several modifications of many physiological cellular 
processes, such as proliferation, differentiation, growth, signal transduction, cytoskeletal 
architecture, motility and gene expression. Moreover, immune cells are severely affected by 
microgravity, T lymphocyte functions were found altered in more than 50% of crewmembers 
in space. In a previous work my Ph.D. advisor and colleagues reported that functionalized 
multi-walled carbon nanotubes (f-MWCNTs) lead to an up-regulation of CD25 and CD69 
marker expression in human primary immune cells, in particular in monocytes. In this study we 
wanted to evaluate the possibility of taking advantage of f-CNT immunostimulatory properties 
against spaceflight dysregulation of immune functions. Oxidation and functionalization of the 
nanotubes were performed with the ammonium groups and a fluorescent probe (FITC). First of 
all, we have seen with Transmission Electron Microscopy (TEM) that microgravity not affected 
the functionalization and the structure of f-CNTs. Moreover, flow cytometry and confocal 
microscopy analysis show a dose-dependent uptake of f-CNTs after 24h. Interestingly, we did 
not detect significant difference in the internalization under microgravity (0 x g). To evaluate 
the activating ability of f-CNTs to counteract spaceflight immune suppression, Peripheral 
Blood Mononuclear Cells (PBMC) were left untreated for 24 h or incubated with 50 µg/ml of 
f-CNTs in static controls and under microgravity conditions using a Random Positioning 
Machine (RPM). Lipopolysaccharides (LPS) and concanavalin A (ConA), due to their well-
known activation properties, were used as positive controls for monocytes (CD14+) and T cells 
(CD3+) respectively.  f-CNTs led to an increase expression of the activation marker CD25 on 
monocytes, both in static controls and under microgravity conditions. Instead, in microgravity 
we noticed a down-regulation of CD25 also in ConA treated samples due to the immune 
suppression as already reported. Interestingly, our results demonstrate that f-CNT together with 
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ConA counteract the down-regulation of CD25 due to the microgravity condition. We have 
seen indeed that nanotubes have a clear synergic effect with ConA both in static controls that 
in simulated microgravity. Cytokine analysis also confirm these data. Our experiments show 
that the effect of nanotubes appears to be particularly linked to an up-stimulation of the 
molecular effectors involved in the IL2 pathway. We assume that f-CNTs could promote the 
patching and capping of the ConA receptor. This action, together with IL2 pathway stimulation, 
can explain the synergic effect between f- CNTs and ConA in 0 x g. These preliminary findings 
open new perspectives on the capability of carbon nanotubes to act as immunomodulators 
proving this property by fighting immune function dysregulation under microgravity 
conditions, especially for T lymphocytes. We aim at reinforcing the concept that functionalized 
carbon based materials such as carbon nanotubes are able to stimulate immune cells having 
very interesting broad future applications in immunotherapy as vaccine adjuvants and, with 
data shown, as possible fighters to contrast spaceflight immune cell dysregulation.  
Paper II: In the last few years, there has been enormous interest in graphene oxide (GO) for its 
promises in medicine fated to change the known medical practice in many healthcare 
applications. To improve the knowledge about the immune impact of GO, this work look at the 
molecular effects of two types of thin graphene oxide sheets (GOs), different only in their lateral 
dimension, on primary human immune cell populations using a wide range of assays, including 
high throughput screenings.  GOs were thoroughly characterized by TEM, AFM, Raman 
spectroscopy and several other techniques to determine the specific lateral dimensions, number 
of graphene layers, and surface properties of each GO used. PBMCs from healthy donors were 
used, being a pool of immune cells that provide a closer insight to real in vivo conditions in 
humans, better than isolated sub-populations. The extent of early and late apoptosis, necrosis, 
cell activation, cytokine release were determined following exposure to the GO materials. 
Moreover, the impact on 84 genes related to innate and adaptive immune responses were 
analyzed. Lastly, whole genome analysis was conducted on T lymphocytes (Jurkat cells) and 
monocytes (THP1 cells). Both GOs used at increasing concentration form 25 to 75g ml-1 
generally did not show significant reduction in cell viability. However, exposure to small GO 
sheets (100-500 nm) was found to have a more significant impact on immune cells compared 
to the large sized GO (1- 10μm). The pilot expression analysis of 84 gene evidenced the higher 
genes induction of small GO compared to the large GO, confirmed in the secretion of many 
cytokine such as: IL1, IL1, TNF, and IL6. Microarray data confirmed the small GO impact 
on immune cells. Particularly the activation was underlined by the up regulation of genes such 
as CCL5 and the induction of the chemokine pathways such as CXCL10 ligand pathway and 
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CXCR3 receptor, that are commonly associated with inflammation, immune-mediated tumor 
rejection and pathogen clearance. Furthermore, also a significant switch on energy-dependent 
pathways was found. In this work we demonstrated that the distinct shape dimensions could 
regulate the nature of GO interactions with immune cells. These findings represent the first step 
of a comprehensive molecular-characterization of different sized GOs on immune cells impact 
giving crucial information for the design of graphene for the control of its biocompatibility; 
paving the foundations for future preclinical studies with well-designed GOs as i.e. 
immunotherapy tools or safety drug delivery platform. 
Paper III: The rationale of this work was driven by the common hope of a nanotechnology 
translation into the everyday clinical practice. However, such dream has to face something that 
can make the difference for almost any successful bio-application: the potential impact on the 
complex system of blood immune cells. The understanding of the interactions between 
nanoparticles and immune cells is hindered by the scant implementation of high throughput 
technologies in nanotechnology. Recently, a novel tool for flow cytometry analysis has been 
developed, gaining leverage with the precision of mass spectrometry. The use of the technique 
termed single-cell mass cytometry provides the measurement of more than 40 simultaneous 
cellular parameters at a single-cell resolution. We propose, for the first time in the context of 
nanotechnology, a new analytical strategy able to dissect the immunological impact of 
nanomaterials, at the single-cell level. The analytical pipeline here reported encompass the 
immunological characterization of the most studied nanomaterial in the last years: graphene. 
Mass cytometry enables us to describe the immune cell interactions of thin graphene oxide 
(GO) flakes and GO functionalized by amino groups (GONH2) on 15 cellular populations 
corresponding to 200 nodes of distinct but logically interconnected cell sub-populations. 
Together we performed whole-transcriptomic analysis (Illumina BeadArray) for functional and 
molecular characterization on human T-cells and monocytes as a representative for the adaptive 
and innate response. Our results emphasize the importance of the functionalization on 
enhancing the biocompatibility of GO-based nanomaterials. Notably, only the functionalized 
GONH2 was able to induce a specific monocytoid dendritic cell and monocyte activation 
skewed toward a T helper 1/M1 response. The positive impact of GONH2 on specific immune 
cells could serve as a starting point for the development of new nanoscale platforms in medicine 
as novel immunotherapy, vaccine carrier, or nanoadjuvant tools.  
Paper IV: Nanotechnology and specifically nanomedicine could provide new tools for an 
effective treatment of several diseases such as cancer, not only by taking advantage of the 
ability to functionalize and target the nanomaterials but also of their possible intrinsic biological 
properties. In this work, we developed a new few-layer graphene (FLG) dispersions prepared 
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by a mechano-chemical approach employing melamine as the exfoliating agent of graphite. The 
biological impact of new FLG on multiple human immune primary cell population (T, B and 
Natural Killer lymphocyte, monocytes, macrophages and dendritic cells) looking at cell 
viability and cell activation using a wide range of analysis were explored. We found an intrinsic 
specific impact of FLG on cells belonging to the monocytic lineage (CD14 positive) showing 
neither toxic nor activation effects on the other immune cells. Thanks to this intrinsic biological 
property, we further explored the possible therapeutic application of FLG on neoplastic 
monocytes ex vivo, from acute myeloid leukemia and chronic myelomonocytic leukemia 
patients. Intriguingly we demonstrated the FLG unique ability to target and successfully boost 
the necrosis of monocytic cancer cells. Moreover, the comparison between FLG and a common 
chemotherapeutic drug (i.e. Etoposide) confirmed the specificity and higher toxicity of FLG on 
cancer cells, evidencing the absence of toxicity of other immune cell populations. The 
functionality in terms of viability and activation of the other immune cell populations was also 
not affected, suggesting the ability of our graphene to preserve the normal function of the 
immune system. We here showed, for the first time, the great intrinsic biological properties of 
graphene obtained by exfoliation from graphite and applied them in oncology research versus 
an aggressive form of blood cancer. As a further step, in the near future, we can imagine not 
only to use the specific effect of FLG to improve the cancer cell toxicity but also, thanks to its 
high surface area, to take advantage of the conjugation with other drugs to enhance cancer 
therapy. 
Paper V: Following the necessity to understand the immunological fate of different 
nanomaterials. In this manuscript we wanted to deeply investigate the action of three differently 
coated lipid nanocapsules (NCs) on human PBMCs. Considering the wide variety of NC 
applications in biomedicine a possible immune response to this type of nanomaterials is a 
crucial issue to be addressed. To the best of our knowledge this is the first comprehensive study 
on bio and immune-compatibility comparison analysis of differently functionalized NCs with 
chitosan, pluronic and PEG, fully characterized. We analyzed the impact of three different 
functionalizations of NCs looking first at the hemolytic impact.  We then focused on human 
PBMCs and subpopulations (T, B, NK cells and monocytes) from healthy donors. Uptake 
assays were performed to assess whether a specific coating could be more suitable for the cell 
internalization. We explored the possible necrosis, apoptosis and proliferation of PBMCs and 
subpopulations of T cells and monocytes, as representative of the adaptive and innate immune 
response after NC treatment. The functionality effect was tested looking at the cell diameter 
modification, at the expression of the most critical activation markers (CD25 and CD69) and at 
the production of a wide variety of cytokines. In this work we demonstrated that the NCs impact 
on the immune cells response is strictly dependent on their coating. All three coated NCs were 
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well internalized inside all immune cell populations studied. Intriguingly, Pluro-NCs were able 
to induce immunomodulation of innate immunity through a clear induction of monocyte 
activations. Chito-NCs instead, mediated the activation of monocytes and T helper response 
that give the whole enhancement of the immune response after treatment. All these actions are 
exclusive for Chito-NCs that in our screening resulted as good starting material for further 
studies in the context of vaccine delivery, immunotherapy and immunomodulation activities. 
On the contrary, PEG-NCs were completely inert for the population of immune cells analyzed 
opening their perspectives as inert drug carriers.  
Paper VI: In this manuscript we deeply investigate the immune impact of novel cystine 
functionalized SPIONs (Cy-SPIONs) exploring also their potential as ultrasound contrast 
agents. SPIONs are deeply investigated for many biomedical applications such as imaging for 
diagnostic and therapeutic purposes. A good functionalization that can combine the imaging 
goals together with a good biocompatibility remains one of the challenge for particles 
translation into medical practice. In this work, we focused on a novel functionalization of 
SPION with cystine (Cy-SPIONs); cystine, indeed, is able to make SPION stable and 
dispersible in culture cell media being an aminoacid easily biosynthesized in humans. To prove 
their potential as biomedical tools, we first gave new insights into the biological and immune 
effects of Cy-SPIONs with a wide variety of standard and molecular assays to evaluate 
cytotoxicity, cell activation, cytokine release and the expression of 84 genes related to the 
immune response. A good immune biocompatibility of Cy-SPIONs on ex vivo primary immune 
cells as well as in vitro cell lines was found. Moreover, an interesting potential of Cy-SPIONs 
for in vivo studies was pointed out where the preferential route of administration is by 
intravenous injections, thus in contact with immune cells. Currently, many studies focus on the 
use of SPION on Magnetic Resonance Imaging (MRI), instead our study focused on 
ultrasonography, which is a safer, less expensive and common imaging technology. The good 
echogenic properties of Cy-SPIONs in water and in whole blood were shown both in a phantom 
vein and in a microfluidic device for bloodstream simulations. Moreover, we report no cell 
toxicity under Cy-SPION treatment together with ultrasound irradiation, giving new insight on 
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Spaceflights lead to dysregulation of the immune cell functionality affecting the expression of 
activation markers and cytokine production. Short oxidized multi-walled carbon nanotubes 
functionalized by 1,3-dipolar cycloaddition have been reported to activate immune cells. In this 
Communication we have performed surface marker assays and multiplex ELISA on primary 
monocytes and T cells under microgravity. We have discovered that carbon nanotubes, through 




Gravity is the force of attraction by which terrestrial bodies tend to fall toward the Earth. In 
space, living organisms are confronted with two important factors: microgravity and cosmic 
radiation. A microgravity environment imparts to an object a lower acceleration compared to 
that produced by Earth at its surface. Experiments conducted by American, Russian, and 
European investigators, in dedicated space missions as well as in simulations on Earth, have 
shown that mammalian cells are sensitive to gravitational changes.1-8 It is well known that the 
constant influence of weightlessness leads to several modifications of many physiological 
cellular processes, such as proliferation, differentiation, growth, signal transduction, 
cytoskeletal architecture, motility and gene expression.1-4 Moreover, immune cells are severely 
affected by microgravity.5 T lymphocyte functions were found altered in more than 50% of 
crew members in space.6 A severe inhibition of T cell activation in real and simulated 
microgravity conditions has been extensively demonstrated. Hashemi et al. reported a down 
regulation of CD25 and CD69 cell membrane activation markers in T cells after 24 hours of 
microgravity condition.7 These findings were recently confirmed on US Astronauts onboard 
the Space Shuttle.8 CD25 and CD69 are important markers in the T Cells mediate immune 
response. CD25 (alpha chain of the IL-2 receptor) is a late activation antigen. Activation 
mediated by the T-cell receptor (TCR) and costimulatory molecules induce an up-regulation of 
CD25 in T cells making them highly sensitive to IL-2. Whereas, CD69, member of the C-type 
lectin superfamily (Leu-23), is one of the earliest cell surface antigens expressed by T cells 
following activation. 
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We reported that functionalized multi-walled carbon nanotubes (f-MWCNTs) lead to an up-
regulation of CD25 and CD69 markers expression in human primary immune cells, in particular 
in monocytes.9 Very recently, through a whole genome wide study we proposed functionalized 
CNTs (f-CNTs) as immunomodulator systems showing their potential as immune activators 10. 
We would like to highlight that in contrast to other types of CNTs, different in functionalization 
and shape investigated in immune cells,9-12 we found that oxidized MWCNTs, further 
functionalized by 1,3-dipolar cycloaddition, can act as immunomodulators.9 No data are present 
in literature regarding the interaction of CNTs and immune cells under microgravity conditions. 
Encouraged by our recent results, we wanted to evaluate the possibility of taking advantage of 
f-CNT immunostimulatory properties against spaceflight dysregulation of immune functions.  
The high cost of experiments on board of spacecraft and space station facilities and the limited 
number of doubling experiments do not allow scientists to give continuity to the studies in real 
microgravity outside Earth. Currently, thanks to different and advanced facilities, it is possible 
to carry out studies in microgravity simulating in part the spaceflight conditions. In this work, 
a tridimensional clinostat or Random Positioning Machine (RPM) was used to simulate 
microgravity (M; 0xg) to evaluate if f-CNTs are able to compensate immune microgravity 
induced dysregulation. Static control cell cultures were installed in the basement of the RPM. 
We first assessed the possible impact of microgravity on the functionalization of CNTs by 
transmission electron microscopy (TEM) and Kaiser test. To assess whether microgravity affect 
CNT uptake on primary human T cells and monocytes, we studied their internalization in 
microgravity by flow cytometry and confocal microscopy. Taking into consideration the results 
reported on activation markers by Hashemi et al.,7 we then focused on CD25 expression on 
monocytes and T cells through peripheral blood mononuclear cells (PBMCs) analysis and 
CD69, both on T cells present on PBMCs and isolated T lymphocytes, T-helper cells (CD4+) 
and cytotoxic T cells (CD8+). To gain a larger picture about CNT effect on immune 
microgravity dysregulation, we also performed a multiplex cytokine assay on PBMCs (TNFα, 
IL6, IL10, IL13, IFNγ, IL2) and on isolated T lymphocytes (IFNγ, IL2).  
By screening a series of functionalized carbon nanotubes, we previously obtained the major 
effect on immune activation treating human primary cells with oxidized MWCNTs 
subsequently functionalized by 1,3-dipolar cycloaddition of azomethine ylides.9, 10 The present 
study was carried out with the same type of nanotubes in terms of functionalization and shape 
(Fig. S1). Characterization and functionalization methods of the MWCNTs has been previously 
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described by our group.13 Kawanami et al. focused on the effect of microgravity on CNT 
synthesis,14 but no data are reported in the literature about the possible impact of microgravity 
on f-CNTs. We first assessed by TEM and Kaiser test that MWCNTs (OX-MWCNT-NH3+) 
were not affected in their functionalization in microgravity. TEM images do not display 
differences in the morphology of the tubes under the microgravity (Fig. 1), while Kaiser test 
gave approximately the same values (within the uncertainty of this type of measurement) in 
term of amount of ammonium groups before (~40 µmol/g) and after (~50 µmol/g) treatment 
under microgravity. We previously showed a clear uptake on monocytes and T cells by the 
same type of nanotubes.9  
 
Figure 1. TEM images of OX-MWCNT-NH3+ before (A) and after microgravity treatment (B). 
 
To make sure that the equivalent internalization can be possible under microgravity conditions, 
we used the same fluorescently labeled nanotubes (Fig. S2). As expected, data from flow 
cytometry showed a dose-dependent uptake of f-CNTs after 24 h. Interestingly, we did not 
detect significant difference in the internalization at 0xg (Fig. S3A). We confirmed our data at 
100 µg/ml concentration for both the samples treated in static control or in microgravity by 
confocal microscopy (Fig. S3B). The absence of difference in cell uptake prompted us to go 
ahead in understanding the potential of carbon nanotubes to modulate the immune spaceflight 
effects. Cellular uptake results led us to choose a working concentration of 100 µg/ml of f-
CNTs. We fixed the time of incubation at 24 h, the best time point to assess a possible immune 
response on primary human cells as used in the space mission and microgravity experiment on 
activation markers.7 
To evaluate the ability of activator MWCNTs to counteract spaceflight immune suppression,9 
PBMCs were left untreated for 24 h or incubated with 100 μg/ml of OX-MWCNT-NH3+ in 
static controls and under microgravity conditions. Lipopolysaccharides (LPS) and concanavalin 
A (ConA), due to their well-known activation properties, were used as positive controls for 
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monocytes (CD14+) and T cells (CD3+) respectively (Fig. 2). In addition to our previous data 
obtained in static conditions,9 we here tested a possible synergic action of f-CNTs in the 
presence of traditional activators (LPS or ConA + OX-MWCNT-NH3+ samples). We first 
performed a functionality assay on CD14+ monocytes focusing on CD25 marker (Fig. 2A). f-
CNTs led to an increase of CD25 expression on monocytes, both in static controls and under 
microgravity conditions (M).  
 
Figure 2. Activation marker assay. Microgravity (M) was compared with static controls. Peripheral blood 
mononuclear cells and isolated human T lymphocytes were left untreated (medium) for 24 h or incubated with 100 
μg/ml OX-MWCNT-NH3+ alone or in the presence of cell activators (LPS or ConA).  (A) Monocytes: CD25 
expression was assessed by flow cytometry on CD14+ monocytes present on PBMCs. LPS (2 μg/ml) was used as 
positive control. (B and C) T cells: CD25 (B) and CD69 (C) expression was assessed by flow cytometry on CD3+ 
T cells present on PBMCs. ConA (10 μg/ml) was used as positive control. (D and E) Isolated T lymphocytes from 
PBMCs: staining for CD4+ (D) was performed to identify T-helper cell on isolated T lymphocytes; staining of 
CD8+ (E) was performed to identify cytotoxic T cells. Difference in statistical significance (Student’s t-test) is 
indicated by * = p < 0.05 and ** = p<0.01. Bars indicate the compared samples under the different conditions; No-
asterisk marked samples are compared to controls (medium). 
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This finding suggests that the ability of OX-MWCNT-NH3+ to act as monocyte activators 9, 10 
is not affected by microgravity conditions. We then evaluated CD25 expression on CD3+ T 
lymphocytes (Fig. 2B). f-CNTs showed a synergic effect with ConA on CD25 expression in 
static controls. In microgravity we noticed a down-regulation of CD25 on ConA activated 
samples due the immune suppression as already reported.7 Interestingly, in microgravity, 
samples treated with f-CNTs together with ConA did not show the down-regulation of CD25. 
Since it was also previously shown a down-regulation of CD69 early activation marker during 
clinorotation in spaceflight,7 we decided to evaluate CD69 expression on T lymphocytes (Fig. 
2C). Our results demonstrate again that f-CNTs have a clear synergic effect with ConA in static 
controls. The nanotubes counteract the down-regulation of CD69 due to the microgravity 
conditions. These findings show that the functional effect on T cells of f-CNTs in presence of 
ConA is not deeply affected by microgravity in comparison to the treatment with only this 
activator. It is well known that the activation of T cells by ConA is inhibited in 0xg condition. 
17 Action of ConA on T cells is mediated by G protein that induce phospholipase C and then 
trigger the activation cascade of IL2. Patching and capping of ConA receptor are slightly 
retarded in microgravity. This action dramatically reduce the IL2 secretion therefore the T cell 
activation. 17  
To thoroughly evaluate CNT effect on CD69 expression in T cell in absence of other cells 
present in PBMCs, T lymphocytes were isolated and incubated for 24 h with 100 μg/ml of f-
MWCNTs alone or in the presence of ConA, and compared to untreated control cells, CD4+ 
and CD8+ subpopulations were analyzed by flow cytometry (Fig. 2D and 2E). We confirmed 
that f-CNTs with ConA in both subpopulations are able to contrast the effect of microgravity. 
Moreover, these results clearly show that f-CNTs can act on T lymphocytes even in the absence 
of monocyte interactions.  
The altered immune cell functionalities have been reported in different studies looking also to 
the cytokine production.8, 15-19 Crucian et al. showed on Space Shuttle crew members that post-
flight monocytes significantly reduced their production of IL-6, TNFα, and IL-10.15 This 
reduction may impact overall immunocompetence. More recently, during the flight it has been 
shown a down-regulation of IFNγ, TNFα, IL10, IL4 and IL6 on whole blood sample of crew 
members after phorbol 12-myristate 13-acetate and ionomycin treatment.8 The authors showed 
that a mitogenic stimulation led to a lower production of IFNγ and IL10, and to an up-regulation 
of TNFα and IL2.8 Moreover, the strongly reduced T lymphocyte activation under spaceflight 
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conditions has been reported not only for CD25 marker but also for the production of IL2 after 
ConA stimulation.17 To further confirm the ability of f-CNTs to act as immunomodulator 
systems and better investigate their interaction with immune cells under microgravity, we 
performed an assay on a wide range of cytokines. The samples were activated with ConA or 
left untreated in the presence of f-CNTs or without them. Figure 3A illustrates the cytokine 
production by multiplex ELISA on PBMCs supernatants. We confirmed the activator action of 
f-MWCNTs for the classical innate cytokines, TNFα and IL6, as previously reported,9, 20 and 
we found the synergic effect of f-CNTs with ConA in static controls and under microgravity. 
Interestingly, in microgravity, also f-CNTs alone are able to up-regulate the IL6 production as 
they do in static controls. For the other investigated cytokines (IL10, IL13, IFNγ and IL2) we 
found that f-CNTs alone did not boost their production but they seem to act in concert with 
ConA potentiating its stimulation both in static controls and in 0xg conditions. To better 
understand the interaction of f-MWCNTs with T lymphocytes, the major population affected 
by microgravity, we assessed the release of two classical adaptive cytokines, IFNγ and IL2, on 
T isolated cell population (Fig. 3B).  
 
Figure 3. Cytokines secretion assay. Cytokine production was assessed by multiplex ELISA on PBMCs (A) and 
on isolated human T lymphocytes (B). Microgravity (M) were compared with static controls. Peripheral blood 
mononuclear cells and isolated T cells were left untreated (medium) for 24 h or incubated with 100 μg/ml 
MWCNTs, alone or in addition with 10 μg/ml ConA. Values are expressed in pg/ml. The statistical significance 
of differences between the samples versus medium controls was calculated by Student’s t-test (*, p<0.05).  
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Cell functionality was inhibited by microgravity even in the presence of ConA stimulation. In 
static samples treated with ConA and nanotubes we found instead a statistically significant 
production of IFNγ and IL2 versus medium. Our experiments show that the effect of nanotubes 
appears to be particularly linked to an up-stimulation of the molecular effectors involved in IL2 
pathway. We assume that f-CNTs could promote the patching and capping of ConA receptor; 
this action, together with IL2 pathway stimulation, can explain the synergic effect between f-
CNTs and ConA in 0xg. 
 These findings, together with the surface marker data, open new perspectives on the capability 
of carbon nanotubes to act as immunomodulators proving this property by fighting immune 
function dysregulation in microgravity conditions, especially for T lymphocytes.  
In conclusion, carbon nanotubes had attracted in the last years a huge interest from the scientific 
communities in a wide variety of biomedical applications.21 Among other purposes, we and 
others focused on their possible relevance in biomedicine as drug carriers or contrast agents.12, 
13, 22, 23 Encouraged by our recent studies on functionalized carbon nanotubes we wanted to 
confirm the potential of specific functionalized carbon nanotubes as immunomodulators.9, 10 
NASA is working to achieve the goal of returning humans to Moon by 2020 and put footprints 
on Mars by 2024 (www.nasa.gov.html last access 12/12/2013). Even if this is a dreaming 
scenario for humanity, the immune system suppression related to spaceflight should be 
considered more thoroughly before taking in consideration long space voyages. In this context 
nanotechnology may bring additional help for the future of humans on space missions.24 Based 
on the results of this study together with further future possible investigations, we can envision 
an immune system pretreatment of space crew members with functionalized CNTs intravenous 
administration. We aim at reinforcing the concept that functionalized carbon nanotubes are able 
to stimulate immune cells having very interesting broad future applications in immunotherapy, 
as vaccine adjuvants and, with data here shown, as possible fighter to contrast spaceflight 
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Material and Methods 
Carbon nanotubes, TEM analysis and Kaiser test 
Carbon nanotubes were obtained as purified material from Nanocyl (Sambreville, Belgium; 
Thin MWCNTs 95+% C purity, Nanocyl 3100®, batch n° 071119). The average diameter and 
length were 9.5 nm and 1.5 μm, respectively. Oxidation and functionalization of the nanotubes 
with the ammonium groups and a fluorescent probe (FITC) were performed as previously 
described.1-3 The amount of ammonium groups per gram of nanotubes was assessed using 
Kaiser test as described in reference 1. CNTs were homogeneously dispersed at 1 mg/ml in 
sterile ultrapure water, then they were sonicated 45 min with a Branson 3200 water bath 
sonicator and vortexed for a few seconds. An additional sonication was performed for 15 min 
before each cell experiment. 
 
Simulated microgravity conditions 
Random Positioning Machine (RPM) is able to simulate microgravity very close to real 
spaceflight conditions (experiments carried out in space are from 1×10-6 to 1×10-4xg, whereas 
the simulations with RPM are in the order of 1×10-3xg). This apparatus has two rotating frames, 
driven by two separate motors. It rotates in such a way as to simulate weightlessness by 
removing the effects of gravity in any specific direction. As the rotation is autonomous and 
with random speeds and directions, it is termed Random Positioning Machine.  
The Random Positioning Machine used in this work was developed by Fokker Space (Leiden, 
The Netherlands). It was located in a 37°C room and it was under the control of a computer 
with a dedicated program (RPM Control Software 14A, developed by Fokker Space, Leiden, 
The Netherlands). The rotation velocity of the frames was 60°xs-1. PBMCs and T lymphocytes 
were incubated under microgravity conditions for 24 h in 2.5 ml cryotubes (1×106 cells/ml). 
Control cell cultures were installed in the basement of the RPM. 
 
Cell cultures and isolation of human primary T lymphocytes  
Experiments were performed using both PBMCs and isolated T lymphocytes. In both cases 
cells were obtained from informed healthy male donors (25-45 years old). At least three 
different donors were enrolled for each experiment. Cell separation was performed immediately 
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after blood withdrawing. PBMCs were isolated from fresh heparinized blood by FicollePaque 
PLUS (GE Healthcare) density gradient centrifugation. For each experiment, cells were 
suspended at the concentration of 1x106/ml in fresh medium. Cell viability was evaluated 
through a Trypan Blue exclusion test and cells were maintained in RPMI 1640 and 
supplemented with 10% (v/v) heat-inactivated FBS, 20 mM HEPES, 10 ml/L 
penicillin/streptomycin at 37°C. 
T lymphocytes were purified from PBMCs using high affinity CD3+ T-cell enrichment 
columns (R&D Systems, Minneapolis; MN). Columns allow purification of human T cells via 
high affinity negative selection. Total CD3+ cell recovery ranges between 37% and 54% and 
the purity of recovered cells ranges between 87% and 95%. Cell suspensions were stored for at 
least 12 h at 37°C to allow recovery from stress due to isolation procedure. Cells were 
suspended at the concentration of 1x106/ml in fresh RPMI medium. 
 
Uptake experiments 
PBMCs were incubated in 2.5 ml cryotubes (1×106 cells/ml) with increasing amounts of OX-
MWCNT-FITC (1, 10 and 100 μg/ml) for 24 h in microgravity or static conditions. Cells were 
then washed in phosphate buffered saline (PBS), centrifuged and stained with fluorochrome-
conjugated monoclonal antibodies to identify major immune cell populations according to the 
expression of specific cell surface markers (clusters of differentiation [CD]). Phycoerythrin 
(PE)-, peridinin chlorophyll protein (PerCP)-, or allophycocyanin (APC)-conjugated anti-CD3 
(SK7 clone), anti-CD14 (Mf9 clone), anti-CD25 (2A3 clone) were purchased from BD 
Biosciences (Mountain View, CA, USA). Flow cytometry measurements were performed using 
a FACSCalibur® (BD Biosciences). Ten-thousand and fifty-thousand  events were collected. 
 
Activation marker assays 
Human primary cells were cultured in the presence or in the absence of f-MWCNTs, 
concanavalin A (ConA; 10 μg/ml) or bacterial endotoxin lipopolysaccharides (LPS; 1 μg/ml). 
ConA and LPS were purchased from Sigma-Aldrich. After 24 h incubation, cells were 
centrifuged and stained to identify immune cell populations of monocytes and T lymphocyte 
subpopulations and to analyze activation marker expression. Fluorescein isothiocyanate 
(FITC)-, phycoerythrin (PE)-, peridinin chlorophyll protein (PerCP)-, or allophycocyanin 
(APC)- conjugated anti-CD3 (SK7 clone), anti-CD14 (Mf9 clone), anti-CD69 (L78 clone), anti-
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CD25 (2A3 clone), anti-CD4 (SK3 clone) and anti-CD8 (SK1 clone) were purchased from BD 
Biosciences (Mountain View, CA, USA). Staining was performed in the dark for 20 min. After 
washing, cells were then analyzed by flow cytometry. 
 
Multiplex cytokine analysis 
Cell culture supernatants from PBMCs and isolated T lymphocytes were used to quantify the 
production of cytokines using a MILLIPLEX MAP 5-plex Cytokine Kit (HCYTOMAG-60K -
05, Millipore, Billerica, MA), according to manufacturer’s protocol. The following human 
cytokines were measured: TNFα, IL6, IL10, IL13, IFNγ and IL2. Briefly, supernatants were 
centrifuged for 10 min to remove debris and 25 ml were added to 25 ml of assay buffer. Then 
25 ml of magnetic beads coated with specific antibodies were added to this solution and 
incubated for 2 h under shaking. At the end of the incubation, the plate was washed twice in 
buffer and incubated for 1 h with 25 ml of a secondary biotinylated antibody at room 
temperature. Then, the plate was incubated for 30 min with Streptavidine Phycoerythrin, 
washed twice, and incubated with 150 ml of sheath fluid for 5 min. The plate was observed 
immediately on a Luminex_ 100_/200_platform (Luminex Corporation) with xPONENT 3.1 
software. Standard curves for each cytokine were generated (in duplicate) by using the supplied 
reference cytokine concentrations. Cytokine/chemokine concentrations in the samples were 
determined with a 5-parameter logistic curve. Final concentrations were calculated from the 
mean fluorescence intensity and expressed in pg/ml. The assay was performed in a 96-well 
plate, using all the assay components provided in the kit. All incubation steps were performed 
at room temperature and in the dark. 
 
Statistical analysis 
Statistical analyses were performed using Student’s t-test. Data indicated with * and ** were 
considered statistically significant (p value *< 0.05; **<0.01). Data are presented as mean ± 
SD (n = 3). Incubations were performed in triplicate and experiments were carried out 
separately in cells from at least 3 different donors.  
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Figure S2. Structure of multi-walled carbon nanotubes functionalized with fluorescein isothiocyanate (OX-
MWCNT-FITC). 
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Figure S3. Uptake of OX-MWCNT-FITC by human primary immune cells. A) Peripheral blood 
mononuclear cells (PBMCs) were either left untreated or incubated for 24 h with 1, 10 and 100 μg/ml of OX-
MWCNT-FITC. Uptake of increasing doses of fluorescent CNTs was investigated into T cells (CD3+) and 
monocytes (CD14+) after 24 h incubation in static controls on the left or in microgravity on the right. The 
highest uptake was detected at 100 μg/ml concentration in both cell types and conditions. B) f-CNT uptake 
was also assessed by confocal microscopy. PBMCs were incubated with 100 μg/ml of f-CNTs for 24 h and 
visualized by a Microradiance Nikon Eclipsa from Biorad (40 X). Microgravity conditions (bottom) were 
compared with static controls (top). Cells on left image are reported on the right as consecutive plans from 
the top to the bottom showing the presence of f-CNTs into the cytoplasm. Experiments were repeated three 
times with similar results. 
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Graphene oxide (GO) is attracting great interest in biomedical sciences. The impact of GO on 
immune cells is one fundamental area of study that is often overlooked, but critical in terms of 
clinical translation. This work investigates the effects of two types of thoroughly characterized 
GO sheets, different in their lateral dimension, on human peripheral immune cells provided 
from healthy donors using a wide range of assays. After evaluation of cell viability, the gene 
expression was analyzed, following GO exposure on 84 genes relat- ed to innate and adaptive 
immune responses. Exposure to GO small sheets was found to have a more significant impact 
on immune cells compared to GO large sheets, reflected in the upregulation of critical genes 
implicated 
in immune responses and the release of cytokines IL1β and TNFα. These findings were further 
confirmed by whole-genome microarray analysis of the impact of small GO sheets on T cells 
and monocytes. Activation in both cell types was underlined by the overexpression of genes 
such as CXCL10 and receptor CXCR3. Significant energy-dependent pathway modulation was 
identified. These findings can potentially pave the foundations for further design of graphene 
that can be used for immune modulation applications, for example in cancer immunotherapy. 
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 In the last few years, thanks to their remarkable characteristics and unique properties, 
there has been enormous interest in nanomaterials, including graphene [1], among the scientific 
community and the public [2]. Pristine graphene and graphene oxide (GO) have been used in a 
growing number of biomedical applications for therapy and diagnosis such as drug delivery and 
photodynamic therapy [3, 4]. Most studies have focused on GO [5], thanks to its ability to be well 
dispersible in aqueous media [6], but more systematic studies are needed urgently to fully 
explore graphene in medicine [7]. Most studies to date using intravenous administration (i.v.) 
have indicated accumulation of graphene-based materials (GBM) in organs of the 
reticuloendothelial system (RES), mainly liver, spleen and lungs [8, 9]. Immune cells will be the 
initial biological components that will interact with the GBM [10]. A recent study on GO in vivo 
biocompatibility indicated an inflammatory response typical of a foreign body reaction [11]. 
Wang K et al. i.e studied the toxicity of GO after injection on mice and found that GO at low 
(0.1 mg) and middle dose (0.25 mg) did not exhibit clear toxic effects to mice, while at high 
dose (0.4 mg) the authors evidenced chronic toxicity. In this contribution, the authors 
underlined the importance of further work on the possible mechanism of interaction between 
GO and immune cells in human body or mice [9]. 
 Therefore, immunotoxicological evaluation is critical for most future clinical 
developments.  
The interactions and potential modulation of the immune system by GBM exposure may also 
offer interesting possibilities for the development of immunotherapeutics or novel vaccination 
strategies [12, 13]. The impact exerted by GBM exposure is still controversial. Different studies 
report good biocompatibility and no cellular damage after exposure to GBM [14, 15], while others 
have evidenced cell toxicity, manifested as enhanced apoptosis and necrosis [16, 17]. Such 
reported discrepancies can be due to differences in the characteristics of GBM in terms of 
dimension, functionalization and purification. 
  The impact of well-characterized GO of different dimensions on human monocyte-
derived macrophages (hMDM) has been reported [18]. However, in order to offer further 
understanding of the differential impact between large and small graphene flakes on the 
immune system, cell populations, other than macrophages, present in the systemic blood 
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compartment still need to be intensively investigated. Sasidharan et al. have considered the 
immune cell functionality besides biocompatibility, focusing on a few classic response 
parameters such as activation markers and cytokine production [19]. Although these approaches 
can elucidate the effect of GO flakes on the expression of some specific proteins, they are 
limited in their ability to provide a reliable insight into a global genomic effect that better 
reflects overall impact of exposure on the immune system. Our group previously described the 
effect of functionalized carbon nanotubes (f-CNTs) on immune cell activation [20, 21]. Moreover 
we and others underlined the importance of looking at the genomic level by using large genome 
expression analysis and high-throughput technologies to better understand the overall impact 
into immune cells [22, 23]. Recently, Chatterjee et al. used microarray analysis to investigate the 
effects on human liver cells of GO and reduced GO [24], but, to our knowledge, no report has 
used large genomic data approaches to investigate the impact of GO materials on immune cells. 
 In this work, we employed two types of thin GO flakes (between 1-2 graphene layers) 
thoroughly characterized by transmission electron microscopy (TEM), atomic force 
microscopy (AFM), Raman spectroscopy and several other techniques to determine lateral 
dimensions, number of graphene layers, and surface properties. Human peripheral blood 
mononuclear cells (PBMCs) from healthy donors were used. This pool of immune cell 
populations was able to provide closer relevance and insight to clinical conditions, rather than 
cell lines or specific sub-populations. The extent of early and late apoptosis, necrosis, cell 
activation, cytokine release were determined following exposure to the GO materials. The 
impact on 84 genes related to the immune response was then analyzed. Lastly, whole genome 
analysis was conducted on T lymphocytes (Jurkat cells) and monocytes (THP1 cells) as 
representative populations of the adaptive and innate immune responses. 
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Materials and Methods 
Synthesis and characterization of graphene oxide 
Graphene oxide (GO) was prepared by the modified Hummers’ method in Ali-Boucetta et al. 
[7] with slight modifications. Briefly 0.2 g of graphite flakes (Barnwell, UK) was mixed with 
0.1 g of NaNO3 (Sigma-Aldrich, UK) and 4.6 ml of 96% H2SO4 (Fisher Scientific, UK). After 
obtaining a homogenous mixture, 0.6 g KMnO4 (Sigma-Aldrich, UK) was then added slowly. 
Temperature was monitored carefully during the reaction and was kept between 98−100°C. The 
mixture was further diluted with 25 ml of deionized H2O and 3% H2O2 (Sigma-Aldrich, UK) 
was added gradually for the reduction of the residual KMnO4, MnO2 and Mn2O7. The 
resulting graphitic oxide suspension was exfoliated and purified by several centrifugation steps 
until the pH of the supernatant was around 7 and a viscous orange/brown layer of pure GO 
appeared on top of the oxidation by-products and thick graphitic pieces. This layer was 
seperated carefully and diluted in deionized water. TEM was performed using a BioTwin 
electron microscope (Philips/FEI), Tecnai 12 instrument operated at 120 kV accelerating 
voltage. A drop of sample was placed on a formvar / carbon coated copper grid. Excess material 
was removed by filter paper. Lateral size distributions were carried out using ImageJ software, 
after counting the lateral dimension of more than 100 individual GO sheets, from several TEM 
images.  A multimode AFM was used on the tapping-mode with an E-type scanner, Nanoscope 
VI controller, Nanoscope v614r1 control software (Veeco, Cambridge, UK) and a silicon 
tapping tip (NSG01, NTI-Europe, Apeldoorn, The Netherlands) of 10 nm curvature radius, 
mounted on a tapping mode silicon cantilever with a typical resonance frequency 150 kHz and 
a force 14 constant of 5.5 N/m. Images were captured in air, by depositing 20μl of the GO 
dispersion on a freshly cleaved mica surface (Agar Scientific, Essex, UK) and allowed to adsorb 
for 30 seconds. Excess unbound material was removed by washing with filtered distilled water, 
and then allowed to dry in air. Thickness distributions were carried out using ImageJ software, 
after counting the height of approximately 100 individual GO sheets, from several AFM 
images. Fourier Transform Infrared Spectroscopy (FT-IR) at the mid-infrared range was carried 
out on dry samples using a PerkinElmer Spectrum 100 spectrophotometer and the transmittance 
results were analysed with the built-in spectrum software. Thermogravimetric analysis (TGA) 
we used a Pyris 6; Perkin-Elmer Ltd was used from 25 to 800◦ C at 10◦ C/ min. Samples (1-2 
mg) were weighed into a ceramic crucible. Nitrogen (20 mL/min) was used as a purge gas. 
Electrophoretic mobility (µ) was measured by Malvern Zetasizer Nano ZS (UK) after dilution 
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of samples with water in disposable Zetasizer cuvettes (Malvern Instruments). Default 
instrument settings and automatic analysis were used for measurements,  µ was converted 
automatically by the equipment software to zeta potential (ζ) values which is directly related to 
zeta potential by Henry’s equation [25]. All values for samples prepared are triplicate 
measurements, values were mean ± SD. For Raman spectroscopy all samples were recorded 
after preparing the aqueous dispersions and drop casting them on glass slides and evaporating 
the solvent. Measurements were carried out using a 50x objective at 633 nm laser excitation 
using a Renishaw micro-Raman spectrometer. An average of at least three different locations 
within each sample was measured. Absorbance spectroscopy of samples was measured by a 
Varian Cary winUV 50 Bio-spectrophotometer, USA. Samples were diluted 100 times in water 
before measurement in a 1ml glass cuvette with 1 cm path length. Dual beam mode and baseline 
correction were used throughout the measurements to scan the peak wavelength and maximum 
absorbance between 200 and 800 nm.  
 
Cell culture, viability and activation 
 Jurkat cells (T cell line), THP1 (Monocyte cell line) and peripheral blood mononuclear cells 
(PBMCs) were cultured as previously reported [22]. PBMCs were obtained from EDTA-venous 
blood samples from informed healthy male donors (25-50 years old) using a standard Ficoll-
Paque (GE Healtcare) separation.  Informed signed consent was obtained from all the donors. 
The cytotoxicity was evaluated by Flow cytometry (FACS Canto, BD Biosciences, Mountain 
View, CA, USA). PBMCs were incubated for 24 h. with increasing doses of GO-S and GO-L 
(25, 50 and 75 µg ml-1). Ethanol was used as a positive control, while samples incubated with 
cell medium alone was used as negative control. All staining kits were purchased from 
Invitrogen, CA, USA: Annexin-V FITC (apoptosis), LIVE/DEAD FITC (late apoptosis and 
necrosis), propidium iodide (necrosis). PBMCs were treated with GO at the intermediate 
concentration of 50 µg ml-1 and stained to identify immune cell populations and activation 
markers, CD25 and CD69 (APC-conjugated anti-CD25, 2A3 clone, PE-conjugated anti-CD69, 
L78 clone, BD-Bioscience Mountain View, CA, USA). Concanavalin A (ConA, 4 μg/ml) and 
lipopolysaccharides (LPS, 2 μg/ml) were used as positive controls (Sigma-Aldrich, St. Louis, 
Missouri, USA). Staining with fluorochrome-conjugated monoclonal antibodies was performed 
in the dark for 20 min. Cells were analyzed by flow cytometry.  
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Immune gene array, cytokine assay, microarrays. 
Total RNA was extracted and RNA purification was performed with TriZol Reagent (TriZol, 
Invitrogen, Carlsbad, CA, USA). After extraction, cDNA synthesis was performed using a 
SuperScript III reverse transcriptase (Invitrogen, Carlsbad, CA, USA). The expression of 84 
immune response genes were performed with a RT2 Profiler PCR Array (PAHS-052ZD, 
Superarray Bioscience Corporation, Frederick, MD), (instrument CFX96 Bio-Rad).  Cell 
culture supernatants from PBMCs were used to quantify the secretion of cytokines using a 
MILLIPLEX MAP 10-plex Cytokine Kit (HCYTOMAG-60K -10, Millipore, Billerica, MA) 
(IL1α, IL1β, IL2, TNFα, IFNγ, IL6, IL8, IL10, IL4, Rantes). Experiments and statistical 
analysis were performed as previously showed [22]. Total RNA was extracted and purified using 
the RNAeasy mini kit (Qiagen, Valencia, CA, USA). RNA purity was assessed by 
spectrophotometric analysis and integrity by microfluidic molecular sizing using the 
Bioanalyzer 2100 (Agilent). Samples with RIN (RNA Integrity Number) less than 8 were 
discarded. RNA (1 μg) was converted in cRNA and labeled (Illumina totalPrep RNA 
amplification kit, Ambion). Biotinylated cRNA was hybridized onto the Illumina HumanHT-
12 v4 (Illumina, Inc., San Diego, CA, U.S.A.). The Illumina HumanHT-12 v4 interrogates the 
expression of 47.000 gene probes derived from the National Center for Biotechnology 
Information (NCBI) Reference Sequence RefSeq Release 38 (November 7, 2009) and other 
sources. Probe intensity and gene expression data were generated using the Illumina 
GenomeStudio software V2011.1 (Gene Expression Module V1.9.0).  
 
Statistical analysis. 
Statistical analyses for Raman ID/IG and D band width were performed using Student’s t-test 
(two-side p value < 0.05). Data for Raman analysis and zeta potential are presented as mean ± 
SD. Data analysis for flow cytometry was performed using FACSDiva software (BD-
Bioscience Mountain View, CA, USA).  All the experiments were performed at least in 
triplicate. Statistical analyses for multiple cytokine assays were performed using Student’s t-
test. Data indicated with a star were considered statistically significant (two-side p value <0.05). 
Data are presented as mean ± SD. Multiplex ELISA tests on isolated human primary PMBCs 
were performed in samples from at least 3 different donors. Immune gene array data were 
analyzed by the comparative threshold cycle (CT) method.  Relative quantification of gene 
expression using the 2−ΔΔCt method correlated with the absolute gene quantification obtained 
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using a standard curve. Data were analyzed with RT2 profiler PCR array data analysis software 
(http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php). Whole genome expression 
measurements were extracted and normalized using the Illumina Genome Studio software 
V2011.1 (Gene Expression Module V1.9.0). The same software was used for QC analysis of 
the Beadchips. Statistical analysis and visualization of gene expression data were performed 
using BRBArrayTools, developed by R. Simon and the BRBArrayTools Development Team 
(http://linus.nci.nih.gov/BRB-ArrayTools.html). We identified genes that were differentially 
expressed among the two classes by using a multivariate permutation test [26]. We used the 
multivariate permutation test to provide 80% confidence that the proportion of false discoveries 
did not exceed 5%. The test statistics used are random variance t-statistics for each gene [27]. 
Although t-statistics were used, the multivariate permutation test is non-parametric and does 
not require the assumption of Gaussian distributions.   
 We identified gene ontology (gene on.) groups of genes whose expression was 
differentially regulated among the classes. This analysis is different than annotating a gene list 
using gene on. categories. For each gene on. group we computed the number n of genes 
represented on the microarray in that group, and the statistical significance P value for each 
gene in the group. These P values reflect differential expression among classes and were 
computed based on random variance t-tests or F-tests. For a gene on. group, two statistics are 
computed that summarize the p values for genes in the group; the Fisher (LS) statistic and the 
Kolmogorov-Smirnov (KS) statistic as described in (Simon R and Lam A. BRB-ArrayTools 
User Guide, version 3.2. Biometric Research Branch, National Cancer Institute; 
http://linus.nci.nih.gov/brb).  Samples of n genes are randomly selected from genes represented 
on the array and the summary statistic computed for those random samples. The significance 
level associated with the gene on. category is the proportion of the random samples giving as 
large a value of the summary statistic as in the actual n genes of the gene on. category. For each 
gene on. category, two significance levels are computed, corresponding to the two summary 
statistics. We considered a gen. on. category significantly differentially regulated if either 
significance level was less than 0.01. We considered all gene on. categories with between 5 and 
100 genes represented on the array. Some of the categories were overlapping.  We also uploaded 
the gene expression data to the “ingenuity Pathway analysis” (ipa) to visualize the expression 
levels of genes in relevant pathway charts. 
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Graphene Oxide (GO) material characteristics 
 Structural characterization using TEM and AFM imaging techniques of small GO sheets 
(GO-S) and large GO (GO-L) is shown in Fig.1A and Supporting Fig. S1A-D. The lateral size 
distribution is shown in Fig. 1B for both GO-S (100-500nm) and GO-L (1-10μm) determined 
from analysis of several TEM images. AFM height images revealed that the sheets were 1 or 2 
layers thick (1-2 nm). Thickness distribution for GO-S is shown in S. Fig. 1E, however for GO-
L it were proven technically more challenging to obtain accurate thickness distributions due to 
folding and wrinkling that commonly distorted measurements. Despite that, in the few GO-L 
sheets accurately measured, thickness between 1-2nm was observed. FT-IR was used to identify 
the functional groups on the surface of GO (Fig. 1E). Both GO samples showed a broad band 
around 3100-3600 cm-1 due to the O-H stretching vibrations, and an intense peak at 1730 cm-1 
for the C=O stretching vibrations. Aromatic and unsaturated bonds were apparent by the intense 
band at 1590 cm-1 and the broad band around 3000 – 3100 cm-1. Several bands were detected 
around 1000-1070 cm-1 for the epoxy (C-O-C) symmetric stretching vibrations [28]. FT-IR 
spectra confirmed that the oxidation resulted in the formation of hydroxyl, carboxyl and oxide 
groups with the presence of aromatic regions, typical of GO materials [29], with very little 
differences between the two types of GO (the starting graphite material did not show any 
distinct peaks in the FT-IR spectrum).  
 Quantification of the functional groups was also correlated by thermogravimetry (TGA) 
(Fig. 1F). TGA curves for the two GO materials and the starting graphite were obtained. Two 
main weight loss steps were observed after subtracting 10% due to evaporation of the water 
content up to 100oC (S. Tab. 1). The first mass loss in the TGA curves between 100 and 260oC 
was due to the decomposition of the labile oxygen groups (such as carboxylic and aldehyde 
groups) and the removal of any residual water. The second weight loss occurred between 260 
and 460oC and was due to the pyrolysis of the stable oxygen groups (mainly epoxides) [30]. No 
significant differences in the TGA melting curves were detected between GO-S and GO-L 
material. However, they were both significantly higher than graphite, which further confirmed 
their extensive surface oxidation. Raman spectra (Fig. 1G) indicated bond stretching of sp2 
hybridized carbon atoms resulted in the distinct Raman G band around 1590 cm-1 [31] in all 
samples. This band appeared wider and slightly blue shifted in both GO samples compared to 
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graphite. The D band at 1330 cm-1 due to disorder [32] created during oxidation was more distinct 
in the GO samples, while the 2D band near 2700 cm-1 disappeared, compared to the starting 
graphite. The D-to-G band intensity ratio (ID/IG), corresponding to a disorder metric [31] is also 
shown for each spectra (Fig. 1G). No statistical significance (using Student’s t-test) was 
detected between the two GO samples (GO-S and GO-L) in both ID/IG ratio and also in the D 
band width, however both were significantly different than the starting graphite.  
 
Figure 1. Physicochemical characterization of GO-S and GO-L. (A) Representative TEM images (left) and 
AFM images (right) of GO-S and GO-L (all scale bars are 1.5µm); (B) Size distribution detected by counting more 
than 100 GO sheets from several TEM images of GO-S and GO-L; (C-F) FT-IR spectra, TGA curves, Raman and 
UV-visible spectra respectively, for GO-S (red) and GO-L (blue) compared to the starting graphite (black). 
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 In terms of surface charge, both GO samples were strongly negative, due to the multiple 
surface oxygen groups (S. Fig. 1F), but GO-L was of slightly higher negativity compared to 
GO-S. UV-Visible spectroscopy was then used to confirm the optical properties of the GO 
structures. Both GO samples showed a characteristic absorbance peak around 230 nm, with a 
shoulder around 300 nm with slight difference between the two samples, while graphite had 
featureless spectrum with high scattering due to the poor aqueous solubility (Fig. 1H). Such 
absorbance peaks have been described to arise from the delocalization of the π electrons due to 
the oxidation process, the 230nm peak due to C-C transitions, while that at 300nm due to C=O 
transitions [33]. 
 
Cell viability and activation markers 
The first step in the interaction with immune cells was to study the impact in dose response of 
the two GO materials on cellular viability of PBMCs from healthy donors (Fig.2). Different 
staining for FACS were performed to detect: i) early apoptosis, ii) late apoptosis, iii) necrosis. 
AnnexinV staining showed the absence of a significant number of early apoptotic cells in 
treated samples at all tested GO concentrations (Fig.2A). An amine-reactive fluorescent 
staining was used to detect cells with compromised membranes (late apoptotic and necrotic 
cells) (Fig.2B).  
 
Figure 2. Viability of human primary immune cells. PBMCs were incubated for 24 hours with GO-S and GO-
L at increasing doses of 25, 50, and 75 μg ml-1 or left untreated (medium), ethanol was used a positive control. (A) 
Early apoptosis was assessed by Annexin V staining. (B) Data from staining with an amine-fluorescent dye able 
react with amine free of compromised membranes of late apoptotic and necrotic cells. (C) To detect necrotic cells, 
propidium iodide staining was performed. Experiments were performed at least in triplicate and analyzed by flow 
cytometry; (* = P value <0,05). 
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The materials did not show significant cell toxicity. The only exception was a reduction in cell 
viability at high doses (75 µg ml-1) for GO-S. The percentage of dead cells was then evaluated 
by propidium iodide staining (Fig.2C). Cell viability at exposures of 25 µg ml-1 GO was similar 
to controls, whereas at GO concentrations of 50 and 75 µg ml-1
 
PBMCs displayed mortality 
levels ranging between 15% and 20%, a statistically significant value when compared to the 
controls, but still very low in relation to the positive controls (Fig. 2). To investigate the 
functional impact of GO exposure on primary immune cells, considering their activation as a 
crucial endpoint, we measured the expression of CD69 and CD25 markers (S. Fig. 2). CD69, a 
member of the C-type lectin superfamily (Leu-23), is one of the earliest cell surface antigens 
expressed by immune cells following activation, while CD25 (alpha chain of the IL-2 receptor) 
is a late activation antigen. CD69 and CD25 expression in GO-exposed samples was 
comparable to the untreated negative controls (S. Fig. 2).  
 
Immune gene expression array 
 To evaluate the possible effect on key pathways controlling innate and adaptive immune 
response, we performed a deep genomic analysis on the expression of a large number of highly 
selected immune genes (Fig. 3). The impact on GO-L or GO-S treated PBMCs was assessed 
by a 84 immune genes array. As a first step, the expression ratio between GO-L or GO-S and 
control samples for all 84 genes were clustered and displayed as heat map where individual 
elements of the plot are colored according to their standardized expression values (Fig.3A; red 
squares= up-regulated genes; green squares= down-regulated genes). The major impact on gene 
expression due to GO-S exposure was apparent when compared to the values obtained for GO-
L (heat map values and gene names are reported in the S. Fig. 3). To better illustrate the 
different effects between GOs on the gene expression, the standardized expression values of 
modulated genes are also displayed as a heat-map detail in the Fig. 3A for the control, GO-S 
and GO-L samples, respectively (Fig.3B; red squares= high expression; green squares= low 
expression). The bright red strip marks indicate the enhanced effects of GO-S compared to GO-
L. All genes reported in Fig.3B were up-regulated in GO-S, while GO-L samples displayed 
values similar to the untreated controls. By using a fold regulation cutoff (FR>4, both 
directions) we identified 16 up-regulated genes for GO-S and 5 up-regulated genes for GO-L 
(Fig. 3C and 3D).  
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Figure 3. Immune gene expression array. A) Heatmap comparison of 84 genes after exposure to GO-S or GO-
L. Genes were displayed for fold-change variations in respect to the controls and colored by their standardized 
expression value (Red= high expression, green= low expression). B) Heat map detail showing the immune 
transcript upregulated by GO-S in PBMCs; data are reported as mean of experiments carried out in triplicate. C) 
Scatter Plots chart. Genes upregulated with fold change greater than 4 are showed with red round, gene with fold 
change less than 4 are showed with green round; in black unmodulated genes. D) Table of modulate genes in GO-
S e GO-L versus control. Red show genes with a fold change greater than 4, green show genes with a fold 
regulation less than 4. E) Analysis of representative GO-S and GO-L modulated genes, summarized into their own 
pathways expressed as 2 Δct values (* P value <0,05). 
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Moreover, we found that GO-L was able to induce down-regulation of 4 immune genes 
compared to only 1 of GO-S with a fold change minor than 4 (Fig. 3C and 3D).  Most 
modulated genes were up-regulated compared to control samples, as it can also be more easily 
observed in the scatter-plot shown in Fig.3C. Some of the genes that offered a statistically 
significant difference in expression were: CSF2, TNF, IL6, IL10, CD80, IL1, IL1R1, TICAM1, 
IL8, IL23A, NFKB1, TBX21, CD40, CCR6 and IFNAR1. All of them were up-regulated at 
least 4-fold in GO-S treated samples. A list of all the modulated genes by GO-S and GO-L 
exposure, in terms of at least a 4-fold down or up regulated, is displayed in Fig. 3D.  
To better understand the involvement of specific pathways in the possible immune system 
modulation process triggered by GOs, we looked at the expression of specific groups of genes 
involved in controlling precise signaling aspects of the immune response (Fig. 3E). By looking 
at the RNA expression levels as 2-avg.ΔCt values, we queried several pathways including Th1 and 
Th2 immune response, pattern recognition receptor (in particular toll-like receptors), 
cytokines/chemokines and cytokine receptors. We observed that following GO-S treatment, a 
marked up-regulation of genes involved in the Th1 immune response such as CD80 and TBX21 
occurred (Fig. 3E). Regarding the toll-like receptor (TRL) pathways, TLR3, TLR5 and TLR9 
showed a fold regulation greater than 2 (S. Fig. 4). The most regulated was TLR2 by GO-S (p-
value <0.05) (Fig. 3E). Cytokines/Chemokines and cytokine receptors up regulated by GO-S 
(p-value <0.05) were: IL1R1, IFNAR1, CSF2, TNF, CCL5, IL6, IL1α, IL1β and IL8. 
 
Cytokine secretion assay 
 To investigate the cytokine production, multiplex ELISA was used to measure IL1β, 
TNFα, IL10, IL6, IL8, IL2, IFNγ, IL4 and CCL5 (Fig. 4). Both types of GO were able to 
stimulate the release of some of the cytokines analyzed such as IL1β, IL1α, TNFα and IL10 (p-
value < 0.05). The production of IL1β, TNFα, IL10 was significantly induced by GO-S 
exposure (Fig.4A). IL6 and IL8 increased equally following treatment with either types of GO 
(Fig.4B). On the other hand, IL2, IFNγ, IL4 and CCL5 production were not stimulated by either 
GOs (Fig.4C). 
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Figure 4. Cytokine secretion assay. Cytokine release was assessed by ELISA on PBMCs. Cells were incubated 
with GO-S and GO-L at 50 μg ml-1 . After 24h the supernatants were collected and analyzed for the secretion 




Whole genome expression analysis 
 
 Since a significant impact from GO-S exposure was revealed in terms of immune-
related gene and protein up-regulation, we wanted to further investigate the effects on whole-
genome expression at a higher definition. To achieve this goal we used the microarray approach 
(Illumina Beadchip technology) looking at more than 47000 genes on GO-S treated T 
lymphocyte cell line (Jurkat cells) and monocyte cell line (THP1 cells). Unsupervised Multi-
Dimensional Scaling (MDS) identified four well-separated clusters identifying cell type and 
GO-S treatment as the parameters correlated to the first two components of variability (Fig.5A). 
To compute the probability of genes being differentially expressed, we used a random variance 
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t-test as implemented in BRB Array-Tools. To control the false discovery rate (FDR) in our list 
of genes, we used a permutation test to provide evidence that family-wise error rate was less 
than 5% within the 80% confidence interval (CI). Using this cutoff value (FDR<5%, CI 80%), 
we identified, for T cells, 738 genes up-regulated (FC >1) and 409 genes down-regulated (FC 
>1) out of 1147 genes differentially expressed (S. Tab. 2). In monocytes, 243 genes were up-
regulated (FC >1) and 333 were down-regulated (FC >1) out of 576 total genes identified, 
compared to the control group (S. Tab. 3). 
 
Figure 5. Gene expression analysis. A) 3D cluster graph identifies two different cell types treated and untreated 
with 50 μg ml-1 of GO-S. B) Heatmap and Venn diagrams show the number of probe-sets differently modulated 
by comparison of T cell and monocytes gene sets resulting after GO-S treatment, overlapping areas indicate the 
number of transcripts commonly modulated in both cell types. The heatmap indicate the change in expression in 
each subset (Red= high expression, green= low expression). 
 
As can be observed in Supporting Tables 2 and 3 all the genes passing the cut-off value were 
tabulated along with parametric p-value, fold change and links to major annotation sources. We 
clustered in a Venn diagram the genes differentially expressed in three groups (T cells, both T 
cells and monocytes, and monocytes) and displayed their standardized expression values as 
heat-maps (Fig. 5B). Only 341 significantly modulated genes were common in both cell lines, 
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and only one of these was differently regulated. We searched for evidence suggesting the 
consistency of our gene expression data with known features of the analyzed cell lines and with 
the results from our previous experiments in the immune gene arrays (Fig. 3). 
 The previous observations made using the immune array were confirmed since the 
analysis showed increased expression of genes such as: IL10, CCL5, CCR6, TYK2, IFNAR1, 
IRAK1, STAT6 in both cell types, CSF2, HLA-A, IL18, TLR9 and NFKB1 in T cells and 
DDX58, TLR3, TLR6, TLR7 and STAT3 in monocytes. To better understand at the 
mechanistic level the physiological significance of the changes in gene expression observed, 
we used the gene set comparison tool in BRB Array-Tools as a scoring tool to assign the 
functional category definitions according to the Gene Ontology Database. As a result, 559 and 
532 gene sets were scored as significantly modulated in monocytes and T cells, respectively 
(Supp.Tab.4 and 5). The immune activation mediated by GO-S was confirmed by the over 
expression of some relevant pathways: T cell migration, regulation of T cell chemotaxis, 
macrophage activation, receptor signaling involved in phagocytosis and leukocyte chemotaxis 
pathways (Fig. 6 A). In particular, we found an up- regulation of genes closely related to 
inflammation such as CCL5 and the induction of the chemokine pathways such as CXCL10 
ligand pathway and CXCR3 receptor (Fig. 6 A, red box). We confirmed this trend using the 
ingenuity pathways analysis (IPA) software. Figure 6B highlights the up-regulation of some 
genes that correlated with inflammation, illustrating the GO-S induced activation in T Cells. 
On monocytes, the IPA analysis did not reveal a significant activation on the same pathway. 
 This trend was confirmed also by the induction of IL10 pathway in T cells, displayed 
using IPA, by which we obtained a clear up-regulation pathway of IL10 and IL10R (S. Fig. 
5A). Thus, IL10 overexpression is IL1-mediated by the induction of SP1 transcription factor 
(S. Fig. 5A). By contrast the absence of stimulation of IFNγ was also confirmed with the IFNγ 
pathway analysis. We have seen a marked down-regulation of STAT1 in T cells, the principal 
effector of IFNγ mediated cell activation (S. Fig. 5B). 
Modification of cell metabolism was evident in both cell lines, characterized by the down-
regulation of transcripts involved in the oxidative phosphorylation, mitochondrial ATP 
synthesis coupled proton transport and protein synthesis (large and small ribosomal subunit 
pathways) (S. Fig. 6), including cellular and mitochondrial ribosomal S and L proteins such as: 
RPS17, RPS26, RPS27, RPS27A, RPL4-RPL10, RPL39L (S. Fig. 6). Conversely, transcripts 
encoding glycolytic enzymes were up-regulated (S. Fig 6).  
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Figure 6. Gene expression of GO-S modulated pathways. A) Heatmap representation for relevant modulated 
pathways using Gene Ontology categories. B) Inflammation pathway in T cells after treatment with GO-S. The 
image was done with Ingenuity software. Bold lines indicate direct interaction, dotted lines indicate indirect 
interaction. Genes up-regulated by GO-S are highlighted in red, genes down-regulated are highlighted in green.  
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 There is a rapidly growing literature on the use of graphene-based materials, particular 
in its oxide form (GO), for biomedical uses [6, 34]. Compared to carbon nanotubes (CNTs) [20, 35] 
graphene has a larger available surface area [36] making it highly promising in the context of 
drug delivery and imaging [37]. As for any other nanomaterial designed to be a drug carrier, it is 
important to understand the possible adverse responses to GO and particularly its impact on the 
immune system [38]. Until today, there has been an inconclusive discussion whether GO should 
be considered immune-compromising or not [12]. As we previously reported for CNTs, the 
immune impact could be different between GOs with different lateral dimensions and 
functionalization [12]. Sasidharan et al. underlined that the toxicity effects of pristine graphene 
towards macrophage cells can be easily averted by surface functionalization [16, 19]. However, 
other studies are needed on the effect of different functionalized GOs on immune cells ex vivo 
and in vivo in order to assess the appropriate functionalization strategy. 
 The present study reports on the impact at the molecular level of well-characterized GOs 
on primary human immune populations. Previous works have studied only one or two cell 
population types, not in a complex human ex vivo cell pool [19, 39]. We carried out the present 
study on PBMCs from healthy donors that included different cell populations, T cells, B cells, 
monocytes, dendritic cells and natural killer cells to better reflect the effects on the pool of cell 
populations relevant to in vivo immune responses. 
 Regarding the graphene material characteristics, the question of whether the GO lateral 
dimensions can be a determinant factor of biological effects has been highlighted [4]. In this 
study GO of two different sizes (GO-S and GO-L) were prepared and characterized in terms of 
shape, structure, lateral size, thickness, functionalization, optical and surface properties. The 
two GO samples were only significantly different in lateral dimension as determined by TEM 
and AFM, while no significant differences were found in other properties. The second step was 
to characterize their possible cytotoxic effect and the impact of GO-S and GO-L on immune 
cell populations. We did not find significant differences in human PBMCs viability by the 
exposure to both GO types. Such findings were in agreement with previous studies on 
macrophages [18, 40]. Only few studies have been performed to date to understand the effect of 
graphene on the immune system [12], and in addition most previous work has focused only on 
the impact from graphene oxide exposure on traditional immunity markers, such as surface 
cluster of differentiation and cytokine release [15, 41]. 
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 The understanding of how the immune system is regulated and responds to 
nanomaterials cannot overlook the genomic level [22, 42]. Chatterjee et al. used an OMICS 
strategy to characterize the GO impact on hepatocytes (HepG2 cell line). They found a strong 
cytotoxic response induced by reduced GO mediated by a strong activation of ROS pathways 
[24]. Following these considerations, we used here for the first time an OMICS approach to point 
out the global function of exposure of small-sized sheets of GO (GO-S) on immune cells using 
bead array Illumina technology. To the best of our knowledge, no work used a genomic 
approach to point out the interaction of different GOs with immune cells today.  
 In this study we found a well-detectable difference in immune gene expression profiling 
between the two GO types. Our results suggest that the different sizes of GO flakes can impact 
PBMCs at the molecular level. This finding was also in agreement with Russier et al. [18], that 
focused only on macrophages to demonstrate that the small size of GO can have a higher impact 
compared to the large size GO. Based on this data, Bianco and colleagues have proposed “the 
mask effect of graphene” suggesting that the small size GO has the capacity for higher 
interactions with the cell membrane, a greater ability to enter into the cells and, therefore, 
inducing more biological effects compared to large-sized GO [18].  
In our work the effect of GO-S particularly enhanced genes such as IL1, IL6, IL10, TNF, CD40, 
CD80 and CSF2 related to the innate response and also other genes such as TBX21, CD86 and 
CCL5 related with the adaptive immunity, not leading to apoptosis or necrosis. Moreover, the 
only 5 genes up-regulated by GO-L are also responsible for an innate immune cell response. 
Our results are in agreement with Zhi et al. who showed that the incubation with GO induced 
a specific activation of the innate immune system with a secretion of primary pro-inflammatory 
cytokines such as IL6, TNF and IL1β [43]. The data obtained in our study by immune array 
provided convincing evidence that the adaptive immune response is not directly but indirectly 
affected by GO-S, due to the major effect on antigen presenting cells in terms of activation. 
Indeed, genes implicated in direct T cell activation such as IL2 and IFNγ were not influenced. 
This was in perfect agreement with the absence of CD69 and CD25 expression, which is related 
to the IL2 secretion.  
To confirm the indirect activation of T cells we showed a clear enhancement of CD80 
and TBX21, essential genes for efficient cell-mediated recruitment of T cells [44]. These 
observations were further supported by whole genome array data that identified the immune 
activation of some relevant pathways correlated with T cell chemotaxis: T cell migration, 
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regulation of T cell chemotaxis and leukocyte chemotaxis pathways. Intriguingly, we found in 
both T cell and monocytes the modulation of CXCL10 ligand pathway and CXCR3 receptor, 
commonly activated during acute inflammatory processes [45]. The main mechanism of action 
of immunotherapeutic agents (i.e. anti-CTLA4 mAbs) is represented by the induction of 
specific chemokines (such as CXCL10 and CXCR3). These chemokines, by binding to their 
corresponding receptors activated T helper 1 cells and NK cells which can mediate tumor 
rejection [46]. 
 We previously showed that functionalized CNTs could act only as ‘monocyte activating 
tools’ [22], while here we found that GO-S could impact on both T cell and monocyte gene 
expression. Indeed a direct impact of GO-S on T cells was found, with 1148 genes differentially 
expressed (738 genes up-regulated, FC >1) (Supp. Tab. 2). We evidenced also the impact on 
TLR expression. Chen et al. found a GO-mediated TLR9 modulation inducing the expression 
of TNF receptor-associated factor 6 (TRAF6) that we have seen modulated also in our studies, 
thus suggesting a similar induction mechanism [47]. However, further experiments will be 
needed to assess a possible toll-like receptor mediated interaction i.e. with specific siRNAs. 
Moreover, the GO-S mediated secretion of IL1β and TNF cytokines is closely related to 
lymphocyte recruitment factors promoting the TLR mediated NF-kB and MAPK pathway 
activation, and is associated with the TRAF family. Speculatively, we consider that GO-S could 
elicit an innate but also an adaptive response providing strong recruitment of immune cells (in 
tumors for example), offering alternative strategies towards nano-immunotherapeutics as 
suggested by Goldberg for other nanomaterials [13].  
 Another interesting effect of GO-S was on cell metabolism with a strong modulation of 
energetic pathways by a down-regulation of oxidative phosphorylation (OX-PHOs) and 
mitochondrial ATP synthesis (S. Fig. 6) followed by a switch-on of glycolytic pathways in both 
cell types. Normally the metabolic switch occurs in cancer cells that change their metabolic 
phenotypes to adapt to microenvironmental modifications giving a selective advantage to 
cancer cells under an unfavorable environment [48]. Fantin et al. [49] confirmed the metabolic 
switch of cancer cells by a glycolysis suppression, through the use of inhibitors such as lactate 
dehydrogenase A (LDH-A). They found significant inhibition of tumor proliferation when 
glycolysis was suppressed. Intriguingly, our data indicated that GO-S was able to strongly 
down-regulate the oxidative phosphorylation pathways in the cell lines tested. This result was 
in agreement with the proteomic results of Zhou et al. [50] that showed a GO-induced inhibition 
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of breast cancer cell metastases by selective down-regulation of the protein PGC-1α, which 
accounts for the inhibition of OX-PHOs. Following these findings, a future perspective is the 
development of a nanosystem able to combine the action of our GO-S against the activation of 
oxidative phosphorylation pathway, with a targeted suppression of glycolysis through inhibitors 
such as LDH-A, may be effective in blocking cancer cell proliferation. 
 
Conclusion 
This work presented a wide-range approach to analyze the immunotoxicological impact of 
differently sized GOs on human PBMCs from healthy donors not previously reported. We 
demonstrated that different dimensions of 2D graphene materials could regulate the immune 
response and eventual biological responses of immune cells reflected in the differential immune 
gene and activation molecule expression patterns. We found that thin (few layer) GO sheets 
with small (100-500 nm) lateral dimensions had a more pronounced effect on immune cells. 
Moreover, the whole genome expression assay data obtained from cells in response to small 
GO sheet interactions suggested many interesting pathways implicated that could in the future 
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S. Fig. 1 Further Characterizations of GO-S and GO-L. (A) and (B) are TEM images of GO-S and GO-L 
respectively. (C) and (D) are AFM images of GO-S and GO-L respectively. All scale bars are 1µm. (E) Thickness 
of GO-S sheets determined by counting the height of more than 100 GO sheets from several AFM images. (F) 



















































































Zeta Potential (mV) 
ζ=-40.9 ± 1.9 mV 
ζ=-66.8 ± 2.4 mV 
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S. Fig. 2. Impact of GO-Small and GO-Large on human primary cell activation markers. PBMCs were 
incubate for 24h with 50μg/ml of graphenes or left untreated. Cell activation was assessed looking at the expression 
of CD25 and CD69. Concanavalin A (4 μg/ml) and lipopolysaccharides (2 μg/ml) were used as positive controls. 
Analysis was assessed by flow cytometry. Statistical significance compared to untreated cells (student’s t test) is 
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S. Fig. 3 Heat Map description tab. Tables show the values of log 2 fold change for all genes taken into 
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S. Fig. 4. Modulate genes in GO-Small e GO-large versus control. Red show genes with a fold change greater 
than 2, green show genes with a fold change less than 2. 
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S. Fig. 5. Signal transduction pathway of IL10 (A) and IFNγ (B), after treatment with GO-Small. Over-
expressed genes are highlighted in red down-expressed are in green. Pathways were identified by ingenuty 




S. Fig. 6. Gene set enrichment with Gene Ontology. Identification of altered metabolism pathways after 





S. Tab. 1 Thermogravimetric analysis. 
  
Glycolisis 
Small ribosomal subunit 
GO Medium GO Medium 
  
Large ribosomal subunit  
GO Medium GO Medium 
GO Medium GO Medium 




ATP synthesis coupled H+ transport 
GO Medium GO Medium 
Tempreture (oC)  % Weight Loss Tempreture (oC)  % Weight Loss
GO-S
186,27 6,47 408,53 34,84 41,31
GO-L
165,97 5,59 389,35 41,41 47
Graphite
221,26 0,44 415,21 0,87 1,31
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Total % Weight LossSample
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Understanding the biomolecular interactions between graphene nanomaterials and human cells 
is a prerequisite for the utilization of graphene-based nanomaterials as a diagnostic or 
therapeutic tool. Currently, the impact of exposure to graphene and its derivate graphene oxide 
(GO) on the immune system remains elusive. To characterize the complex interactions between 
graphene nanomaterials and immune cells, we propose an integrative analytical pipeline 
encompassing the evaluation of molecular and cellular parameters. Single-cell mass cytometry 
was used to dissect the effect of GO flakes and GO functionalized with amino groups on 15 
immune cell populations, interrogating 30 markers at the single-cell level. Next we integrated 
single-cell mass cytometry with genome-wide transcriptome analysis and we could conclude 
that the amino groups reduce the perturbations caused by GO on cell metabolism and increase 
biocompatibility. Moreover, GONH2, but not GO, polarizes T-cell and monocyte activation 
toward a T helper-1/M1 immune response. These observations support the implementation of 
nanoscale platforms for immunotherapy, as vaccine carrier and nanoadjuvant. This study 
describes an innovative approach for the comprehensive analysis of nanomaterial interactions 
with distinct immune cells laying the foundation for the incorporation of single-cell mass 
cytometry for the characterization of nanomaterial immune cell interactions. 
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A the most promising frontier of nanotechnology is the development of nanomaterials for 
medical and diagnostic applications1. Graphene, a single layer of hexagonally arranged carbon 
atoms, and graphene oxide (GO), the oxidized form of graphene, are carbon nanomaterials 
characterized by extraordinary physicochemical properties and biocompatibility that enable 
their utilization in biomedical applications2, 3, 4.  The impact exerted by GO on the immune 
system is still unclear6, 7, 8, 9. Differences among reports could be attributed to variability in the 
physicochemical characteristics of materials used in terms of lateral dimension, 
functionalization, and purity.  Indeed, the role of  lateral size and chemical functionalization on 
the immunological proprieties of GO is poorly characterized and deserves further 
investigation14, 15, 16.  
The understanding of the complex interactions between nanoparticles and immune cells is 
hindered by insufficient implementation of high throughput, deep phenotyping technologies in 
the field10, 11, 12, 13. The immune system is a sophisticated machine meant to protect the body 
against pathogens or tumors. Its dysfunction can induce pathologies such as autoimmunity 
diseases, allergies and cancer17, 18. Revealing the interactions of different GOs with this 
complex system remains a challenge. A comprehensive study of nanomaterial-immune system 
interactions should include tool that permit multiplex analysis of cell type, activation status, 
and release of soluble mediators with stimulatory and inhibitory properties18, 19. 
 Flow cytometry has been primarily used to address single cell behavior through the 
measurement of multiple markers commonly associated with complex cellular systems such as 
the immune cells. Recently, a novel tool for flow cytometry analysis has been developed that 
leverages the precision of mass spectrometry. The combination of the two techniques, termed 
single-cell mass cytometry (CyTOF), allows the simultaneous measurement of more than 40 
cellular parameters at single-cell resolution with over 100 available detection channels. The 
improvement of computational algorithms is expected to double these numbers within the next 
few years20 therefore augmenting the ability to evaluate complex cellular systems and 
processes21. 
Compared to fluorescence-based cytometry, mass cytometry employs element-tagged 
probes that exploit the resolution of isotopes mass discrimination with minimal signal overlap. 
Furthermore, mass cytometry uses rare earth elemental tags that are not naturally found in cells, 
thereby avoiding the measurement of background cellular signal. All these attributes simplify 
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the large panel experimental design, thus uniquely enabling high-dimensional cytometry 
experiments not possible otherwise20, 22, 23, 24. For the first time in the context of 
nanotechnology, we demonstrate the use of single-cell mass cytometry to dissect the 
immunological effects of nanomaterials on individual cells. Thin GO flakes (single to few 
graphene layers) and GO conjugated to amino groups (GONH2)25 via epoxide ring opening 
were investigated (Materials and Methods). The physicochemical characterization of both GO 
and GONH2 is reported in the Supporting Information (Figure S1). Briefly, the morphology 
was studied by both TEM and AFM (Figure S1a-d). These techniques indicate that the lateral 
dimensions of both GO and GONH2 sheets ranged between approximately 50 nm and 1 µm, 
with a thickness corresponding to single to few (2-3) layers. The GONH2 sheets were shown to 
be approximately 3 times thicker than the non-functionalized GO. The increased thickness of 
graphene-based materials following functionalization has been reported and is attributed to the 
presence of functional groups on the surface26, 27. Raman spectroscopy evidenced the presence 
of the characteristic D and G bands (1330 cm-1 and 1595 cm-1, respectively) in both GO 
materials, confirming their graphenaceous structure. The I(D)/I(G) ratio, commonly used as a 
parameter of disorder28, did not increase significantly, as expected, since the epoxy ring opening 
reaction conditions used for amination do not add further defects to the GO surface29.  FT-IR 
measurements of the samples however, showed a clear difference between GO and GONH2. 
Importantly, the presence of an extra band in the 1260-1330 cm-1 range in GONH2 compared 
to the GO samples can be explained by the amine C-N stretching and C-H bending. 
Furthermore, the presence of a new band around 2900 cm-1, indicative of the presence of the 
aliphatic C-H stretch, supports the successful amination of GO by epoxide ring opening due to 
the presence of the TEG chain. These results confirm the successful production of both GO and 
GONH2 to be applied in our experiments25, 30.  
We used single-cell mass cytometry to analyze simultaneously 30 markers discriminating 
distinct subpopulations of peripheral blood mononuclear cells (PBMCs) to understand the 
response to nanomaterial exposure. CyTOF analysis allowed to check differential viability of 
15 immune cell subpopulations exposed to GO and GONH2 for 24 h. A concentration of 50 
µg·mL-1 was chosen for these experiments as it was identified as an appropriate concentration 
for different GO-based biomedical applications10, 15, 31. One qualitative difference between flow 
cytometry and mass cytometry is the absence in the latter of the spectral overlap that 
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complicates the analysis of fluorescence data. Another advantage is the absence of cell-
dependent background signals in the mass cytometry data32.  
Immune cell populations are identified according to the expression profile of “cluster of 
differentiations” (CDs) markers present on the cell surface. When immune cells go through 
different stages of maturation and differentiation the CD marker profiles change. Mass 
cytometry with its high dimensionality is an ideal approach to simultaneously characterize 
several cell markers. CyTOF could analyze the effect of GO and GONH2 on a wide variety of 
immune cell populations determining also different maturation and activation stages. To reduce 
the dimensionality of the dataset we used SPADE (spanning-tree progression analysis of 
density-normalized events) clustering algorithm (Figure 1a), as reported by Bendall et al32.  
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Figure 1. Cell viability analysis using CIS reagent with CyTOF. PBMCs were treated with GO and GONH2, 
at the concentration of 50 µg·mL-1. a) The SPADE tree plots show the different gated immune cell subpopulations. 
The size of each cluster in the tree indicates relative frequency of cells that fall within the dimensional confines of 
the node boundaries. Node color is scaled to the median intensity of marker expression of the cells within each 
node, expressed as a percentage of the maximum value in the data set (CIS is shown). b) The graph reports the 
CIS median intensity in all subpopulations analyzed. The analysis is made out of three experiments. Th: T-helper; 
CTL: Cytotoxic T lymphocytes. 
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To construct the SPADE tree, we used 11 cell surface markers in treated and untreated 
healthy human PBMCs to identify the major immune cell populations. Sixteen additional 
markers were acquired. Among them, five extracellular markers were used to better define cell 
subpopulations. The remaining 11 intracellular makers were employed for the cytokine 
detection, and were excluded from the tree construction. Each node in the two dimensional 
representation describes a n-dimensional boundary encompassing a population of 
phenotypically similar cells. The size of each node in the tree is proportional to the number of 
cells within each population. Node color is scaled to the median intensity of marker expression.  
The approach uses a minimum-spanning tree algorithm, in which each node of cells is 
connected to its “most related” node as a means to convey the relationships between the cell 
clusters. As a result, the 15 manually assigned populations were segregated in 200 nodes of 
distinct but logically interconnected populations. These trees provide a convenient approach to 
map complex n-dimensional relationships into a representative 2D structure32. In this analysis, 
cisplatin (CIS) was used as marker for viability33. CIS is a molecule able to enter into the late 
apoptotic and necrotic cells that have lost membrane integrity. The SPADE tree clustering 
shows that GO induced cytotoxicity in all B cell subpopulations (Figure 1a). Monocytes and 
activated Th cells were also affected by the presence of GO. On the other end, the functionalized 
GONH2 significantly reduced CIS signal in all subpopulations (Figure 1b, CIS median 
expression in distinct subpopulations). GONH2 highlighted 3 times more biocompatibility in all 
B-cell populations than non-functionalized GO. This effect was also evident in activated 
cytotoxic T Lymphocytes (CTLs) and Th cells, where GONH2 induced half of the GO toxicity. 
Overall, the functionalization of GO enhanced its biocompatibility towards the immune 
populations analyzed (Figure 1a-b) with the exception of natural killer (NK) cells and memory 
CTLs (see material and methods for gating strategy), in which both GO and GONH2 induced 
minimal cytotoxicity. These results emphasize the importance of the amino group 
functionalization on enhancing the biocompatibility of GO-based nanomaterials. Interestingly, 
the same type of functionalization used to modify GO was previously found to improve the 
biocompatibility of other nanomaterials such as carbon nanotubes11, 12 We further applied 
CyTOF to understand the functional impact of GO and GONH2 on the immune subpopulations. 
The heatmap visualizes the median expression values of all intracellular markers used for each 
immune population (Figure 2a). GO caused a broad, non-cell-specific activation triggering the 
production of all cytokines analyzed in a variety of cell populations (Figure 2a), while GONH2 
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was more specific affecting, for instance, the production of only few cytokines in selected cell 
subpopulations.  Among T-cells, GO induced the secretion of interleukin (IL) 2, 4 and 5 by Th 
and CTLs (Figure 2b).  
 
Figure 2. Analysis of the immune cell behavior using CyTOF. PBMCs were treated with GO and GONH2 at 
the concentration of 50 µg·mL-1labeled with markers of immune cell lineages and cytokines, detected with CyTOF 
2. a) Heat maps of median marker expression ratio for gated immune cell populations. Histograms of intracellular 
cytokine median expression. b) IL4, IL5, IL2 and TNFα in T-cell subpopulations. c) IL4, IL5 and IL2 median 
expression in B-cell subpopulations. d) IL6, TNFα and MIP1β median expression in monocytes and mDCs. The 
analysis is made out of three experiments (*= P value < 0.05, **= P value <0.01 Statistical analysis performed by 
One-Way ANOVA test between the median expression of each node into the boundaries compared with the 
control).  
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Functionalized GONH2 instead selectively induced production of IL2 by activated T cells 
and a production of TNFα in several cells subpopulations. Moreover, GONH2 did not affect 
production of IL5 by T-cells, and only modestly that of IL4 (Figure 2b). IL4/IL5 are markers 
of Th2 while TNFα/IL-2 of Th1 differentiation. Thus, it appears that GONH2 elicits polarized 
Th1 immune response and a non-specific Th response. GONH2 tropism for Th1 cytokines was 
mirrored in B-cells (Figure 2c). Moreover, GONH2 was able to induce dendritic cell and 
monocyte activation skewed toward a M1 response, as demonstrated by increased production 
of classic M1 cytokines such as TNFα, IL6, and the CCR5 ligand CCL4 (MIP1) (Figure 2d)34, 
35, 36. Th2 responses are involved in asthmatic reactions and induction of allergy.37 Moreover 
Th2 responses (sustained by M2 macrophages) favor cancer growth38.  Conversely, Th1 
responses (sustained by M1 macrophages) counteract cancer development39, 40. In fact, 
intratumoral Th1 (but not Th2) signatures have been invariably associated with favorable 
prognosis and responsiveness to immunotherapy 39, 41, 42, 43, 44, 45, 46, 47.  These data are of 
particular interest for further translational applications of amino-functionalized GOs in the 
immunotherapy of cancer or as a vaccine adjuvant. M1 cytokine production such as IL6, TNFα, 
and MIP1 after treatment with GO and GONH2 is represented in Figure 3.  
Negative controls are reported in Figure S2. We found increased expression of IL6 in 
monocytes, mDCs (monocytoid dendritic cells) and activated Th cells (red nodes) mediated 
mainly by GONH2 (Figure 3a). As expected TNFα secretion was mediated by GONH2 in 
monocytes, mDCs, activated CTLs, Th cells and in NK cells (Figure 3b). The expression of 
MIP1 was clearly observable in monocytes, mDCs and activated Th in response to both GOs. 
However, as previously mentioned the median intensity was higher in GONH2 treated samples. 
GO, instead induced MIP1 expression also in B cell populations (Figure 3c). SPADE 
visualization could give further information on the impact played by GOs on single cells 
through heterogeneity analysis within nodes. Indeed, not all the cells into the same family 
display the same cytokine secretion intensity, underlining possible different maturation and/or 
activation stages. An example is given by TNFα secretion by CD16- NK cells treated with 
GONH2 (Figure 3b) where half of the nodes included did not secrete TNFα. Overall the SPADE 
data suggest a cross-talk between monocytes/mDCs and CTLs/Th cells that could sustain a 
specific cell-mediated immunity, avoiding humoral response and possible hypersensitivity.  
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Figure 3. Summary of SPADE analysis of significantly secreted cytokines. The tree plots were constructed in 
the same way of Figure 1. Node color is scaled to the median intensity of marker expression of the cells within 
each node, expressed as a percentage of the maximum value in the data set. The spade trees show the median 
expression intensity of a) IL6; b) TNFα, and c) IL2 for GO and GONH2-treated samples. The analysis is made out 
of three experiments. 
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Since this new single-cell mass cytometry technique was not previously applied to 
nanomaterials, we corroborated the analysis with several classical techniques to analyze cell 
apoptosis, necrosis, and activation and cytokine secretion. Analysis of human PBMCs using 
flow cytometry confirmed the trend observed with the CyTOF experiments. Figure 4a displays 
the histograms related to apoptosis and necrosis experiments [expression of Annexin V 
(apoptotic) and PI (necrotic) positive cells after treatment with GO and GONH2] using the same 
conditions reported for the CyTOF analysis (P value <0.05). Data were also confirmed by a 
dose-response analysis (5, 25 and 50 µg·mL-1) using 7-amino actinomycin D (7AAD) to detect 
cells with compromised membranes (late apoptotic and necrotic cells). As expected, the 
functionalization improved the biocompatibility of GO with a reduction of necrotic events, 
from 42% to 24.7% (P value 0.045) (Figure 4a). Similar results are reported in Figure 4b. 
Indeed, at the highest concentration used, we found a reduction of necrotic events from 27.3% 
to 6.7% (P value 0.039) in GONH2-treated samples. The improvement of biocompatibility 
mediated by GONH2 was confirmed by hemolysis analysis in red blood cells (RBCs). 
Hemolysis is reported to be an undesirable effect mediated by GOs at high concentrations48. 
The release of hemoglobin from damaged RBCs after treatment with increasing doses (5, 25, 
50 and 100 µg·mL-1) of GO and GONH2 was analyzed (Figure S3).  The highest concentration 
of GO was able to induce a significant release of hemoglobin, showing damage to RBCs. On 
the other hand, the functionalized GONH2 did not damage RBCs at any of the tested 
concentrations (Figure S3). Further activation analyses were performed by flow cytometry, 
measuring CD69 and CD25, early and late activation markers, respectively (Figure 4c). Total 
PBMCs were treated with both GO and GONH2 at the concentration of 50 µg·mL-1 for 24 h. 
GONH2 induced higher (15.03%, P value 7.89E-05) expression of CD25 compared to GO 
(8.7%, P value 0.009) (Figure 4c). A similar trend was observed for CD69 expression with 
8.4% (P value 0.001) and 5.8% (P value 0.012) of cells expressing the marker in GONH2 and 
GO, respectively. Chances in cell diameter reflect the status of immune cell activation with 
larger size corresponding to an active status. The effect of GO and GONH2 on cell size was 
analyzed using Scepter™ 2.0. PBMCs were treated with GO and GONH2 at the concentration 
of 50 µg·mL-1 for 24 h. Figure 4d shows the cell diameter of lymphocytes, inactivated 
monocytes [Figure 4d (i)], and activated monocytes [Figure 4d (ii)]. GONH2 induced higher 
changes in monocyte diameter compared to the untreated sample. In line with previous results 
on the action of GONH2, we found 2.65×104 cells with a diameter larger than 11.75 μm, 
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compared to 9.78×103 cells for the control [Figure 4d (iii)]. The effect of GONH2 was studied 
also by multiplex ELISA on the PBMC supernatants.  The secretion of classical Th1/M1 
cytokines such as CCL5, IL6, IL1β, and TNFα increased after stimulation with GONH2 but not 
GO treatment (Figure 4e; P value < 0.05). 
 
Figure 4. Standard cell viability and activation assays in ex vivo PBMCs. PBMCs were incubated with GO 
and GONH2 at increasing doses (5, 25 and 50 µg·mL-1) and at a fixed dose (50 µg·mL-1) or left untreated (Ctrl). 
Data were analyzed using different stainings by flow cytometry. a) Necrosis and apoptosis were assessed treating 
the cells with 50 µg·mL-1using propidium iodide and Annexin V staining; ethanol was used a positive control. b) 
Percentage of late apoptotic and necrotic cells was assessed by staining with an amine-reactive dye (7AAD) after 
24 h of incubation; ethanol was used as a positive control. Experiments were performed at least in triplicate (*= P 
value < 0.05 ** =<0.001, ***= P value 0.0001). c) Percentage of CD25 and CD69 cell surface activation marker 
expression in monocytes (50 µg·mL-1) (CD14 positive cells) analyzed by flow cytometry. d) Morphological 
analysis (count and diameter) of PBMCs using Scepter 2.0 highlighting the monocyte peaks (i), and activated 
monocytes (ii) with a diameter higher than 11.25 μm. The experiment is reported out of three; e) Cytokine release 
was assessed by multiplex ELISA on PBMCs and expressed as pg·mL-1. Surfactants of cells incubated with GO 
and GONH2 (µg·mL-1) were harvested and analyzed by multiplex ELISA. Concanavalin A (ConA, 10 µg·mL-1) 
and lipopolysaccharides (LPS 2 µg·mL-1) were used as positive controls. All the experiments were performed at 
least in triplicate (*= P value < 0.05, **= P value <0.01 Statistical analysis performed by two tales student t test). 
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All data obtained through the use of classical techniques confirmed the CyTOF main 
findings, therefore supporting its use as a robust technique for comprehensive analyses of 
nanomaterial-immune cell interaction. To obtain a higher intensity portray of the interaction 
between nanomaterials and immune cells we used the Illumina Beadchip HumanHT-12 v4 
genome wide technology analyzing about 47000 transcripts in GO and GONH2-treated T 
lymphocyte (Jurkat cells) and monocyte (THP1) cell lines as representative of adaptive and 
innate immune responses respectively. These cell lines were incubated with GO and GONH2 
(50 µg·mL-1, 24 h) in the same conditions used for the previous CyTOF experiments. To 
compute the probability of genes being differentially expressed, we used a random variance t-
test as implemented in BRB Array-Tools [see Supporting Tables S1 and S2. Results were 
controlled for false discovery rate (FDR)]. We confirmed that the functionalization significantly 
reduced (P value <0.001 and FDR <0.05) the magnitude of the perturbations induced by GO 
(Venn diagram, Figure 5a-c). Overall, the number of transcripts modulated by GONH2 was 
less than one third of the transcripts altered by GO. Following the treatment with functionalized 
GONH2, 1163 transcripts were altered in T-cells and 977 in monocytes as compared with 4509 
transcripts in T-cells and 3528 in monocytes in GO-treated samples (Figure 5 and Supporting 
Tables S1 and S2). However, the effect of GONH2 was clearly more specific. In fact 2845 
transcripts were modulated in both T-cell and monocytes by GO. In contrast, only 390 
transcripts were modulated in both treated cells by GONH2 (Figure 5a). Venn diagrams in 
Figures 5b and 5c describe the different modulation induced by GO and GONH2 in the treated 
cells. To provide a functional interpretation of the transcriptional changes, we applied Ingenuity 
Pathways Analysis (IPA). The most differentially affected canonical pathways in GO- 
compared to GONH2-treated T cells and monocytes are shown in Figure 5d while the 20 top 
canonical pathways are shown in Figure S4). While the perturbations induced by GO reflect 
the triggering of cytotoxic mechanisms, the changes induced by GONH2 consist in selective 
immune activation of T-cells and monocytes. Indeed, the most significantly affected canonical 
pathway by GO are Eukaryotic Initiation Factor 2 (EIF2) signaling, oxidative phosphorylation 
and mTOR signaling, all related to cell metabolism and proliferative function. This effect is 
visible in both cell types (Figure 5d).  More in detail, protein synthesis, as indicated by the 
negative Z-score of the EI2F pathway, was suppressed by GO treatment, in line with the 
induction of apoptotic mechanism showed by the CyTOF and flow cytometry analyses. 
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Conversely, the functionalized GONH2 induced a coordinated induction of immune-activator 
pathways with limited impact on cell metabolism. Almost all the top 20 canonical pathways 
modulated by GONH2 are related with immune functions (Figure S4).  
Figure 5. Gene expression impact of GO and GONH2 on T- and monocyte cell lines. a) Venn diagrams for T-
cells and monocytes reporting the number of transcripts modulated in response to graphene administration. Each 
Venn diagram is divided in four areas, one for each type of GO and GONH2 in T-cells and monocytes. The total 
number of modulated genes in each areas are reported between the parentheses. b) Venn diagrams of differently 
expressed transcripts in T-cells and c) in monocytes. Overlapping areas indicate the number of transcripts 
commonly changed in their expression level between GO and GONH2. Colored circles indicate the number of up-
regulated (red), and down-regulated (green) transcripts with an absolute Fold Change > 1. d) Top 5 first canonical 
pathways ranking according to significance level [Fisher exact test es log (p-value) reported in red] modulated by 
the GO and GONH2 in T-cells and monocytes identified using gene enrichment analysis. The Z-score of each 
pathway is expressed under each column; the –log(P value) is reported in red in top of each histogram. e) 
Expression heatmap of chemokines, cytokines, dendiritc cell maturation, and interferon signaling pathway genes 
(as listed in IPA software) in GONH2 and GO treated cells vs Controls; P-value <0.001 and FDR <0.05. 
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Such pathways include intracellular signaling implicated in the activation of T cells and in 
the maturation and activation of monocytes [e.g, interferon signaling, interferon regulatory 
factor (IRF) activation by pattern recognition receptor (PRR), antigen presenting and 
inflammasome pathways] (Figure 5d and S4). These differences for the two graphene oxides 
was confirmed using the gene set comparison tool in BRB Array-Tools as a scoring test to 
assign the functional category definitions according to the Gene Ontology database (GOd), with 
a P value <0.005 (see Supporting Tables S3 and S4). The perturbation of the oxidative 
phosphorylation (OXPHOS) highlights IPA the impact on GO on cell metabolism (Figure S5a 
and S5b). The modulation of IFN-signaling in T-cells and DC-maturation pathway in 
monocytes induced by GONH2 are represented in Figure S6 and S7. Thus, GO compared to 
GONH2 induces a stronger alteration of pathways related to cellular replication and metabolism 
(Figure S4 and Supporting Tables S3 and S4) with a downregulation of OXPHOS pathway 
(Figures S5a and S5b). In summary, GONH2 was confirmed to upregulate immune-activation 
pathways without disrupting intracellular homeostasis. A list of immune-related genes 
modulated by GONH2 in T cells and monocytes is reported in Figure 5e. These genes include 
Th1 chemokines49  such as CXCL10 (CXCR3 ligand), CCL3, CCL3L3, CCL4L1, CCL4L2 and 
CCL5 (CCR5 ligands), pro-inflammatory cytokines such as TNFα and IL1ß (Figure 5e), and 
master regulators of the cross-talk between innate and innate immune response such as IRF1 
and STAT1. To validate the Illumina Beadchip data, we performed real-time PCR with highly 
specific Taq-man probes. Again, IRF1, CCL3L3, IL1B, and CCL5 genes were consistently 
over-expressed only after GONH2 treatment (Figure S8a). Further confirmation of the GONH2 
action at the protein level were given by ELISA through the assessment of the secretion of IL6, 
TNFα, and IL1β by monocytic cells (Figure S8b). Remarkably, these genes (i.e., 
CXCR3/CCR5 ligand genes, and the transcription factors STAT1 and IRF1) are central in the 
induction of immune-mediated tumor rejection41, 44, 50 and their over-expression in resected 
tumors has been associated with favorable prognosis43, 45, 46, 51. Such transcripts are up-regulated 
in tumors from patients who are more likely to respond to immunotherapeutic approaches such 
as IL252, vaccine53, adoptive therapies42, and checkpoint inhibition54, 55.  Moreover, the efficacy 
of cancer immunotherapy relies on the ability to trigger a Th-1/M1 anti-tumor response through 
the induction of the expression of the aforementioned transcripts38, 41. Recently, the use of 
different kinds of nanomaterials as immune modulators for vaccine adjuvant or immunotherapy 
applications have been described56, 57, 58. All the nano-adjuvants could greatly enhance the 
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immunogenicity of antigens, particularly in antigen presenting cells (APCs) such as DCs, thus 
helping the prevention or treatment of infectious diseases or cancer59. Recently, Xu et al. 
proposed the use of functionalized GO as vaccine adjuvant. GO functionalized with both 
polyethylene glycol and polyethyleneimine was found to promote the maturation of DCs, 
enhancing their cytokine secretion through the activation of multiple toll-like receptor (TLR) 
pathways while showing low toxicity60. In a similar and extensive way, the current 
morphological and genomic analysis suggest that GONH2 might enable the initiation and 
induction of monocyte and DC activation possibly through TLR/PRR interactions. Moreover, 
our data suggests that amino-functionalized GO is likely to facilitate the differentiation of 
monocytes into monocyte-derived DCs (moDCs). MoDCs pulsed with certain tumor-associated 
antigens (and eventually prompted with functionalized GO) could expand tumor-specific T-
cytotoxic cells and elicit anti-tumor immunity61, 62, 63 
In conclusion we propose a new high-throughput strategy for the characterization of complex 
interactions between nanomaterials and the plethora of immune cell populations. The analysis 
of multicellular systems where cells carry out a diverse array of complex, and specialized 
functions is still a big challenge23. Regarding the immune system, a central issue has been the 
identification of the distinct subpopulation phenotypes of the specialized cells. This 
specialization occurs mostly through the expression of cell type-specific genes and proteins that 
generate the appropriate structures and molecular networks tracking their function during any 
different biological function and response. Single-cell mass cytometry enters successfully in 
this context with its unique capacity of simultaneously resolving a large amount of probes on a 
per-cell basis at high acquisition rates, thereby providing researchers with an unprecedented 
ability to phenotypically and functionally profile different cell subpopulations. This technology 
allows the sophisticated analysis of multiple immune cell interactions with nanomaterials, while 
overcoming the limitations of spectral overlap present in flow cytometry and, revealing all the 
possible modulations at the single-cell level.  
We here focused on graphene oxide, one of the most recent biomedically promising 
nanomaterials. Thanks to this advanced technology, confirmed by classical flow cytometry 
methods, we report that amino-functionalization improves the biocompatibility of GO.  
Moreover, GONH2 was found to induce a cell-specific activation of T cells, DCs and 
monocytes, which were polarized to sustain a M1/Th-1 immune response. The positive impact 
of nanomaterials on specific immune cells can serve as starting point for the development of 
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new nanoscale platforms in medicine as novel immunotherapy, vaccine carrier and 
nanoadjuvant tools 17. Our pilot study paves the way for the future use of single-cell mass 
cytometry for a deep characterization of immune responses to any type of nanomaterials useful 
for biomedical applications.  
 
Materials and Methods 
 
Synthesis of GO 
GO was prepared by a modified Hummers’ method described in Ali-Boucetta et al.64 with slight 
modifications. Briefly, 0.2 g of graphite flakes (Barnwell, UK) were mixed with 0.1 g of NaNO3 
(Sigma-Aldrich, UK) and 4.6 mL of 96% H2SO4 (Fisher Scientific, UK). After obtaining a 
homogenous mixture, 0.6 g of KMnO4 (Sigma-Aldrich, UK) was slowly added. Temperature 
was carefully monitored during the reaction and was kept between 98 and 100 °C. The mixture 
was further diluted with 25 mL of deionized H2O and 3% H2O2 (Sigma-Aldrich, UK) was added 
gradually for the reduction of the residual KMnO4, MnO2, and Mn2O7. The resulting graphitic 
oxide suspension was exfoliated and purified by several centrifugation steps until the pH of the 
supernatant was around 7 and a viscous orange/brown gel-like layer of pure GO appeared on 
top of the oxidation by-products and thick graphitic pieces. This layer was extracted and diluted 
in MilliQ water.  
 
Synthesis of GONH2 
2,2’-(Ethylenedioxy)bis(ethylamine)  (410 µL) was  added  to a 20 mL of a  GO  dispersion  (1 
mg∙mL-1) in deionized water, and the mixture was stirred for two days at room temperature. 
The solution was then filtered using an Omnipore® polytetrafluoroethylene (PTFE) membrane 
(0.45 µm, Millipore). The solid was dispersed in methanol (100 mL), sonicated for 2 min and 
filtered again. This procedure was repeated with DMF and methanol. The solid was dispersed 
in deionized water and dialyzed against deionized water using a dialysis membrane of MWCO 
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Characterizations of the materials  
For TEM characterization, 20 μL of sample (100 μg·mL-1) were deposited on a carbon coated 
copper grid (Electron Microscopy Services, USA). Excess material was removed by filter 
paper. Imaging was performed using a FEI Tecnai 12 BioTWIN microscope (Techni, 
Netherlands) at an acceleration voltage of 100 kV. Images were taken with a Gatan Orius 
SC1000 CCD camera (GATAN, UK). Lateral size distributions were carried out using ImageJ 
software after counting the lateral dimension of more than 100 individual GO sheets from 
several TEM images. For AFM, freshly cleaved mica (Agar Scientific, UK) was used as a 
substrate. Pristine GO samples required a pre-coating step of the negatively charged mica 
surface with 20 μL of 0.01% poly-L-lysine (Sigma-Aldrich, UK). All samples were prepared 
by depositing 20 μL aliquots of the respective GO dispersions (100 μg·mL-1) on the mica 
substrates and allowing them to adsorb for 2 min. Unbound structures were removed by gentle 
washing with 2 mL of MilliQ water and samples were left to dry at 37ºC. AFM images were 
acquired in air using a Multimode 8 atomic force microscope (Bruker, UK) in tapping mode, 
using an OTESPA tip (Bruker, UK) mounted on a tapping mode silicon cantilever with a typical 
resonant frequency of 300 kHz. Areas corresponding to 512x512 points were scanned at a rate 
of 1 Hz, using an integral gain of 1 and a proportional gain of 5; amplitude set point values 
were approximately constant across all measurements. The acquired height images were 
processed using the Nanoscope Analysis software (Version 1.4, Bruker, UK) in order to assess 
lateral dimensions and thickness of the GO samples.  A drop of the original GO dispersions 
was placed onto a Tensor 27 FTIR spectrometer (Bruker, UK) equipped with a 3000 Series 
High Stability Temperature Controller with RS232 Control (Specac, UK) and a MKII Golden 
Gate Single Reflection ATR system (Specac, UK) for measurements in ATR mode. The drop 
was allowed to dry on the plate for 5 min at 60°C, until a dry powder remained. Transmittance 
spectra of GO were recorded by acquiring 32 scans between 700 and 4000 cm-1 with a resolution 
of 4 cm-1. Data processing was completed using OriginPro 8.5.1 software (Origin Lab, USA). 
For Raman spectroscopy, the samples were prepared for analysis by drop casting 20 μL of 
sample (100 μg/mL) dispersion onto a glass slide. The samples were left to dry for at least 2 h 
at 37°C. The spectra were collected using a DXR micro-Raman spectrometer (Thermo 
Scientific, UK) using a λ = 633 nm laser. The spectra were considered between 500 and 3400 
cm-1, enabling visualization of the D and G bands. The spectra were collected at a laser power 
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of 0.4 mW at a magnification lens of 50× with 25 ms exposure time, and averaged over 5 
different locations. 
 
Cell culture, viability, proliferation and activation assays 
 Jurkat cells (T-cell line), THP1 (monocyte cell line) and PBMCs were cultured in RPMI-1640 
medium added with FBS 10% and 1% of Penicillin/Streptomycin solution. PBMCs were 
obtained from ethylenediamine tetraacetic acid (EDTA)-venous blood samples from informed 
healthy male donors (25-50 years old) using a standard Ficoll-Paque (GE Healthcare) 
separation.  Informed signed consent was obtained from all the donors. The study was reviewed 
and approved by the Ethics Committee of the University of Sassari. All the experiments were 
carried out in accordance with the approved guidelines.  
The cytotoxicity was evaluated by flow cytometry (FACS Canto, BD Biosciences, Mountain 
View, CA, USA). PBMCs were incubated for 24 h with increasing doses of GO and GONH2 
(5, 25 and 50 µg·mL-1). Ethanol was used as a positive control, while samples incubated with 
cell medium alone were used as negative controls. All staining kits were purchased from 
Invitrogen, CA, USA: Annexin-V FITC (apoptosis), PI (necrosis), and 7AAD (late apoptosis 
and necrosis).  
To perform the proliferation assay, the Click-iT® EdU Alexa Fluor® 488 Flow Cytometry 
Assay Kit (Life Technologies) was used. Experiments were performed according to the 
manufacturer’s instructions. Cells were seeded at the concentration of 1x106 cells·mL-1 in 96-
multiwell rounded bottom plates. T-cell and monocyte cell lines were treated with GO and 
GONH2 at the concentration of 50 µg·mL-1 and 20% of FBS or left untreated (10% FBS). 5-
Ethynyl-2-deoxyuridine (EdU) were added in sterile conditions 16 h before analysis. After 48 
h of incubation, cells were harvested, washed with PBS, fixed with 4% paraformaldehyde, 
washed in PBS plus 1% Bovine Serum Albumin (BSA), permeabilized with a saponin-based 
reagent and prepared for the Cu-assisted EdU-Azide Click-iT reaction. The reaction occured 
after adding 500 μL of Click-iT reaction cocktail (PBS, CuSO4, fluorescent dye azide and 
reaction buffer additive) to each sample. Analyses were performed by flow cytometry (C6 
Accuri using C6 software, BD Biosciences). A total of 50,000 events per sample were recorded. 
PBMCs were treated with GO and GONH2 at the intermediate concentration of 50 µg·mL-1 and 
stained to identify immune cell populations and activation markers, CD25 and CD69 (APC-
conjugated anti-CD25, 2A3 clone, PE-conjugated anti-CD69, L78 clone, BD-Bioscience 
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Mountain View, CA, USA). Concanavalin A (ConA, 4 μg·mL-1) and lipopolysaccharides (LPS, 
2 μg·mL-1) were used as positive controls (Sigma-Aldrich, St. Louis, Missouri, USA). Staining 
with fluorochrome-conjugated monoclonal antibodies was performed in the dark for 20 min. 
Cells were analyzed by flow cytometry.  
 
Single-cell mass cytometry 
Single-cell mass cytometry analysis was completed using PBMCs purified form Buffy-Coat. 
The volume of the Buffy-Coat was reinstated 1 to 10 adding PBS, after that the PBMCs were 
purified using a standard Ficoll-Paque (GE Healthcare) separation. PBMCs were seeded at a 
concentrations of 3×106 cells per well (6 multi-well plates) and treated with GO and GONH2 at 
a concentration of 50 µg·mL-1 for 24 h. After the incubation period, cells were harvested and 
washed with PBS. The further procedure was made following the Maxpar® 
Cytoplasmic/Secreted Antigen Staining protocol. Briefly, before the staining, the cells were 
suspended in Maxpar Cell Staining Buffer (Fluidigm, Cat# 201068) in a volume of 100 μL, into 
15 mL polystyrene tubes for each sample to be stained. One hundred μL of the antibody cocktail 
was added to each tube. The final staining volume was 200 μL (100 μL of cell suspension plus 
100 μL of antibody cocktail, in a final dilution of 1:100 for each antibody). Cells were stained 
using Maxpar® Human Peripheral Blood Phenotyping and Human Intracellular Cytokine I 
panel kits (Fluidigm® Cat# 201304 and 201308). Samples were gently vortexed and incubated 
for 30 min at room temperature (RT). After incubation, the samples were washed twice by 
adding 2 mL Maxpar Cell Staining Buffer to each tube, centrifuged for 5 min at 600 × g and 
the supernatant discarded. Cells were resuspended in residual volume by gently vortexing and 
incubated for 1h at RT in the intercalation solution, composed of Cell-ID Intercalator-Ir 
(Fluidigm, Cat# 201192A, 125 μM) into Maxpar Fix and Perm Buffer (Fluidigm, Cat# 201067) 
to a final concentration of 125 nM (a 1000× dilution of the 125 μM stock solution). Cells were 
washed twice by adding 2 mL of Maxpar Cell Staining Buffer and centrifuged for 5 min at 
800 × g. Pellets obtained were resuspended with 2 mL of Milli-Q water (Millipore). Prior to 
mass cytometry data acquisition, the cell concentration was adjusted to 2.5–5 × 105/mL with 
Milli-Q water and the cell suspension was filtered into 5 mL round bottom polystyrene tubes 
with a 30 μm-cell strainer cap. Data was analyzed using mass cytometry platform, of DVS 
Sciences (CyTOF2), after stabilization and calibration of the instrument. To construct the 
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SPADE tree, we used 11 cell surface markers listed as follow: CD45, CD3, CD4, CD8a, CD20, 
CD19, CD14, CD16, CD11c, CD123 and HLADR. 
 
Hemolysis analysis 
Hemolysis test was conducted following previously used protocols as described by Li H et al.65 
Fresh human whole blood was taken from volunteer healthy donors stabilized with 0.2% 
EDTA. Serum was removed from blood samples by centrifugation at 200 g for 5 minutes. 
Resulting RBCs were washed five times with sterile isotonic PBS and then diluted 10 X with 
0.2% EDTA. The hemolytic activity of GO and GONH2 at different concentrations (5, 25, 50, 
100 µg·mL-1) were determined by the incubation of graphenes with the RBC suspension (0.2 
mL, 4×108 cells·mL-1) in a final volume of 1 mL, completed with PBS. After vortexing, the 
mixtures were left at room temperature for 2 h, NCs and intact RBCs were removed by 
centrifugation. A microplate reader (Sunrise, Tecan) measured the absorbance (A) of the 
hemoglobin in the supernatant at 570 nm, with the absorbance at 620 nm as a reference.  
 
Cytokine assay and microarrays analysis 
Total mRNA was extracted with TriZol Reagent (TriZol, Invitrogen, Carlsbad, CA, USA) and 
purified using the RNAeasy mini kit (Qiagen, Valencia, CA, USA). RNA purity was assessed 
by spectrophotometric analysis and integrity by microfluidic molecular sizing using the 
Bioanalyzer 2100 (Agilent). Samples with RIN (RNA Integrity Number) less than 8 were 
discarded. RNA (1 μg) was converted in cRNA and labeled (Illumina totalPrep RNA 
amplification kit, Ambion). Biotinylated cRNA was hybridized onto the Illumina HumanHT-
12 v4 (Illumina, Inc., San Diego, CA, U.S.A.). The Illumina HumanHT-12 v4 interrogates the 
expression of 47,000 gene probes derived from the National Center for Biotechnology 
Information (NCBI) Reference Sequence RefSeq Release 38 (November 7, 2009) and other 
sources. Probe intensity and gene expression data were generated using the Illumina 
GenomeStudio software V2011.1 (Gene Expression Module V1.9.0). After extraction, cDNA 
synthesis was performed using a SuperScript III reverse transcriptase (Invitrogen, Carlsbad, 
CA, USA).  
Cell culture supernatants from PBMCs were used to quantify the secretion of cytokines using 
a MILLIPLEX MAP plex Cytokine Kit (HCYTOMAG-60K, Millipore, Billerica, MA) [IL1β, 
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Real-time PCR was performed as follows: 1 mg of total RNA was reverse transcribed using the 
superscript IV reverse transcription kit (Invitrogen) following standard protocols. The cDNA 
reaction (20 mL) was brought to a 100 mL volume with H2O and 1 mL used for each PCR 
reaction. Real-time PCR was performed on an Applied Biosystems 7300 thermal cycler, using 
the Applied Biosystems real-time PCR master mix and the following premade Taqman gene 
expression assays: GAPDH Hs99999905_m1 and ACTB Hs99999903_m1 as housekeeping 
genes, IRF1 Hs00971966_g1, CCL3L3 Hs03407473_uh, CCL5 HS99999048_m1 and IL1B 
Hs01555410_m1. All experiments were performed in triplicate. Gene expression 
measurements were computed by the 2ΔΔcT method. 
 
Statistical analysis 
The statistical analysis of CyTOF data was performed as described by Bendal SC et al. 32. 
Briefly, normalized, background-subtracted FCS files were imported into Cytobank for single 
cell and population gating. The gating strategy for the different subpopulations is reported in 
Figure S9.  Cytobank was also used to create the heatmap comparing fluorescence and mass 
cytometry measurements using log2 ratio of the stimulated population with mean fluorescent 
intensity (MFI) versus the unstimulated control. For spanning tree visualization and 
comparison, singlet-gated FCS files were analyzed in Cytobank using the SPADE tool 
comparing the median fluorescence intensity.  
Statistical analyses for flow cytometry were performed using FACS Diva software (BD-
Bioscience Mountain View, CA, USA). All the experiments were performed at least in 
triplicate. Statistical analyses for multiple cytokine assays were performed using Student's t-
test. Data indicated with a star were considered statistically significant (two-tales P value 
<0.05). Data are presented as mean ± SD. Multiplex ELISA tests on isolated human primary 
PMBCs were performed in samples from at least 3 different donors. Immune gene array data 
were analyzed by the comparative threshold cycle (CT) method. Relative quantification of gene 
expression using the 2ΔΔCt method correlated with the absolute gene quantification obtained 
using a standard curve. Data were analyzed with RT2 profiler PCR array data analysis software 
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(http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php). Whole genome expression 
measurements were extracted and normalized using the Illumina GenomeStudio software 
V2011.1 (Gene Expression Module V1.9.0). The same software was used for QC analysis of 
the Beadchips. Statistical analysis and visualization of gene expression data were performed 
using BRBArrayTools, developed by R. Simon and the BRBArrayTools Development Team 
(http://linus.nci.nih.gov/BRB-ArrayTools.html). We identified genes that were differentially 
expressed among the two classes by using a multivariate permutation test. We used the 
multivariate permutation test to provide 80% confidence that the proportion of false discoveries 
did not exceed 5%. The test statistics used are random variance t-statistics for each gene. 
Although t-statistics were used, the multivariate permutation test is non-parametric and does 
not require the assumption of Gaussian distributions. We identified gene ontology database 
(GOd) groups of genes whose expression was differentially regulated among the classes. This 
analysis is different than annotating a gene list using GOd categories. For each group, we 
computed the number of genes represented on the microarray in that group, and the statistical 
significance P value for each gene. These P values reflect differential expression among classes 
and were computed based on random variance T-tests or F-tests. For a GOd group, two statistics 
are computed that summarize the P values for genes in the group; the Fisher (LS) statistic and 
the Kolmogorov-Smirnov (KS) statistic as described in (Simon R and Lam A. BRB-ArrayTools 
User Guide, version 3.2. Biometric Research Branch, National Cancer Institute; 
http://linus.nci.nih.gov/brb).  Samples of n genes are randomly selected from genes represented 
on the array and the summary statistic computed for those random samples. The significance 
level associated with the gene ontology database category is the proportion of the random 
samples giving as large a value of the summary statistic as in the actual n genes of the database 
category. For each GOd category, two significance levels are computed, corresponding to the 
two summary statistics. We considered a GOd category significantly differentially regulated if 
either significance level was less than 0.005. We considered all GOd categories with between 
5 and 100 genes represented on the array. Some of the categories were overlapping. We also 
uploaded the gene expression data to the "Ingenuity Pathway analysis" (IPA) to visualize the 
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Figure S1. Physicochemical characterization of GO and GONH2. GO structural characterization using Ai) 
AFM, scrutinized for ii) lateral dimension and iii) thickness. Bi) Representative TEM micrographs with ii) lateral 
dimension distribution. GONH
2 
characterization using Ci) AFM, scrutinized for ii) lateral dimension and iii) 
thickness. Di) Representative TEM micrograph with ii) lateral dimension distribution.
 
E) Raman spectra of GO 
(red) and GONH
2
 (blue). F) FT-IR spectra of GO (red) and GONH
2
 (blue). G) UV-Vis spectra of GO (red) and 
GONH
2
 (blue). H) Summary of the characterization.   
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Figure S2. Summary of SPADE analysis. SPADE tree plots of untreated samples (CTRL) for significantly 
expressed cytokines (IL6, TNFα and MIP1β). 
 
 
Figure S3. Hemolysis analysis. GO and GONH
2
 were incubated (at increasing concentrations of 5, 25, 50, 100 
µg·mL
-1
) with red blood cells (RBCs) at 25°C for 2 h. a) Sample absorbance measured at 570 nm. b) Pictures of 
human RBCs treated with the different GOs. The red color of the solution is due to the release of hemoglobin from 
the damaged RBCs. PBS mixed with RBCs (-) and ultrapure water mixed with RBCs (+) served as negative and 
positive control, respectively. PBS alone was used as additional control (W). The experiments were performed in 
triplicate (**= P value <0.01 Statistical analysis performed by two tales student t test). 
  
Chapter 4 | Results 
 
Dr. Marco Orecchioni. Titolo “Biomedical applications of different nanomaterials: 
Characterization and interaction with the immune system”  






Figure S4. Ingenuity pathways analysis. Top 20 canonical pathways and Z-score ranking according to 
significance level [Fisher exact test  -log (p-value)] modulated by GO and GONH
2
 in a) T-cells and b) monocytes 
identified using IPA software.  
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Figure S5. Gene set enrichment with Gene Ontology and IPA analysis. a)OXPHOS pathway found 
modulated in GO sample. b) Gene ontology visualizationheatmap of OXPHOS pathway after treatment with GO 
and GONH2 in T-cells. 
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Figure S6. Significant canonical pathways. DC maturation pathway in monocytes after treatment with GONH
2
. 
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Figure S8. Microarray data validation in monocytes cell line. mRNA levels were measured in triplicate by 
quantitative real-time PCR. Histograms show residual mRNA level expressed as 2-
ΔΔct
 that gives the measure of 
fold changes between GO and GONH
2 
and controls (always expressed as 1) (*= P value < 0.05, **= P value <0.01 
Statistical analysis performed by two tales student t test).   
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Figure S9 Gating strategy of different immune cell subpopulations. The used gating strategy for the 
identification of the different immune cell subpopulations in shown for the control sample as a contour dot plots. 
The gating was performed following the Fluidigm instruction of the Maxpar panel used. The cell events 
discrimination was performed first using Ir 191 Di(DNA1) and Ir 193 Di (DNA2), LD stands for CIS.  
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In the cure of cancer, a major cause of today’s mortality, chemotherapy is the most common 
treatment, though serious frequent challenges are encountered by current anticancer drugs. We 
discovered that few-layer graphene (FLG) dispersions have a specific killer action on 
monocytes, showing neither toxic nor activation effects on other immune cells. We confirmed 
the therapeutic application of graphene on an aggressive type of cancer, i.e. myelomonocytic 
leukemia, where the monocytes are in their malignant form. We demonstrated that graphene 
has the unique ability to target and boost specifically the necrosis of monocytic cancer cells. 
Moreover, the comparison between FLG and a common chemotherapeutic drug, etoposide, 
confirmed the higher specificity and toxicity of FLG. Since current chemotherapy treatments 
of leukemia still cause serious problems, these findings open the way to new and safer 
therapeutic approaches. 
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The scientific and medical battle against cancer remains one of the biggest challenges of our 
times. Cancer is still one of the major causes of mortality.[1] The blood-related cancers, such as 
leukemia in its multiple variants, are among those ones with the highest incidence of 
mortality.[2] Acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML) 
represent two different subtypes of the so called myeloid neoplasms.[3] This type of cancer is 
usually dominated by the rapid growth of abnormal immature white blood cell precursors, that 
accumulate in bone marrow and peripheral blood interfering with the normal hematopoietic 
function.[4,5] Both AML and CMML are characterized by circulating monocytic neoplastic 
cells. The conventional treatment of these disorders is usually based on different 
chemotherapeutic regimens, which are often characterized by disappointing remission rates 
especially in elderly patients. Traditional therapies to counteract cancer in general, and also 
myelomonocytic leukemia, are limited by multiple problems, including nonspecific systemic 
distribution of antitumor agents, inadequate drug concentrations reaching the tumor site, 
intolerable cytotoxicity, limited ability to monitor the therapeutic responses, and development 
of multiple drug resistance.[6] 
In this scenario, nanotechnology could be the hoped medical revolution allowing to treat 
cancer effectively, reducing undesired side effects.[7] The development of new nanomaterials 
endowed of unique properties could represent a strong enhancement in the cure of cancer. 
Graphene is one of the nanomaterials that has raised tremendous interest in the scientific 
community and the society.[8] Graphene is being explored for many potential applications due 
to its exceptional physicochemical characteristics.[9] Very recently, different types of graphene 
have been investigated in a growing number of medical applications, including drug delivery, 
diagnosis, tissue engineering and gene transfection.[10] 
In this work, we studied FLG dispersions,[11] and discovered a highly specific toxicity on 
primary human monocytes. Based on this interesting result, we evaluated the killing activity of 
graphene in monocytic neoplastic cells from a cohort of AML and CMML patients. 
The majority of the biomedical studies using graphene-based nanomaterials have focused on 
graphene oxide, while there are only a limited number of biological studies on graphene.[12] The 
reason for this is the difficulty of having graphene directly in water or in culture media. In this 
context, we have prepared few-layer graphene by exfoliation of graphite through interaction 
with melamine using a ball-milling process, in solvent-free conditions.[11] This methodology 
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allows to produce 3-4 layer graphene dispersions in water (0.1 mg mL-1). Moreover, water can 
be easily replaced by filtration or lyophilisation with cell culture medium to form stable 
graphene dispersions.[13] Figure 1 shows the relevant characterization data of the FLG material. 
Thermogravimetric analysis (TGA) was used to quantify the presence of functional groups in 
FLG (Fig. 1A).  
 
Figure 1. Characterization of FLG. A) Thermogravimetric analysis. B) Normalized Raman spectrum. 
C) TEM micrograph of FLG in cell culture medium and D) lateral dimension distribution. 
 
The low weight loss observed in FLG (7%) confirms the low quantity of oxygen groups 
generated during the exfoliation process, which was also corroborated by elemental analysis 
(see Experimental Section in SI). Further proof of the non-oxidative milling process was 
confirmed by Raman spectroscopy (Fig. 1B and SI). Graphene exhibits G and 2D modes around 
1573 and 2700 cm-1, respectively. The D to G band intensity ratio, be used to quantify the 
defects, was calculated at different topographies, giving a significantly low value (0.2). A 
representative TEM image of FLG dispersions in cell culture medium is shown in Figure 1C, 
evidencing the typical wrinkled aspect of the graphene flakes. Statistical analysis of TEM 
images afforded a major population with lateral size around 500-750 nm, with a small fraction 
above 2000 nm (Fig. 1D). Additional XPS data are shown in Fig. S1. 
FLG stable in cell culture media resulted immediately an interesting material to study its 
impact on primary human immune cells. The use of these cells is at the forefront in the study 
of the effects of new materials in a biomedical or toxicological context.[7c, 14] For this purpose, 
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we analyzed the impact of FLG on peripheral blood mononuclear cell (PBMC) populations 
looking at T, B, NK, dendritic cells and monocytes. The cells were treated with different doses 
of FLG from 0.5 g mL-1 to 75 g mL-1 for 24 h (Fig. S2), which we consider the optimal time 
for graphene cellular internalization, and were analyzed by flow cytometry.[14b, 15]  
 
Figure 2. Impact of FLG on different immune cell populations. A) Relative percentage of the different 
immune cells either incubated for 24 h with 50 μg mL-1 FLG or left untreated. Statistical significance 
compared to untreated cells (student’s t test) is indicated by ** = p < 0.01. B) Relative morphological 
dot plots out of at least three experiments of total PBMCs treated with FLG or left untreated. The gate 
on monocytes was done looking at the CD14 positive events (red dots). The other immune populations 
are left in green. 
Chapter 4 | Results 
 
Dr. Marco Orecchioni. Titolo “Biomedical applications of different nanomaterials: 
Characterization and interaction with the immune system”  




Very interestingly, we found a specific cytotoxic activity of FLG on monocytes (CD14+ 
cells), while the percentage of events reported for T, B, NK and dendritic cells remained 
unchanged. This effect is appreciable also in the dot plots, where the positive events for the 
CD14+ completely disappeared (Fig. 2), and it was not due to the presence of residual melamine 
(Fig. S4). The other immune cell populations remained unaffected in terms of cell viability 
(Fig. S3). The highly specific effect of FLG was also confirmed by evidencing its non-cytotoxic 
impact on other types of cells (Fig. S5). 
As we could not record any direct activation of monocytes (i.e. no significant increase of 
CD86 expression, Fig. S6), we decided to investigate whether an indirect activation of 
monocytes via the activation of T cells was occurring. Indeed, FLG-mediated activation of T 
cells could induce a strong stimulation of monocytes triggering their death.[16] We analyzed the 
expression of specific lymphocyte activation markers, namely CD25 and CD69. Their 
expression in FLG-exposed samples was comparable to the untreated negative controls (Fig. 
S7). These data exclude any T cell activation mediated by FLG. The absence of activation of 
the T cells suggested a direct action of FLG on monocytes. The hypothesis of a selective activity 
of the FLG towards monocytes is consistent with the transmission electron microscopy (TEM) 
analysis on total PBMCs (Fig. S7). The fact that only monocytes are able to internalize FLG 
could explain our results on cellular activation and cytokine production. Other reports showed 
an effect of graphene, and in particular of GO, on macrophages or DCs.[17] However, none of 
them reported such strong specific killing on monocyte compared to other immune cell 
populations. In fact we evidenced that treatments of PBMCs with a commercial graphene oxide 
do not affect the monocyte population (Fig S9).[18]  
We then investigated the cell death on monocytes isolated from PBMCs. Monocytes were 
treated with FLG at 50 µg mL-1 and at different time points (1, 4, 12, and 24 h) to analyze the 
induced specific death processes (Fig. 10A). The morphological dot plots (Fig. S10B) show the 
progressive reduction of monocytes (CD14+ cells). Even at early time points (1 and 4 h) of 
incubation a significant induction of dead cells was observed (Fig. S10C). The necrotic cells 
increased also significantly from 6.2% in the control sample to 29% after 1 h and 36.5% after 
4 h (Fig. S10A). Mortality of monocytes reached 71.3% after 24 h of incubation with FLG (P-
value<0.01). We also observed the absence of a significant number of apoptotic cells in all FLG 
treated samples (Fig. S10A) suggesting that graphene directly triggers necrosis on monocytes. 
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To investigate the mechanisms of FLG mediated cell death we first performed a whole-
genome expression, looking at more than 41,000 transcripts on isolated monocytes from healthy 
patients. Venn diagram in Figure S11A shows the number of genes that passed the cutoff at 
the different time points. As expected the number of genes modulated by FLG increased from 
773 after 30 min to 836 and 966 after 90 and 270 min, respectively. The genes up-regulated by 
FLG were mainly chemokines and cytokines (Table S1). They all account for the activation 
process played by FLG on monocytes that increased proportionally with incubation time. To 
understand the biological function of FLG we then performed a pathway analysis. Figure S11B 
displays the 10 most significantly modulated pathways corresponding to IL-10, IL-6 and 
TREM1 signaling. All these pathways confirmed again the activating action of FLG on 
monocytes. IL-10 signaling pathway is in general induced by the activation of toll-like receptors 
(TLR) 2 and 4 with the regulation of the inflammation through the inhibition of pro-
inflammatory cytokines TNFα and IL-6.[19] It was previously evidenced how the internalization 
of graphene could be mediated by TLR2 and TLR4.[20]  The toxicity of our FLG is likely 
induced by the activation of both TLR signaling via TNFα production.[19, 21] To investigate 
whether TLR2/TLR4 receptors were involved in the selective cytotoxic effect of FLG on 
monocytes, we analyzed ex vivo the monocytes treated with and without TLR2/TLR4 blocking 
antibodies. The experiments revealed that TLR4 seems not or only partially involved in the 
mechanism inducing selective cell death of monocyte by FLG (Fig. S12A). Instead, the 
inhibition of TLR2 blocked the expression of CD25 in treated monocytes (Fig. S12B). 
Moreover, the inhibition of TLR2 was able to restore the number of monocytes compared to 
the controls. Together with the gene expression analysis, these results suggest that the FLG 
toxicity on monocytes is mediated by the interaction of FLG with TLR2 and the subsequent 
expression of TNFα and TNFR family (see also SI).[22]  
The high selective capacity of our FLG to kill human monocytes is promising for the 
treatment of myelomonocytic leukemia, which presents high percentages of circulating 
monocytic neoplastic cells. Therefore, we analyzed the effect of FLG as a new 
chemotherapeutic tool in myeloid malignancies. In particular, we evaluated the monocytoid 
CD14+ cell viability in PBMCs obtained from a cohort of seven patients (6 male and 1 female) 
with a median age of 70, newly diagnosed with AML or CMML, before starting the therapeutic 
treatment (Fig. 3). The presence of FLG accumulated into the monoblasts (Fig. S13A) was 
observed into the peripheral blood smear of AML (Fig. S13B) and CMML (Fig. S13C) patients.  
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Figure 3. FLG impact on ex vivo PBMCs from AML and CMML patients. Monocytoid cells were 
highlighted by CD14 positivity (right peaks), the other populations were negative (left peaks). 
 
PBMCs of the patients were then treated with increasing doses of FLG to assess the capacity 
of graphene to specifically kill the neoplastic monocytes. In the untreated samples of all patients 
(Fig. 3), two peaks of cells are well visible: the first on the left comprises all cells negative to 
the CD14 marker corresponding to non-neoplastic cells (i.e. T cells, B cells, NK and dendritic 
cells), while the peak on the right identifies CD14+ monocytoid cancer cells. After the treatment 
with FLG, the cancer cell population was strongly reduced in all AML and CMML patients in 
an FLG concentration dependent manner with no effect on the other immune cells (Fig. 3). We 
would like to point out that in the 6 patients, the number of cancer cells was strongly reduced 
even at low concentrations (0.5 and 5 µg mL-1) with two fold, and three fold average decrease, 
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respectively. Regarding the ablation obtained at 25 and 50 µg mL-1, the percentage of cells was 
extremely reduced from an average of 24% to an average of 2.2% and 1.6%, respectively (Fig. 
3 and Fig. S14). In particular, patient 4 was characterized by a critical condition with an 
extremely high number of monocytoid cancer cells comparable to all other immune cells. The 
treatment with FLG even at the lower concentrations has shown 40% and 83% reduction of the 
neoplastic cell number, reaching the total ablation at 25 µg mL-1 (Fig. 3, Pt.4). The analysis of 
the cytokine secretion in CMML patients after the treatment with FLG did not evidence any 
induction of inflammatory processes in other immune cells. Thus, only monocyte-associated 
cytokines were found overexpressed under FLG treatment (Fig. S15). 
Furthermore, we compared the specific effect of FLG with etoposide, a common 
chemotherapeutic agent clinically used in the treatment of both AML and CMML. Etoposide 
was specifically selected because of its ability to selectively induce monocytopenia, the 
deficiency of monocytes mandatory to prevent tumor expansion.[23] We tested concentration of 
etoposide between 50 and 200 µM, normally used to treat AML and CMML.[24] The comparison 
of the effect of FLG at 50 µg mL-1 with the different etoposide doses in PBMCs isolated from 
AML patients underlines the safety use of FLG with no toxic effect on the other immune cell 
populations (Fig. 4A). As expected, etoposide induced a significant T, B and NK cell toxicity 
at all concentrations (Fig. 4A). In B cells, we found a 49.6% of dead cells at the lowest 
concentration and a 68.3% at the highest. We further confirmed the strong specific effect of 
FLG on neoplastic CD14+ cells compared to etoposide (Fig. 4B). These findings open the way 
to a possible application of FLG as a specifically targeted tool against neoplastic cells in AML 
and CMML. This new therapeutic strategy based on graphene might be extremely advantageous 
over the traditional treatments using conventional chemotherapeutic agents such as etoposide, 
cytarabine, anthracyclines or hydroxyurea,[4, 5] that are non specific and impair all immune cell 
subpopulations, causing possible infections and death. Moreover, some of these 
chemotherapies act by activating the apoptosis pathway in tumor cells. Paradoxically, the fact 
that anticancer agents are effective primarily because they activate apoptosis raises the concern 
that tumors intrinsically resistant to chemotherapy are unable to activate the apoptotic 
machinery and may be resistant to any chemotherapeutic drug.[25] The necrosis-mediated action 
of FLG could avoid the resistance of tumor cells.  
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Finally, given the complexity of the toxicology and pharmacokinetic issues with graphene-
based materials, we characterized the systemic body reaction to FLG in vivo. All injected mice 
behaved normally and did not show signs of adverse reactions (see Fig. S16). 
 
Figure 4. Comparison between etoposide and FLG on PBMCs from AML patients.  PBMCs were 
incubated with 50 μg mL-1 FLG and etoposide at different concentrations. After 24 h the cells were 
harvested and stained with a viability marker dye (7AAD). A) Viability screening of different immune 
cell populations (i.e. T, B and NK cells). B) Count of monocytoid cells (CD14+) treated with FLG (50 
μg mL-1) and etoposide or left untreated. Statistical significance compared to untreated cells (student’s 
t test) is indicated by *= p < 0.05 and ** = p < 0.01. 
 
In summary, in this work, we found a specific toxicity of FLG on primary human monocytes. 
In particular, we demonstrated a unique ability of graphene to target and successfully boost the 
necrosis of monocytoid cancer cells for acute myeloid leukemia and chronic myelomonocytic 
leukemia patients. Moreover, the comparison between FLG and a common chemotherapeutic 
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drug confirmed the specificity and higher toxicity of FLG on cancer cells, evidencing the 
absence of toxicity on other immune cell populations. Considering the FLG specific ability to 
target and kill cancer cells of an aggressive form of malignancy, extremely promising potentials 
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Experimental Section  
FLG characterization 
The thermogravimetric analysis was performed with a TGA Q50 (TA Instruments) at 10ºC/min 
in a nitrogen atmosphere. For Raman spectroscopy, the water dispersion was drop-cast onto a 
silicon surface (Si-Mat silicon wafers, CZ). Measurements were carried out using a 100x 
objective at 532 nm laser excitation using a SENTERRA Raman Microscope. X-Ray 
photoelectron spectra (XPS) were obtained with a VG Escalab 200R spectrometer equipped 
with a hemispherical electron analyser with a pass energy of 50 eV and a Mg K α ( h ν = 1254.6 
eV) X-ray source, powered at 120 W. Binding energies were calibrated relative to the C 1s peak 
at 284.8 eV. High-resolution spectra envelopes were obtained by curve fitting synthetic peak 
components using the software “XPS peak”. Symmetric Gaussian–Lorentzian curves were used 
to approximate the line shapes of the fitting components. For TEM analysis, cell culture 
medium (RPMI-1640, ref. R8758) dispersion was dip-cast on a copper grid (3.00 mm, 200 
mesh, coated with carbon film) and dried under vacuum, Sample was investigated by high-
resolution transmission electron microscopy (HRTEM) JEOL 2100. Lateral dimension 
distribution was carried out using Fiji-win32. Elemental analysis (EA) afforded the following 
percentages: %C: 94.84±1.08, %H: 0.30±0.13, N: 0.29±0.02 and %O: 4.58±0.96. From these 
data 0.5% of melamine is present in the sample. EA was performed in a LECO CHNS-932 
analyzer (Model No: 601-800-500). The control GO sample was obtained from NanoInnova 
(Spain) (Batch no° GOZ.10.2-12). 
 
Cell culture and maintenance 
Human peripheral blood mononuclear cells (PBMCs) were obtained from informed healthy 
male donors (25 to 50 years old) and a cohort of seven patients (6 male and 1 female) with a 
median age of 70, diagnosed with AML (3) or CMML (4) before the start of the classical 
therapeutic treatment. Informed signed consent was obtained from all the donors. The present 
research was evaluated and approved by the local ethic committee of the University of Sassari. 
Cell separation and experiments were performed immediately after blood drawing. PBMCs 
were isolated from the fresh heparinized blood by Ficoll-Paque PLUS (FLG Healthcare) density 
gradient centrifugation. Primary monocytes from purified PBMCs were isolated by Dynabeads 
Untouched Human Monocytes Kit (Invitrogen), following the manufacturer protocol. PBMCs 
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and isolated monocytes were cultured in RPMI 1640 medium (Gibco) containing 1% antibiotic-
antimycotic mixture and 10% heat-inactivated fetal bovine serum (FBS) (Gibco).  
 
TEM analysis of PBMCs 
For the TEM observation, cells were exposed to FLG (25 µg mL-1) during 24 h. As the 
monocyte population completely disappears at the highest concentration (50 µg mL-1), we 
decided again to reduce the maximum concentration to 25 µg mL-1 in order to observe the 
interactions between FLG and PBMCs, including monocytes. At the end of incubation time, 
cells were precipitated by centrifugation (1200g during 5 min) and fixed overnight at 4 °C with 
2.5% glutaraldehyde. On the following day, cells were again precipitated and the pellet was 
included in agarose (1.5%). The agarose pellet was collected, washed twice in distilled water 
and then submitted to a secondary fixation with 1% aqueous osmium tetroxide (30 min at room 
temperature). After rinsing cells three times with distilled water, dehydratation was performed 
through a series of baths: twice with 50% ethanol (10 min), once with 70% ethanol (20 min), 
once with ethanol 95% (10 min), twice with absolute ethanol (10 min) and finally twice with 
propylene oxide (for 10 min each). Infiltration with epoxy resin Epon was done using mixtures 
of propylene oxide and Epon resin in 2:1 (1 h) and 1:2 (1 h) ratio and finally with pure resin (1 
h). On the last day, resin was replaced with fresh one and further incubated during three hours. 
Polymerized block with embedded cells were then prepared filling gelatine capsules with fresh 
resin and placing them upon the agarose inclusions in which the pellet of cells was previously 
included. As-prepared capsules were then placed into the oven to polymerize the resin at 60 °C 
for 48 h afterwards ultrathin sections (70 nm thick) were obtained using an ultramicrotome 
(Leica) with a diamond knife (DiATOME). The ultrathin sections were then collected on 
butvar-coated single-slot copper grids and examined by TEM (Hitachi H600). 
Viability and activation analysis of PBMCs from healthy donors 
Healthy PBMCs were incubated for 24 h with increasing concentrations of FLG (0.5, 5, 25, 50 
and 75 μg mL-1). After 24 h cells were stained with Live and Dead staining (Invitrogen). Ethanol 
(70%) treated samples were used as positive controls, while samples incubated with cell 
medium alone were used as negative controls. The viability screening of total PBMCs and 
different immune subpopulations was made by flow cytometry (FACS Canto, BD Biosciences). 
Major immune cell populations from PBMCs were identified by flow cytometry according to 
the expression of specific cell surface markers [clusters of differentiation (CD)] that were 
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detected with fluorescently-labeled monoclonal antibodies. Specifically for the cell 
phenotyping we used anti-CD3, anti-CD14, anti-CD56, anti-CD20 and anti-CD123 antibodies 
purchased from BD Biosciences (Mountain View, CA, USA). Staining with fluorochrome-
conjugated monoclonal antibodies was performed in the dark for 20 min. Cell typing was 
performed using the above mentioned antibodies to recognize the major population of PBMCs: 
CD3+ for T cells, CD20+ for B cells, CD56+/CD3- for NK cells, CD14+ for monocytes and 
CD123+ for dendritic cells. To investigate the functional impact of FLG at the medium 
concentration of 50 μg mL-1 on PBMCs, considering activation of cells as a crucial endpoint, 
we choose CD25 and CD69 that are critical markers for the immune response. Concanavalin A 
(ConA, 10 g mL-1) and lipopolysaccharides (2 g mL-1) were used as positive controls. After 
24 h of incubation, PBMCs were harvested, washed two times with PBS and stained to identify 
immune cell populations and analyze activation marker expression. The specific effect of FLG 
(50 g mL-1) on monocytes (CD14 positive population) was evaluated also with the effect 
comparison with melamine (0.5%) after 24 h incubation.  
Cellular activation was explored through CD86 expression evaluation. Briefly, after FLG 
treatment, PBMCs were collected and stained with PE-Mouse anti-Human CD86 antibodies 
(Clone 2331(FUN-1), BD Pharmingen 555658), prior to flow cytometry acquisition. 
Lipopolysaccharide (LPS, 100 ng mL-1) was used as cellular activation positive control. As the 
monocyte population completely disappears at the highest concentration (50 µg mL-1), we 
decided to reduce the maximum concentration to 25 µg mL-1 in order to observe and analyze 
the effect of FLG on PBMCs including at least few monocytes. The CD86 associated 
fluorescence intensities were determined by acquiring at least 100,000 events using a Gallios 
Flow Cytrometer (Beckman Coulter) and analyzing the data with FlowJo software. 
 
FLG viability on non-immune cell lines 
MDA-MB-231 and  PC3 cell lines cultured in Dulbecco modified eagle edium (DMEM), 
completed with 10% FCS and 1X penicillin streptomycin solution in incubator at 37°C and 5% 
CO2, were exposed to different concentrations of FLG (5 to 50 µg mL-1) for 24 h. Necrosis and 
apoptosis were assessed using 7AAD and Annexin V staining and analyzed by flow cytometry. 
Ethanol was used a positive control. 
 
FLG gene expression analysis  
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Isolated monocytes from healthy donors were incubated at early time points (30, 90 and 270 
min) with 50 μg mL-1 of FLG. After the incubation the total mRNA was extracted with TriZol 
Reagent (TriZol, Invitrogen, Carlsbad, CA, USA) and purified using the RNAeasy minikit 
(Qiagen, Valencia, CA, USA). RNA purity was assessed by spectrophotometric analysis and 
integrity by microfluidic molecular sizing using the Bioanalyzer 2100 (Agilent). Samples with 
RIN (RNA Integrity Number) less than 8 were discarded. RNA (1 μg) was converted in cRNA 
and labeled (Agilent One-Color Microarray-Based Gene Expression Analysis kit). Biotinylated 
cRNA was hybridized onto 072363 SurePrint G3 Human GE 8×60K array slide (60 000 probes, 
Agilent technologies). Slides were then hybridized (Agilent protocol), washed, and scanned on 
an Agilent C Scanner according to the manufacturer’s instructions. Data were finally analyzed 
using the GeneSpring GXI (Agilent Technologies) and Ingenuity Pathways Analysis software 
(Qiagen, Valencia, CA, USA). 
 
Viability of isolated monocytes from healthy donors 
 Isolated monocytes from healthy donors were incubated at different time points (1, 4, 12, and 
24 h) with 50 μg mL-1 of FLG. Live and Dead staining (Invitrogen) and Annexin-V FITC, 
propidium iodide (PI) apoptosis and necrosis kit (Invitrogen) stainings were done. The 
screening was made by flow cytometry (FACS Canto, BD Biosciences). 
 
FLG impact on cancer monocytes from myelomonocytic leukemia patients ex vivo 
MML  PBMCs were incubated for 24 h with FLG at increasing concentrations (0.5, 5, 25, 50 
μg mL-1). After the incubations cells were harvested and washed with PBS. Staining for flow 
cytometry was made with anti-CD14 antibody.  
 
Etoposide and FLG impact comparison on PBMCs from MML patients 
AML and CMML PBMCs were incubated for 24 h with FLG (50 μg mL-1) and etoposide (50, 
100 and 200 μM). After the incubations all cells were harvested and washed with PBS. The 
viability analysis was made with the 7AAD dye in flow cytometry (FACS Canto, BD 
Biosciences). Same staining and gating strategies for healthy PBMCs viability was made for 
the screening of different immune cell populations. The specific effect of graphene and 
etoposide on monocytes (CD14 positive cells) was made through the count of total events 
recorded in treated and untreated samples.  
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In vivo systemic toxicity 
Seven male C57BL/6 mice (weight 15-30 g) were divided into two groups: a treated group 
injected with FLG and a control group injected with fresh, sterile saline. Mice were 
intraocularly injected with FLG at the concentration of 50 µg mL-1 of blood (treatment group) 
or saline (control group). Mice were housed in groups of 3 and 4 animals per cage, fed with 
standard food and water ad libitum and monitored for any sign of adverse reaction or fatality 
for 7 days. After 7 days, mice were sacrificed and several organs and whole blood were 
harvested. Bone marrow cells were flushed from femur and tibia, spleen and lymph nodes were 
mechanical dissociated by gentle trituration and filtered through a cell strainer to create a single 
cell suspension. Collected cells were stained with anti-mouse CD3, CD19/Cd45R, Gr1, CD11b, 
F4/80 and CD14 antibodies to detect, T cells, B cells, granulocytes, DCs, macrophages and 
monocytes analyzed by LSR II flow cytometer (BD Biosciences). The blood count test was 
performed with heart harvested whole blood. The analysis was performed with a Coulter LH 
780 analyzer (Beckman Coulter). 
 
Animal study 
The study was carried out in accordance with current Italian legislation [D.L. 116, 1992], and 
in strict accordance with European Council directives on the matter [n. 2007/526/CE]. All 
possible efforts were made to minimize animal pain and discomfort and to reduce the number 
of experimental subjects. 
 
Statistical analysis 
Data analysis for flow cytometry experiments was performed using FACSDiva software (BD-
Bioscience Mountain View, CA, USA). All the experiments were performed at least in 
triplicate. Statistical analyses were performed using Student’s t-test. Data indicated with star 
were considered statistically significant (two-side p value, *= P Value <0.05; **= P Value 
<0.01). Data are presented as mean   SD. Multiplex ELISA tests and flow cytometry analysis 
on isolated human primary PBMCs from healthy donors were performed in samples from at 
least 3 different donors. 
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Figure S1. Top: C 1s XPS spectra of graphite and FLG. Bottom: results of the XPS C 1s and N 1s curve fittings 
for graphite and FLG. 
 
 
Additional Raman analysis 
It is commonly accepted that the thickness of few-layer graphene nanosheets is reflected in the 
shapes of their 2D Raman bands (around 2700 cm-1). Following the equations reported by 
Coleman and coworkers,[1] we calculated the number of layers of our FLG in water and in cell 
culture medium. The number of layers (NG) is calculated considering also the Raman spectrum 




Where M is equal to: 
 =
 ′( = , ′)/ ′( = , ′)
 ′( = , ′)/ ′( = , ′)
 
















  291.5 eV
   C-C
284.8 eV
  C-O, C-N
  286.3 eV
 C=O, C=N
  287.7 eV
C1s
Graphite
  C1s N1s 
Graphite 284.93 C-C   
  286.31 C-O   
  287.78 C=O   
  291.48    
FLG 284.93 C-C 399.04 N-H 
  286.29 C-O 400.16 N=C 
  287.67 C=O   
  291.33    
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IG’ene and IG’ite correspond with the intensity of G’ band for graphene and graphite, respectively. 
We have analyzed at least 50 individual Raman spectra of few-layer graphene dispersed in 
water and in culture media, obtaining the following average results. Raman results suggest that 












Graphite 0.41 0.20 2.03 1 
 
FLG in water 0.42 0.40 1.04 0.51 3.55 
FLG in culture media 0.41 0.37 1.11 0.55 3.95 
 
Table. Average values for the Intensity of the 2D band at the wavelength associated with the peak of graphite 
(,) (I1) and at the wavelength associated with the low energy shoulder of the graphite 2D band (,) 
(I2) for graphite and FLG dispersed in water and in culture media. Number of layers (NG) for FLG dispersed in 
water and culture media. 
 
Figure S2. Viability of human primary immune cells. A) PBMCs were incubated for 24 h with FLG at 
increasing doses of 0.5, 5, 25, 50 and 75 μg mL-1 or left untreated, ethanol was used a positive control. Data 
obtained from staining with an amine-fluorescent dye able to react with the free amines of compromised 
membranes of late apoptotic and necrotic cells. Experiments were performed at least in triplicate and analyzed by 
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Figure S3. Viability screening of FLG on the different immune cell populations.  A) Percentage of T cells, B cells, 
NK cells and dendritic cells dead events after treatment with increasing doses of FLG (0.5, 5, 25, 50 and 75 μg 
mL-1). B) Count of monocyte events before and after treatment with FLG at different concentrations. All analyses 
were performed by flow cytometry. Statistical significance compared to untreated cells (student’s t test) is 
indicated by *= p < 0.05 and ** = p < 0.01. 
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Figure S4. Immune cell impact of melamine. PBMCs were incubated for 24 h with 50 μg mL-1 of FLG, 0.5% of 
melamine or left untreated. Morphological dot plots were measured with side scatter (SSC) and CD14 antibody 
by flow cytometry. Dot plots were derived from one representative experiment out of three. 
 
In order to exclude that the specific effect of FLG on monocytes was due to the presence of 
residual melamine in the FLG dispersions,[4] we performed a comparative analysis looking at 
the effect of this molecule on the viability of monocytes. The number of monocytes remained 
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similar to the control with 20% of CD14 positive events after the treatment with melamine at 
0.5% (w/v) concentration, which corresponds to the amount of molecule that remained 
complexed to FLG after the exfoliation process. 
 
Figure S5. Flow cytometry analysis of cellular viability of breast cancer and prostate cancer cells. A) MDA-MB-
231 and B) PC3 cell lines were exposed to different concentrations of FLG (5 to 50 µg mL-1). Necrosis and 
apoptosis were assessed treating the cells using 7AAD and Annexin V staining, respsctively. Ethanol was used as 
positive control. Two tails student T test was performed to determine the statistical differences versus control cells. 
The experiments, performed in triplicate, showed no significant differences (P value >0.05) in all cells treated at 
the different concentrations. 
 
Figure S6. Cellular activation in PBMCs. Flow cytometry analysis of CD86 expression in PBMCs exposed 
to different concentrations of FLG. One-Way ANOVA followed by Dunnett’s post-test was performed to 
determine the statistical differences versus control cells (*p<0.05; **p<0.01; ***p<0.001). 
As the monocyte subpopulation completely disappears at the highest concentration (50 µg mL-1), we decided 
to reduce the maximum concentration to 25 µg mL-1 in order to observe and analyze the effect of FLG on 
PBMCs including at least few monocytes. Our data revealed that the activation state of PBMCs (CD86 
expression) was not influenced by the incubation with FLG up to 25 µg mL-1 even if a very little increase 
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Figure S7. Activation analysis of FLG on human immune cells. PBMCs were incubated for 24 h with 50 μg mL-
1 of FLG or left untreated. A specific gate using forward light scatter (FSC) and side light scatter (SSC) on total 
lymphocyte populations (red) was assessed to better visualize the T cell population (CD3 positive events in green). 
Activation test was performed looking at the expression of CD69 and CD25 in T cells. Concanavalin A (10 μg 
mL-1) was used as a positive control. Dot plots of CD69 and CD25 expression on T cells was assessed by flow 





Figure S8. FLG cell uptake by human primary immune cells. TEM caption of PBMCs incubated with FLG (25 
µg mL-1) for 24 h. Arrows are indicating FLG sheets inside the cells. MC: Monocytes; LC: Lymphocytes. Scale 
bar = 2 µm. 
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Figure S9. Comparison of the effect of FLG with a commercial GO. PBMCs from healthy donors were incubated 
with FLG and commercial GO at the concentration of 50 μg mL-1 for 24 h or left untreated. Morphological dot 
plots were performed using side light scatter (SSC) and CD14 by flow cytometry. Dot plots were derived from 
one representative experiment out of three. 
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Figure S10. Viability of isolated monocytes after treatment with 50 μg mL-1 FLG. A) Annexin V and PI staining 
indentify necrotic and apoptotic cells, respectively. Statistical significance compared to untreated cells (student’s 
t test) is indicated by ** = p < 0.01. B) Morphological analysis was conducted with side light scatter (SSC), and 
CD14. C) Viability assay was also performed using Live and Dead staining. Dot plots in the panel B were derived 
from one representative experiment out of three. 
 
CD14+





































Chapter 4 | Results 
 
Dr. Marco Orecchioni. Titolo “Biomedical applications of different nanomaterials: 
Characterization and interaction with the immune system”  





Figure S11. Gene expression impact of FLG at early time points in human isolated monocytes. A) Venn diagrams 
reporting the number of probe-sets modulated in response to FLG incubations for 30, 90 and 270 min. The Venn 
diagram is divided in three areas, one for each time points used. The total number of modulated genes in each 
areas are reported between the parenthesis. B) Top 10 first canonical pathways ranking according to significance 
level [Fisher exact test es log (p-value) reported in red] modulated by FLG identified using gene enrichment 
analysis. The Z-score of each pathway is expressed under each column. 
 
The mechanisms of FLG mediated cell death was studied looking at whole-genome expression 
at early time points using the microarray technology. To achieve this goal, we used the 
microarray approach (Agilent technology) looking at more than 41000 transcripts on isolated 
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monocytes from healthy patients. The cells were incubated with 50 µg ml-1 of FLG at very early 
time points (30, 90 and 270 min) or left untreated. To compute the probability of genes being 
differentially expressed between the treated samples and controls, we used a random variance 
ANOVA test as implemented in Gene Spring GX Software (Agilent Technology). All genes that 
passed the cutoff p-value of 0.001 with a false discovery rate (FDR) lower than 5% are shown 
in Table S1. Venn Diagram is displayed in Figure S11A. To understand the biological function 
of FLG we then used Ingenuity Pathway Analysis (IPA). In Figure S11B are shown the 10 most 




Figure S12. Role of TLR2 and TLR4 receptor in the FLG effect in isolated monocytes.  Flow cytometry analysis 
of cellular viability of ex vivo monocytes exposed to FLG at the concentration of 50 µg mL-1 without or with anti-
hTLR2 and anti-hTLR4-IgG blocking antibodies (1 µg mL-1; Invivogen mabg-htlr2; mabg-htlr4) after 90 min of 
incubation. A) Count of monocytoid cells (CD14+).  B) Activation marker expression (CD25) by monocytes. Two 
tail student T test was performed to determine the statistical differences versus control cells under non-blocking 
and blocking conditions (*p<0.05; **p<0.01). 
 
The experiments aimed to assess the role of TLRs in the absence or in the presence of specific 
blocking antibodies were performed after 90 min of incubation as found by the microarray 
analysis to be the optimal time point to understand the early effect of FLG on monocytes. We 
performed several experiments looking at the cell activation and viability of monocytes using 
CD25 as a marker and the cell event evaluation (Fig. S12). As anticipated in the main text, the 
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contact with specific receptors (the so-called Death Receptors).[5] Our hypothesis is also 
confirmed by the up-regulation of TNFRSF6B found in FLG treated samples. This gene, also 
called FAS receptor, is part of the Death Receptors and after the contact with FAS ligands is 
able to activate the death effector domain leading to cell death.[6] Our data highlight an 
inflammatory induced toxicity played by FLG demonstrating that TLR2 signaling pathway has 







Figure S13. Intracellual presence of FLG on ex vivo PBMCs from AML and CMML patients. PBMCs from AML 
and CMML patients were incubated for 24 h with different FLG concentrations (0.5, 5, 25 and 50 μg mL-1) or left 
untreated. (A) Visualization of FLG into AML monocytoid cancer cells highlighted by red arrows. Pictures of 




Figure S14. Histograms of myeloid CD14 positive cell ablation in PBMCs from AML and CMML patients 
incubated for 24 h with different FLG concentrations (0.5, 5, 25 and 50 μg mL-1) or left untreated. All analyses 
were performed by flow cytometry.  
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Figure S15. Cytokine secretion assay. Multiple cytokine secretion assay (ELISA) on total PBMCs from CMML 
patients. All analyses were performed by flow cytometry. Statistical significance compared to untreated cells 
(student’s t test) is indicated by * = p < 0.05 and ** = p < 0.01. 
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Figure S16. In vivo inflammation and toxicology analysis of FLG. The effects of FLG were evaluated on in vivo 
mice model. After one week from injection with 50µg mL-1 of blood (100 µg injected per mouse), mice were 
sacrificed and several organs and whole blood were harvested. (A) i) Bone marrow cells were flushed from femur 
and tibia; ii) spleen, and iii) lymph nodes were mechanical dissociated by gentle trituration and filtered through a 
cell strainer to create a single cell suspension. Collected cells were analyzed by flow cytometry. B) Blood count 
table on harvested whole blood. Two tails student T test was performed to determine the statistical differences 
versus control cells. 
 
FLG at the concentration of about 50 µg mL-1 of blood were intravenously injected by 
intraocular route in C57BL/6. The effect were compared to negative control mice injected only 
with saline. Inflammatory reaction analysis was assessed. Bone marrow cells, spleen and lymph 
nodes were analyzed (Fig. S16A). We found no significant changes (P value >0.05) on immune 
cell populations in analyzed organs (Fig. S16Ai, ii, iii). As expected only CD14+ bone marrow 
monocytes were significantly reduced in percentage (P value <0.05) compared to controls (Fig. 
Blood Count Ctrl Avg +/- Sd FLG Avg +/- Sd P value Units
WBC 2.28 +/- 1.57 4.125 ± 1.52 0.18 109/L
RBC 4.24 +/- 0.93 4.46 ±0.86 0.76 1012/L
HGB 3.9 +/- 0.82 4.1 ±0.81 0.76 mmol/L
HCT 0.22 +/- 0.05 0.23 ±0.04 0.91 Ratio
MCV 52 +/- 1.68 50.55 ±0.47 0.15 fL
MCH 0.92 +/- 0.009 0.92 ±0.007 0.79 fmol
MCHC 286 +/- 0.72 18.175 ±0.15 0.28 mmol/L
PLT 286 +/- 82.29 434.25 ±162.41 0.22 109/L
MPV 7.87 +/- 0.35 7.48 ±0.21 0.12 fL
PDW 8.1 +/- 0.82 7.38 ±0.21 0.14 fL
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Lipid nanocapsules (NCs) represent promising tools in clinical practice for diagnosis and 
therapy applications. However, the NC appropriate functionalization is essential to guarantee 
high biocompatibility and molecule loading ability. In any medical application, the immune 
system-impact of differently functionalized NCs still remains to be fully understood. A 
comprehensive study on the action exerted on human peripheral blood mononuclear cells 
(PBMCs) and major immune subpopulations by three different NC coatings: pluronic, chitosan 
and polyethylene glycol-polylactic acid (PEG) is reported. After a deep particle 
characterization, the uptake was assessed by flow-cytometry and confocal microscopy, 
focusing then on apoptosis, necrosis and proliferation impact in T cells and monocytes. Cell 
functionality by cell diameter variations, different activation marker analysis and cytokine 
assays were performed. We demonstrated that the NCs impact on the immune cell response is 
strongly correlated to their coating. Pluronic-NCs were able to induce immunomodulation of 
innate immunity inducing monocyte activations. Immunomodulation was observed in 
monocytes and T lymphocytes treated with Chitosan-NCs. Conversely, PEG-NCs were 
completely inert. These findings are of particular value towards a pre-selection of specific NCs 
coatings depending on biomedical purposes for pre-clinical investigations; i.e. the immune-
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Nanomedicine has reached the interest not only of the scientific community but also of the 
public, becoming one of the most promising approaches for developing new tools in clinical 
practice 1,2. Among other nanomaterials, biodegradable lipid nanocapsules (NCs) present 
incredible characteristics as drug carriers or in diagnosis applications as contrast agents 3,4. 
Their useful properties include biocompatibility and biodegradability 5, the ability to perform a 
controlled release of drugs 6,7 and to target specific tissues 8. Specifically, NCs consisting of an 
oil-filled core with a surrounding polymer shell can be used to encapsulate and deliver 
hydrophobic drugs 9,10. The appropriate carrier design and functionalization, particularly the 
composition and surface properties, are essential to ensure high biocompatibility and to protect 
molecules of interest from degradation and premature elimination 11. Biodegradable polymers 
and molecules have been extensively studied as loading molecules for NCs to improve their 
hydrophilicity in biological media, for new possible treatments of many diseases. Well before 
any pre-clinical application, it is of fundamental importance to choose the most suitable coating 
for the NCs. Moreover, for any medical application which requires intravenous injection, the 
first type of cells that will interact with the NCs are the blood immune cells making the NCs 
immunocompatibility assessment of critical importance for any translation into clinical 
practice. Aiming at providing an extensive overview on the immune impact of differently 
functionalized NCs, we report for the first time a comprehensive analysis on immune cell 
interaction with three different NCs coatings: pluronic F68 (Pluro), chitosan (Chito) and 
polyethylene glycol-polylactic acid (PEG-PLA, indicated in the text as PEG). Pluro, Chito and 
PEG coatings have been successfully used for NC functionalization for many applications 12,13. 
PEG has been significantly employed to functionalize several nanomaterials to better deliver 
different genes and drugs such as camptothecin for the cancer treatment 14-17. Controversial 
studies have been published in literature on the ability of PEG coating to be internalized into 
cells. Some studies have already reported the capability of PEG coating to be internalized into 
macrophages and other cells such as hepatocytes 18,19. However, very recently Yang Q and 
colleagues have shown a reduced uptake of PEG coated nanoparticles by macrophages, but 
these interactions with phagocytic cells are critically dependent on the conformation of 
individual PEG chains and on the brush conformation onto the particles. Furthermore, very few 
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results were reported about internalization of PEG coating into other immune cells 
subpopulations 20. NCs loaded with chitosan have been extensively studied to enhance the 
therapeutic use of siRNAs 12,21. Moreover, chitosan is commonly used as a transacylation 
polymer evidencing its non-toxicity 12,21,22. In order to improve the NC drug delivery abilities, 
the NC shell can be also functionalized with pluronic, a nonionic triblock copolymer. Thus its 
amphiphilic structure can be used to increase the water solubility of many substances. For this 
reason, pluronic coated NCs have been evaluated for various drug delivery applications, i.e. in 
cancer cells 13. Moreover, these nanocarriers have been shown to inhibit multiple drug resistant 
proteins (MDR) and other drug efflux transporters on the surface of cancer cells; MDR proteins 
are responsible for drug efflux  from cells and hence decrease the susceptibility of cancer cells 
to chemotherapeutic agents such as doxorubicin 23. All these substances have been successfully 
used to improve the ability of NCs to deliver drugs and genes for the treatment of cancer and 
other diseases.  
Biocompatibility analyses of NCs have been previously conducted, focusing on different organs 
and evidencing low toxicity 24. However, to the best of our knowledge no studies reported a 
comprehensive immune-compatibility comparison analysis of differently functionalized NCs 
on immune cells, specifically ex vivo from healthy donors. For any translational application of 
nanomaterials in medicine, a key step is represented by the assessment of their possible 
interactions with the immune system, independently of their specific purpose 25-28.  In this 
context, the lack of information in literature created an urgent need to better understand 
different NC-coating effects on the immune system.  
Hence, here the impact of three differently functionalized NCs was analyzed, namely Pluronic, 
Chitosan, and PEG, on human primary immune cells populations, in particular on red blood 
cells (RBCs) hemolysis and peripheral blood mononuclear cells (PBMCs) from healthy donors. 
First, we deeply analyzed the possible differences in NC internalization on PBMCs and 
subpopulations, such as T, B, NK cells and monocytes, to assess whether a certain coating could 
be more suitable for the cell uptake. We explored the possibility of necrosis, apoptosis and 
proliferation of PBMCs and subpopulations of T cells and monocytes, as representative of the 
adaptive and innate immune response. The functionality effect was tested observing: (i) the cell 
diameter modification; (ii) the expression of the most critical activation marker, namely CD25 
and CD69; (iii) the production of a wide variety of cytokines.  
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Nanocapsules synthesis and characterization 
Two nanocapsule systems, indicated as EPI and CS in Sánchez-Moreno et al.8, were previously 
obtained and characterized with an anionic (Pluro NCs) and a cationic surface (Chito NCs); 
instead, a new nanocapsule system (PEG NCs) was prepared by a solvent-displacement 
technique following the procedure of Prego et al. 29 by mixing an organic and an aqueous phase. 




Figure 1 Nanocapsule characterization: (A) Schematic details of the nanocapsule composition. (B) 
Electrophoretic mobility vs. pH of nanocapsules. (C) Intensity-weighted size distribution of NCs obtained from a 
DLS measurement. (D) Critical coagulation concentration (CCC) and critical stabilization concentration (CSC) 
data (mM), at pH 7.4, using NaCl and CaCl2 as aggregating salts. (E) Chemical structure of Pluronic F68 (average 
MW 8400 g/mol) with a central hydrophobic fragment of polyoxypropylene (PPO) and identical hydrophilic 
chains of polyoxyethylene (PEO) at both sides. n = 75 PEO units and m = 30 PPO units (upper image). Chemical 
structure of PEG-PLA. PEG average MW 350 g/mol (n = 8 EO) units. ) PLA average MW 1000 g/mol (lower 
image). 
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All nanosystems were formed by olive oil in their hydrophobic core and epikuron on their shell; 
depending on the composition of the aqueous phases (pluronic F68, chitosan or PEG-PLA), the 
final samples showed different shell composition and thus, different interface properties. The 
nanocapsule size and electrophoretic mobility were characterized by dynamic light scattering 
(DLS) while the colloidal stability was spectrophotometrically studied working at physiological 
pH in simple saline media (NaCl and CaCl2) by analyzing the change of particles diameter as a 
function of time.  
The hydrodynamic size of all nanocapsule systems showed a narrow distribution (PDI < 0.15), 
as it is illustrated by the representative intensity weighted size distribution of different NCs 
reported in Figure 1C. In the present study, the synthesis procedure yielded to spherical 
nanocapsules with an average diameter in the nanometric scale that is potentially useful for 
biological applications; in fact, a mean diameter under 200-300 nm is advised in specialised 
literature. The size of PEG NCs was 167 ± 14 nm, while the size of Pluro NCs and Chito NCs 
were 170 ± 20 nm and 340 ± 30 nm, respectively, as previously reported 8. The electrophoretic 
mobility data of PEG NCs, gathered from low-ionic-strength media, are also shown in Figure 
1E. The μe results agree with the nature of the shell and they confirm the presence of the 
different molecules used in their synthesis. Pluro and PEG NCs showed a typical behaviour of 
colloids with weak acid groups, which come exclusively from the epikuron molecules with 
phosphatidyl-choline as the major component, giving lower μe values at acidic pH values than 
those found at neutral and basic pH 30,31. PLA chains absorb onto hydrophobic interfaces, while 
PEG hydrophilic chains remain extended in the hydrophilic phase. Since PEG is a non-ionic 
surfactant it does not alter the electrical state of the surface. A similar pattern was observed for 
Pluro NCs, in which the non-ionic polyethylene oxide chains from pluronic did not influence 
the electric surface behaviour. On the other hand, the μe behavior of Chito NCs radically 
changed as a consequence of the presence of chitosan chains with glucosamine groups, 
presenting with a weak basic character and driving mobility from positive values at acidic pH 
to negative values at basic pH 32. The analysis of coagulation kinetics enabled us to calculate 
the stability factor W, which provides information on the coagulation probability (W = 1 
indicates a completely unstable system, while W = ∞ means total stability); at the same time, 
nanoparticle critical coagulation concentration (CCC) and critical stabilization concentration 
(CSC) were obtained, which are considered fundamental parameters in colloidal-stability 
studies. A thorough explanation of the respective significances of these values and on the 
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method applied to obtain CCC and CSC values from coagulation kinetics data, is given in the 
supplementary section of reference 33. The CCC value is related to destabilization processes 
and it indirectly gives information on the surface-charge density of the particles; thus, a low 
CCC means low stability caused by a low surface-charge density. Instead, the CSC value – 
defined as the minimum salt concentration at which the system begins to re-stabilize when 
salinity is increased– is associated with the surface hydrophilicity. This kind of restabilization 
phenomenon at high salt concentrations is well known in hydrophilic colloidal systems and it 
is governed by hydration forces 34. Figure 1D shows the CCC and CSC values of different NC 
systems. With respect to the stability of the PEG system in NaCl, no aggregation of the particles 
was detected even at concentrations up to 4M because the CCC and CSC concentrations 
overlapped, inducing completely stable systems. An analysis of the colloidal stability in CaCl2 
indicated that Chito NCs were the least stable of the systems 8 since they coagulated as soon as 
the nanocapsules were immersed in the buffer at pH 7.4. In a high-salinity solution this system 
was stable due to the action of the repulsive hydration forces due to the fact that chitosan in an 
hydrophilic material. PEG NCs presented lower CCC value (22mM) compared to Pluro NCs 
(61mM), since the number of polyethylene oxide (PEO) fragments in the pluronic (75 units) 
was higher compared to the number of ethylene oxide (EO) in the PEG (8 units) as shown in 
figure 1B; in conclusion, these molecules contribute to the stabilization of the systems by 
means of a steric mechanism and increase the surface hydrophilicity 32,35.  The CSC data 
corresponding to CaCl2 confirm the presence of pluronic (in Pluro NCs) and PEG (in PEG NCs) 
molecules on the surface, showing a restabilization process typical of surfaces with hydrophilic 
character. Nanoemulsion behaviour in several fluids (water, PBS and DMEM with 10%FBS) 
was also evaluated, revealing high stability in all tested solutions (data not shown). 
 
Functionalized nanocapsule biocompatibility in red blood cells and immune cells. 
The release of hemoglobin from damaged RBCs was observed and any NC-related damage on 
red blood cells was excluded (S. Figure 1). To assess the immune cell internalization ability of 
NCs, they were encapsulated with Courmarin 6 as a fluorophor in the hydrophobic cores of 
Pluro, Chito and PEG NCs. A dose-response analysis of the nanoparticle uptake at 1x1010NCs 
mL-1, 1x1011NCs mL-1 and 1x1012 NCs mL-1 was performed (S. Figure 2A). The ability of 
differently functionalized NCs to enter inside the cells was described through an accurate 
analysis by flow cytometry 33 and confocal microscopy. Moreover, it has been previously 
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determined that after few hours of exposure, the amount of adhering particles is in most cases 
minimal in comparison to the active uptake and the internalized load 36. The performed time 
response showed no uptake difference in the three analyzed time points (at 6, 12 and 24 hours) 
(S. Figure 2B). Furthermore, the Trypan Blue washing was performed to quench the NC signal 
outside the cells, as we previously performed for other nanomaterials 17 (S. Figure 2C). The 
24-hour incubation time was adopted for all the other investigation since this is a good time 
point to study the effect of any nanoparticle or nanomaterial on immune cells, as other research 
groups suggested 39,40. 
Data shown at 1x1011NCs mL-1 and at 1x1012 NCs mL-1 after 24-hour incubation that almost 
100% of cells internalized all three NCs (S. Figure 2A).  
 
 
Figure 2 Uptake analysis of Nanocapsules. A) T cells (CD3+) and Monocytes (CD14+) uptake of Pluro, Chito, 
PEG nanocapsules loaded with Courmarin 6. Samples were analysed by FACS Calibur (BD Biosciences) and 
FlowJo software. On the upper pseuducolor Dot Plot are representative experiments out of 4 independent 
investigations. Down **= P value < 0,01. B) Confocal microscopy imaging of PBMCs incubated with Pluro, Chito 
and PEG NCs loaded with Courmarin 6 at the concentrations of 1x1011 mL-1. Dark field, bright field and overlay 
images were captured with Leica TCS SP5 confocal (Leica). Scale bar 25 μm. 
 
Intriguingly, during the present study no inhibition was observed in NC internalization 
mediated by PEG (Figure 2A and S. Figure 2 A and B). The PEG mediated action on 
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internalization is still under discussion due to its well-known stealth property 20. However, other 
recent studies evidenced how a specific PEG coating can enhance the nanoparticle uptake, such 
as in the case of cancer cells 37,38. On the other hand, the chosen time point (24h) might be also 
responsible for the no PEG mediated uptake inhibition, as it was also reported in the study of 
Sheng Y et al. 41. The concentration chosen for the further experiments was 1x1011NCs mL-1; 
indeed, a high uptake for all NC coatings was found at this amount of particles, ensuring that 
any interaction into immune cells, upon internalization, was missed. Moreover this 
concentration was previously found to be optimal for drug delivery studies 42.  
To confirm the preliminary uptake data, the cell internalization in the subpopulations of 
immune cells was detected. Cells were gated by specific membrane markers for the two major 
subpopulations of PBMCs, T cells and monocytes (Figure 2A). All types of NCs were able to 
target T cells and monocytes with a high frequency close to 100%, as showed by the FACS 
pseudocolor Dot Plot and by histograms. The uptake analysis was tested also on a wide variety 
of other subpopulations, such as lymphocytes T helper, lymphocytes T cytotoxic, natural killer 
cells and B cells gated by different surface marker staining by flow cytometry (S. Figure 3); 
again, NCs were able to enter into all studied cell types with a passive targeting of immune 
cells.  Moreover, the internalization of Pluro, Chito and PEG NCs was confirmed by confocal 
microscopy. PBMCs were treated with NCs at the concentration of 1x1011NCs mL-1 for 24 
hours and then visualized. All pictures confirmed the internalization of Pluro, Chito, PEG NCs 
into cells (Figure 2B). This data gives further proof of the great potential of NCs to perform 
intracellular drug delivery 3,6,33,43-45. The impact of the differently functionalized NCs on cell 
viability was studied performing a live/dead staining. PBMCs were either incubated for 24 
hours with the NCs or left untreated; positive control was set up by ethanol incubation.  Upon 
exposure to the three types of NCs, no significant necrotic cell levels were noticed (Figure 3A). 
The early apoptotic cells with Annexin V staining on T lymphocytes and monocytes were then 
observed. Flow cytometry analysis showed a different impact on cells NC-coating dependent 
(Figure 3B). The Annexin-V staining evidenced that the NC functionalization could influence 
the viability on different cell types. Similar results for both Pluro and PEG NC 
functionalizations were found in lymphocytes: no statistically significant differences were 
observed between the control and the T lymphocytes treated with NCs. On the other hand, the 
incubation with Chito-NCs induced cell apoptosis in T lymphocytes (P value < 0,05). A similar 
action of Chito-NCs was also assessed against monocytes. The apoptosis induction in 
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monocytes was more than three times higher compared to controls. Moreover, in this type of 
cells also pluro-NCs were responsible for a clear induction of apoptosis (P value < 0,01). Cell 
viability was not affected by PEG-NCs in both cell populations (Figure 3B). These different 
actions exerted by Pluro and Chito-NCs were also confirmed by the proliferation assay on total 
PBMCs (Figure 3C).  
 
Figure 3 Viability and proliferation. PBMCs were incubated with Pluro, Chito and PEG NCs at the concentration 
of 1x1011 mL-1 or left untreated (Ctrl). A) Percentage of necrotic cells was assessed by a Live/Dead staining after 
24 hours of incubation, ethanol (70%) was used as positive control. B) Apoptosis was assessed using Annexin V 
staining  for Monocytes (CD14+ cells) and T cells (CD3+ cells), ethanol (70%) was used a positive control. 
Samples were analyzed by FACS Calibur (BD Biosciences). C) Proliferation assay was performed on stimulated 
cells with phytohemagglutinin 2% (PHA) and interleukin 2 (IL2) 30 u/mL for three days. 5-ethynyl-2´-
deoxyuridine (Edu) is incorporated into DNA during active DNA synthesis; Percentage of Edu positive cells is 
reported. All experiments were performed at least in triplicate in independent assays (*= P value < 0,05, **= P 
value < 0,01).  
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Samples were treated with phytohemagglutinin at 2% and 30 /mL of IL2 for three days to 
boost the proliferation in presence of lipid nanocapsules. Control samples were left untreated. 
A staining with 5-ethynyl-2´-deoxyuridine (Edu) alexafluor conjugated was performed; Edu 
was incorporated into DNA during active DNA synthesis. Interestingly, Pluro and Chito NCs 
induced an enhancement of proliferation compared to controls (P < 0,05). PEG-NCs confirmed 
the viability data; in fact, PEG-NCs treated samples were perfectly comparable with controls, 
showing the total absence of cell induction.  
 
Immune cells activation analysis   
The different action of Pluro, Chito and PEG NCs on the immune cell functionality was 
analyzed by two activation assays (Figure 4). Firstly, cell morphological changes in terms of 
diameter after NC incubation were observed. In fact, when immune cells are under activation 
stimuli a change in diameter occurs by increasing the cellular volume. For instance, activated 
monocytes increase their diameter starting phagocytosis. In addition, the naïve T cells before 
the contact with the antigen have a resting diameter of 6-8 μm, in our case the same role can be 
played by NCs; on the other hand, activated T cells increase their diameter of 12 μm or more, 
thanks to the induction of the replication cycle 46. This is the criterion used to deeply analyze 
the immune impact of NCs and to further validate data found with Flow Cytometry. The present 
study was carried out on PBMCs from healthy donors that included different cell populations, 
T cells, B cells, monocytes, dendritic cells and natural killer cells to better reflect the effects on 
the pool of cell populations relevant to in vivo immune responses. 
PBMCs from healthy donors were treated with the three NCs at the intermediate concentration 
of 1x1011 mL-1; experiments and data analysis were carried out with Scepter (Millipore). Figure 
4A shows the cell diameter of monocytes (Figure 4A ii) after treatment with Pluro and Chito 
NCs, compared to controls; in particular, Chito NCs led to similar changes in monocyte 
diameter compared to lipopolysaccharide (LPS) treated samples. Thus, cells with a diameter of 
2,52 x 104 larger than 11,75μm were found in Chito NCs compared to cells of 2,33 x 104 in 
LPS; the relative amount of cells in control samples was 1,35 x 104 (Figure 4A iii). Intriguingly, 
PEG-NCs samples were perfectly comparable with controls having 1,08 x 104 cells, without 
any activation stimuli (Figure 4A iii).  
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Figure 4 Activation assays. PBMCs were incubated with Pluro, Chito, PEG NCs at the concentration of 1x1011 
mL-1 or left untreated (Ctrl) for 24h. Lipopolysaccharides (LPS 2μg/mL) or concanavalin A (ConA, 10 μg/mL ) 
were used as positive controls. A) Morphological analysis (count and diameter) of PBMCs with Scepter 2.0 
(Millipore) i highlights the lymphocytes peaks boxes, ii highlights monocyte peaks and iii highlights activated 
monocytes with a diameter higher than 11,25μm. Percentage of CD25 and CD69 cell surface activation marker 
expression on T cells (B) and monocytes (C) were analyzed by flow cytometry. Experiments were performed at 
least in triplicate (*p value < 0,05). 
 
Afterwards, the different immune activation mediated by Pluro, Chito, PEG NCs was analyzed 
by observing the modulations of CD25 and CD69 cell surface activation markers on T cells and 
monocytes. CD25 and CD69 are critical markers for the immune  response. CD25 (alpha chain 
of the IL-2 receptor) is a late activation antigen. Whereas, the CD69, a member of the C-type 
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lectin superfamily (Leu-23), is one of the earliest cell surface antigens expressed by immune 
cells following activation. PBMCs were treated with the three NCs at the intermediate 
concentration of 1x1011 mL-1. Interestingly, CD25 and CD69 expression on T cells and 
monocytes was not modulated by PEG NCs (Figure 4 B and C), evidencing no induced 
activations on both analyzed cell types. Likewise, Pluro NCs did not boost the expression of 
activation markers on T cells (Figure 4B). However, Pluro NCs were found able to induce 
CD69 expression on monocytes (Figure 4C), highlighting the Pluro NCs specific action on this 
cell population. Notably, Chito NCs were able to strongly activate the immune cells, giving a 
powerful CD25 and CD69 modulation on both immune cell types (Figure 4 B and C).  
 
Cytokine secretion 
To further investigate the Pluro, Chito and PEG NC action on immune cells, the protein level 
was evaluated using ELISA multiplex technology to measure the secretion of a wide variety of 
cytokines: IL4, IL6, IL10, TNFα, IFNγ, IL13, IL12 and IL2 (Figure 5). 
The different impact of the three functionalized NCs on immune cells was confirmed. 
Analytically, figure 5 shows that Pluro and Chito NCs have a higher effect compared to PEG 
NCs. Pluro NCs induced IL6, TNFα (P value < 0,01), IL12 and IL10 secretion (P value < 0,05). 
Moreover, Chito NCs gave a significant enhancement in IL6, IL10, TNFα, IFNγ, IL13 (P value 
< 0,01) IL4 and IL12 secretion (P value < 0,05). Intriguingly, PEG NCs confirmed to be 
perfectly inert for cells. 
The cytokines found expressed such as IL6, TNFα and IL12 are normally secreted by 
monocytes/macrophages and their action is directed on the activation of the acute inflammation 
process 47. IL12, for instance, activates NK cells and T Lymphocytes to produce IFN-γ (which 
we found modulated by Chito NCs) and specifically induce differentiation of T cells in T helper 
1 (Th1) confirm a Th1-mediated protection enhancing also an increased cytotoxic activity 48-51.  
IL10, which we found secreted in both Pluro NCs (P-Value <0.05) and Chito NCs (P-Value < 
0.01), is a cytokine mainly secreted by activated macrophages that through a negative feedback 
directly control the immune response. IL10 plays a crucial role in the innate immunity in 
controlling the immune cell response, which is normally correlated with the inhibition of IL12 
secretion.  
Taken together these results show that Pluro and Chito NCs mediated the induction of both 
innate and adaptive immunity response. However, as showed in figure 5 the action of Pluro 
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NCs was significantly lower than Chito NCs, taking in consideration the expression of IL10 
and TNFα, 2 times and 4 times lower, respectively. This trend was also showed in the activation 
marker analysis on monocytes (Figure 4B). Furthermore, Chito NCs mediated also a 
production of IL13 and IL4 (P-Value < 0,05). Both cytokines are strictly correlated with the 
activation of the lymphocyte T helper 2 52.  
 
Figure 5. Cytokine secretion. Cytokine release was assessed by multiplex ELISA on PBMCs. Cells were 
incubated with nanocapsules: Pluro, Chito and PEG at dose of 1x1011 mL-1 or left untreated. Concanavalin 
A (ConA, 10 μg/mL) and lipopolysaccharides (LPS 2μg/mL) were used as positive controls. After 24 hour 
the supernatants were collected and analyzed. Supernatants were analyzed by MILLIPLEX® MAP 
Multiplex Assays Using Luminex xMAP® Technology. All the experiments were performed at least in 
triplicate (*= P value < 0,05, **= P value <0,01). 
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Functionalized NCs have been developed for biomedical purposes due to many advantages: (i) 
improved biocompatibility and stability; (ii) extended circulation time; (iii) specific targeting 
function; (iv) enhanced drug encapsulation efficiency and reduced drug leakage; (v) great 
potential as multimodal therapeutics. All of these NC properties open new scenarios in 
medicine 53.   
Particularly in the context of drug delivery, our data give many positive inputs for further 
translational medicine research regarding the ability of the three NCs studied to pass through 
the immune cell membrane and to passively target the immune cells. We have previously shown 
that cell internalization might be useful in the context of chemotherapy by using tumor-targeted 
molecules 6,42. Indeed, targeting capacities of these systems can be implemented by surface 
modification with specific molecules (e.g. antibodies) 14,54-58. However, here we have 
demonstrated that molecules used to functionalize NCs might have diverse impacts on immune 
cell viability and activation, evidencing the need to know well, before any medical application, 
the expected action of different functionalized particles on immune cells. Pluro Chito and PEG 
coatings have been well investigated and characterized by many reports 20,59-61. However, this 
is to our knowledge the first study comparing the action on immune cells of three highly used 
nanocapsule coatings for biomedical applications as it is well known in nanoscience the extreme 
importance of evaluating the immune response to different nanoformulations 62. As a matter of 
fact, the possible interactions between nanoparticles with different coatings and the immune 
system, could result into an immunostimulation or an immunosuppression, which might either 
be applied in immunotherapy or may promote inflammatory/autoimmune disorders 63,64. The 
main function of the immune system is to protect the host from foreign substances; however, 
inadvertent recognition of nanoparticles as foreign by the immune cells may result in a 
multilevel immune response against nanoparticles 63. Addressing the need to carry out 
additional evaluation and an overall comparison of the immune impact of different 
nanoparticles, we aimed here at provide a broad a complete picture on the impact of differently 
functionalized NCs on human primary immune cells. The surface modification of systemic drug 
carriers by PEG is one of the preferred ways to decrease opsonization by reducing interactions 
with blood 65. Recent investigations regarding PEG showed a reduced uptake and clearance by 
immune cells when using PEG-coated nanoparticles 20,59,66,67. Jang et al. investigated 
interactions of PEG-coated grafts with embryonic immune cell lines showing that they are able 
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to maintain stemness properties59. Yang et al. demonstrated the well-known stealth property of 
PEG; specifically, they showed a reduced uptake of polymeric nanoparticles by macrophages 
20. A recent report also indicate that repeated injections of PEGylated liposomes induce 
significant immune responses 68.  In this work the overall immune-compatibility of PEG NCs 
was highlighted, proving the absence of toxicity and activation stimuli. Our data may give new 
insights into the use of PEG coating for NCs and other nanomaterials to be used as highly safe 
and inert molecule 15,16,69,70.  A contribution was given to improve the knowledge on the absence 
of immune impact and toxicity of PEG in monocytes, as already reported in literature 18,19 and 
also in primary human immune cells, total PBMCs and specifically in T cell populations. 
Moreover, in the context of PEG nanoparticle uptake, our PEG-PLA coating was able to bypass 
the well know stealth property of PEG, showing a good internalization of NCs into immune 
cells 20. As it was previously proved by Stefanick JF et al., this can be explained through a 
modulation of many parameters such as the brush conformation of the particle surface mediated 
by the used PEG and through a control of PEG concentration compared to PLA 37,38, as it was 
shown by Saw P E et al. Notably, the length of the PEG used in this work is quite short and this 
may explain the higher uptake observed 33. Moreover, Vonarbourg A et al. described that the 
stealth property of PEG NCs  decreased with the increase of NC size, especially for macrophage 
uptake 71. Pluro NCs showed its potential as safe coating without induced necrosis. However, 
data indicated an induction of apoptosis phenomena on monocytes exclusively in the 40% of 
cells. Our hypothesis is that Pluro NCs may have a specific action on monocytes; this is also 
emphasized by the membrane cell markers and cytokine analysis that showed CD69 up-
modulation in monocytes and increased the release of IL6, IL10, IL12 and TNFα. The 
activation observed during our study might also be responsible for the apoptotic induction, a 
phenomenon that normally occurs during the activation process of immune cells 72,73. 
Moreover, pluronic and chitosan were previously studied for vaccine formulations as adjuvants 
able to increase the immune response 74,75. Our new Pluro NCs could be useful for better 
internalizing and delivering vaccines thanks also to their activation properties, through the 
specific activations of monocytes with a systemic immunization of the body enhancing the 
antigen presentation activity of monocytes to T Cells. The abilities of Pluro NCs on monocyte 
activations could be useful for drug delivery combined to immunotherapy for future new tools 
in cancer therapy 76. Intriguingly, our data are not in agreement with the study of Kim HG and 
colleagues, as they declared that pluronic nanoparticles do not modulate immune responses 
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mounted by macrophages. However, for their experiment that research group used a murine 
macrophage cell line (RAW cells) that is a good system to collect preliminary data but is not 
perfectly comparable with the response of human primary immune cells. Moreover, the 
activation that was observed in our study and particularly on cytokine secretions could be a 
result of various cell interactions that are possible in a PBMCs system. For this reason, further 
studies with Pluro NCs for its application in immunotherapy will be carried out by our research 
group; in fact, this may be the new frontier to fight cancer based on specific activation stimuli 
of immune cells against cancer cells, i.e. to treat melanoma, avoiding at the same time the 
immunosuppression of the healthy immune system induced by tumor growth 77-79.  
 Moreover, data showed also an immune activation of cells treated with Chito NCs that is 
similar and even higher compared to those treated with Pluro NCs. Intriguingly, Chito NCs 
induced apoptosis in both populations, monocytes and T cells. The apoptotic induction of Chito 
NCs can be explained in the same way as for Pluro NCs; our data showed, indeed, the Chito 
NCs mediated induction of T cells and monocytes immune response and that action was 
followed by the activation of cell proliferation of both monocytes and T lymphocytes. 
Cytokine analysis clarifies that after incubation with Chito and Pluro NCs, T cell activation 
occurred through the action of monocytes that induce the differentiation of naïve T cells in T 
helper cells. Thus, we observed an induced secretion of TNF and IL12 mediated by 
monocytes/macrophages that normally activate the T cells and NK cells to produce in the pro-
inflammatory phase the same cytokine resulted increased in our experiments, such as the INF-
γ which stimulates macrophages to produce TNF. Moreover, IL12 promotes the 
differentiation of CD4+ T cells in Th1 cells that continue to produce IFN-γ as a reinforcement 
of macrophage immune response 48,49. These cytokines organize inflammatory centers and 
enhance cellular immune response. With the enhancing of cytotoxic activity many intracellular 
pathogens can be killed through the activation of antimicrobial defenses 80,81.  These data 
confirm and extend to a human ex vivo system the work of Shibata Y et al., where authors 
showed in mice that phagocytosable small-sized chitin particles activated alveolar macrophages 
to express cytokines such as IL-12, TNFα, and IL-18, leading to INF-γ production mainly by 
NK cells 82. These results are supported also by the work of Li X et al., where the systemic 
administration of chitosan provides significant priming effects in alveolar macrophages and NK 
cells in mice 60. Interestingly, an action of Chito NCs in the secretion of IL-4 and IL-13 
cytokines was found during the present study.  The effector T helper 2 cells (Th2) produce 
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normally a cytokine profile such as IL-4, IL-6, IL-10, IL-13, here were found up-regulated by 
Chito NCs, that together instruct B cells to proliferate and differentiate into antibody-secreting 
plasma cells. As such, Th2 cells play an important role providing protection against certain 
extracellular pathogens, such as bacteria and a variety of parasites, and are also involved in 
asthmatic reactions 80,81. The possible activation of Th2 cells mediated by Chito NCs could be 
responsible for an induction of allergic response that must be well evaluated by further studies. 
However, the modulation of the Th response is one of the main purposes of immunotherapy 
and it can be useful for other therapy strategies i.e. in the context of vaccines 80. As reported 
above for pluronic, also chitosan is currently used as an adjuvant for vaccines 60,83. Nevertheless 
the evaluation of adjuvant properties is challenging since available data are insufficient to 
demonstrate immunogenicity of chitosan, its mechanism of action and to exclude impurities as 
the active substance 83. Herein, we clearly reported Chito NCs mediated induction of 
monocytes, T cells and NK cells; specifically, we demonstrated an induction mediated by the 
innate immunity of Th1 able to provide a full enhancement of the immune response after 
treatment. All these actions occurred  exclusively for Chito NCs that in our screening resulted 
as an excellent first step for further studies on vaccines delivery perspectives, immunotherapy 
and immunomodulation activities.  
 
Conclusions 
In summary, although lipid nanocapsules harbour interesting medical applications, the potential 
immune impact still needs to be carefully evaluated. To our knowledge, no comprehensive 
studies were carried out on human immune cell populations ex vivo using a wide variety of 
functionalized NCs. In the present work, the immune cell interactions of NCs coated with 
pluronic, chitosan and PEG in immune cell types from healthy donors were investigated. We 
observed that different types of NCs lead to different impacts on immune cells and 
subpopulations of T cells and monocytes: totally inert (PEG NCs) or immune inductive (Pluro 
NCs and Chito NCs). Thanks to our data we open new windows for applications of different 
coated NCs in future nanomedicine-based therapies. Specifically, the Pluro NCs targeted 
induction of monocytes could be extremely useful for macrophage-based immunological 
therapies, particularly against metastases formation. In addition, the Chito-NCs-mediated 
induction of monocytes that activate lymphocytes Th1 response and also a Chito NCs mediate 
Th2 response was evidenced, providing the whole enhancement of the immune response after 
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treatment. Based on these results, it will be useful to focus on Pluro and Chito NCs as future 
tools in vaccines delivery, immunotherapy and immunomodulation activities. In conclusion, 
our findings are of particular value towards a well-defined pre-selection of specific NC coatings 
based not only on their specific biomedical purposes but also in view of their immune-
interaction and immuno-modulation. 
 
Materials and Methods 
  
Nanocapsule preparation 
The nano-systems studied were prepared by a modified solvent displacement technique 
following the procedure of Calvo et al. 29. Briefly, an organic phase composed of 40mg of 
Epikuron 145V and 125 µL of olive oil, dissolved in 0.5 mL of ethanol and 9.5 mL of acetone, 
was added to 20 mL of an aqueous phase under magnetic stirring containing 50mg of Pluronic 
F68 (Pluro NCs), 10mg of chitosan (Chito NCs) or 30mg of PEG-PLA (PEG NCs). Organic 
solvents (acetone and ethanol) plus a portion of the volume of water were evaporated in a rotary 
evaporator at 40°C, obtaining a final volume of 15 mL. Finally, nanoparticles were extensively 
cleaned by dialysis through ultrapure water for 24 hours to remove the unbound surfactant 
molecules.  
Coumarin 6-loaded lipid nanocapsules were formulated by dissolving the dye in the olive oil 
phase at a concentration of 0.025% (w/w). The concentration of the different nanoemulsions 
was estimated by calculating the volume of a single particle with the equation of the volume of 
a sphere: V=4/3.π.r3, using the hydrodynamic mean radius obtained from DLS measurements, 
and then the number of particles that were formed by the total volume of olive oil were used in 
the synthesis.  
 
Size and electrophoretic mobility 
A Zetasizer-nano Z (Malvern Instruments) was used to measure the hydrodynamic mean 
diameter and the electrophoretic mobility (μe) of the nanocapsules. The μe was measured as a 
function of pH while maintaining a constant low-ionic-strength value (0.002 M). The size and 
mobility data were recorded in triplicate. 
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Colloidal stability was spectrophotometrically studied monitoring the turbidity of the 
nanocarriers (Beckman DU 7400 spectrophotometer) working at 570nm in simple saline media 
(pH 7.4). The salts used were NaCl and CaCl2. From the analysis of aggregation kinetics, we 
calculated two important parameters in colloidal-stability studies, the critical coagulation 
concentration (CCC), defined as the minimum salt concentration needed for the most rapid 
aggregation, and the critical stabilization concentration (CSC) defined as the minimum salt 
concentration at which the system begins to re-stabilize when salinity is progressively increased 
and related to the surface hydrophilicity 34. 
 
Peripheral blood mononuclear cell preparation 
For each experiment, human PBMCs were obtained from EDTA-venous blood samples from 
healthy male donors (25-50 years of age) using a standard Ficoll-Paque (GE Healtcare) 
separation and cultured in RPMI medium added with FBS 10% and 1% of 
Penicillin/Streptomycin solution. All donors provided a written informed consent. The study 
was reviewed and approved by the Ethics Committee of the University of Sassari. The studies 
were carried out in accordance with the approved guidelines. 
 
Uptake analysis 
Uptake of coumarin 6-loaded Pluro, Chito and PEG-Nanocapsules by immune cells was 
studied. Nanocapsules were incubated with PBMCs for 24 hours at different concentrations 
(1x1010mL-1, 1x1011mL-1 and 1x1012mL-1). Time points experiments were also conducted at 6, 
12 and 24 hours with all three studied NCs, at the fixed concentration of 1x1011mL-1. After 
incubation, cells were harvested, washed twice in cold phosphate buffered saline (PBS) and re-
suspended for analysis. Cell fluorescence was measured after the cells were washed with a 0.4% 
(w/v) trypan blue solution in order to quench fluorescence from non-internalized NCs 17. 
The gating of cell populations was performed with specific fluorescently-labeled monoclonal 
antibodies: fluorescein isothiocyanate (FITC), phycoerythrin (PE), peridinin chlorophyll 
protein (PerCP), or allophycocyanin (APC) conjugated with anti-CD3, anti-CD4, anti-CD8, 
anti-CD14, anti-CD56 and anti-CD20, antibodies that were purchased from BD Biosciences 
(Mountain View, CA, USA). Uptake analyses were performed with flow cytometry (FACS 
Calibur BD Bioscience) using CellQuest software (BD Biosciences). A total of 50,000 events 
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per sample were recorded. Data analyses and plots were performed with FlowJo software 
(MACS Miltenyi Biotec).  
For the confocal microscopy imaging analysis, PBMCs were incubated with Courmarin 6-
loaded nanocapsules as described above, washed twice with PBS and re-suspended at the 
concentration of 2 x 106 cells/0,5 mL; 30L of the cell solution was put onto a slide, fixed with 
shellac and observed by confocal laser scanning microscopy (Leica TCS SP5, Leica 
Microsystems). Courmarin 6 was excited with an argon laser at 405 nm with 20x camera lens, 
the excitation filter bandwidth was: BP470/40 and the emission filter was: BP525/50. At least 
20 pictures per sample for each experiments were captured.  
 
Hemolysis, cell viability, apoptosis and necrosis assay 
Hemolysis test was conducted following previously used protocols 84. Fresh human whole 
blood was taken from volunteer healthy donors stabilized with ethylenediamine tetraacetic acid 
(EDTA). Serum was removed from blood samples by centrifugation at 200 g for 5 minutes. 
Resulting RBCs were washed five times with sterile isotonic PBS and then diluted 10 X with 
EDTA. To determine the hemolytic activity of different NCs, Pluro, Chito and PEG NCs at the 
concentration of 1x1011NC mL-1 were added to dilute RBCs suspension (0.2 mL, 4 x 108 
cells/mL) in a final volume of 1mL PBS. After vortexing, the mixtures where left at room 
temperature for 2 hours, NCs and intact RBCs were removed by centrifugation. A microplate 
reader (Sunrise, Tecan) measured the absorbance (A) of the hemoglobin in the supernatant at 
570 nm, with the absorbance at 620 nm as a reference. 
For viability assay, PBMCs were transferred to a 24-well plate and treated for 24 hours in 
triplicate with Pluro, Chito, PEG nanocapsules at the concentration of 1x1011NC mL-1 or left 
untreated. Cells were treated with EtOH 70% as a positive control and then washed in cold PBS 
before the staining reaction. After incubation, cells were harvested, washed in cold PBS and re-
suspended in 1mL of PBS at 1 x 106 cells mL-1. Viability was assessed by the LIVE/DEAD® 
Fixable Dead Cell Stain Kit (Invitrogen) following the manufacturer instructions; the kit 
employs an amine-reactive fluorescent dye for cells with compromised membranes (late 
apoptotic and necrotic), the dye reacts with free amines both inside the cell and on the cell 
surface. In viable cells, the dye reactivity is restricted to the cell surface amines, resulting in 
less intense fluorescence. To detect cells undergoing apoptosis, Annexin-V FITC staining was 
employed (Invitrogen). Cells were analysed by flow cytometry (FACS Calibur BD-
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Bioscience). Data analysis was performed by flow cytometry (FACS Calibur, BD Biosciences) 




To perform the proliferation assay, the Click-iT® EdU Alexa Fluor® 488 Flow Cytometry Assay 
Kit (Life Technologies) was used. Experiments were performed according to the 
manufacturer’s instructions. Cells were seeded at the concentration of 1 x 106 cells mL-1 in 96-
multiwell rounded bottom plates. PBMCs were treated with Pluro, Chito, PEG NCs at the 
concentration of 1x1011NC mL-1 and Phytohemagglutinin 2% (PHA) and interleukin 2 (IL2) 
30 /mL or left untreated. 5-ethynyl-2-deoxyuridine (EdU) were added in sterile conditions 16 
hours before analysis. After 72 hours of incubation, cells were harvested, washed in PBS, fixed 
with 4% paraformaldehyde, washed in PBS plus 1% Bovine Serum Albumin (BSA), 
permeabilized with a saponin-based reagent and prepared for the Cu-assisted EdU-Azide Click-
iT reaction. The reaction occurs after adding 500 l of Click-iT reaction cocktail (PBS, CuSO4, 
fluorescent dye azide and reaction buffer additive) to each sample. Analyses were performed 
by Flow cytometry (FACS Calibur BD Bioscience) using CellQuest software (BD 
Biosciences). A total of 50, 000 events per sample were recorded. 
 
Activation analysis 
To investigate the functional impact of Pluro, Chito,  and PEG NCs on primary 
lymphomonocytes, considering their activation as a crucial endpoint, we previously consucted 
an immune cells diameter analysis. PBMCs were incubated with three NCs at the concentration 
of 1x1011 mL-1 for 24 hours. Lipopolysaccharides (2 g/mL) were used as positive controls. 
After 24 hours of incubation, samples were harvested and cells were suspended in PBS. 
Analyses were carried out with Scepter (Millipore) using 40 m sensor; plots and data analysis 
were done with Scepter Software Pro 2.1 (Millipore). 
At a later stage we evaluated the expression of CD69 and CD25 activation markers by flow 
cytometry. Concanavalin A (4 g/mL) or lipopolysaccharides (2 g/mL) were used as positive 
controls. After 24 hours of incubation, PBMCs were stained to identify immune cell populations 
and analyze activation marker expression. Staining with anti-CD3, anti-CD14 anti-CD25 and 
anti-CD69 fluorochrome-conjugated monoclonal antibodies was performed in the dark for 20 
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minutes. After washing, cells were analyzed by flow cytometry (Accuri BD Biosciences). A 
total of 50,000 events per sample were recorded, data analysis was conducted with FlowJo 
software (MACS Miltenyi Biotec). 
 
Multiplex cytokine analysis 
Cell culture supernatants from PBMCs after treatment with nanocapsules were used to quantify 
the secretion of cytokines using a MILLIPLEX MAP 8-plex Cytokine Kit, according to 
manufacturer’s protocol. Concanavalin A (ConA, 10 μg/mL) and lipopolysaccharides (LPS 
2μg/mL) were used as positive controls. The following human cytokines were measured: IL4, 
IL6, IL10, TNFα, IFNγ, IL13, IL12 p70 and IL2. Briefly, supernatants were centrifuged for 10 
minutes to remove debris and 25 mL were added to 25 mL of assay buffer. Then, 25 mL of 
magnetic beads coated with specific antibodies were added to this solution and incubated for 2 
hours under shaking. At the end of the incubation, the plate was washed twice in buffer and 
incubated for 1 hour with 25 mL of a secondary biotinylated antibody at room temperature. The 
plate was incubated for 30 minutes with Streptavidine Phycoerythrin, washed twice, and 
incubated with 150 mL of sheath fluid for 5 minutes. The plate was observed immediately on 
a Luminex 100/200 platform (Luminex Corporation) with xPONENT 3.1 software. Standard 
curves for each cytokine (in duplicate) were generated using the supplied reference cytokine 
concentrations. Cytokine concentrations in the samples were determined with a 5-parameter 
logistic curve. Final concentrations were calculated from the mean fluorescence intensity and 
expressed in pg/mL. All incubation steps were performed at room temperature and in the dark. 
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 concentration) were incubated with red blood cells 
(RBCs) at 25°C for 2 h. (A) Pictures of human RBCs treated with Pluro, Chito and PEG NCs. The red color of the 
solution is due to the release of hemoglobin from the damaged RBCs. PBS mixed with RBCs (Ctrl-) and ultrapure 
water mixed with RBCs (Ctrl+) served as negative and positive control respectively, PBS alone was used as 
additional control (white). (B) Sample Absorbance at the wavelength of 570nm-620nm. Experiments were 
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S. Figure 3. Uptake analysis on PBMC subpopulations. NCs uptake assessment on lymphocytes T helper 
(CD4+), lymphocytes T cytotoxic (CD8+), Natural killer (CD56+) and B cells (CD20+). Cells were incubated for 
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Superparamagnetic iron oxide nanoparticles (SPIONs) have been extensively investigated for 
many biomedical applications. A good quality functionalization that combines imaging goals 
with a high-level biocompatibility remains one of the challenges for particle translation into 
medical practice. Here, we focus on a new functionalization of SPIONs with cystine (Cy-
SPIONs). Cystine is able to make SPIONs stable and dispersible in water and in culture cell 
media. New insights are provided into the biological and immune effects of Cy-SPIONs with a 
wide variety of standard and molecular assays to evaluate cytotoxicity, cell activation, cytokine 
release and the expression of 84 genes related to immune responses.  A good immune 
biocompatibility of Cy-SPIONs on primary immune cells was found. The great potential of Cy-
SPIONs for further in vivo studies and as contrast agents for magnetic resonance imaging (MRI) 
is highlighted. In addition, we also exploited ultrasonography, since it is a safer, less expensive 
and common imaging technology. The good echogenic properties of Cy-SPIONs in water and 
in whole blood are shown, both in a phantom vein and in a microfluidic device for bloodstream 
simulations. Our results open up a new scenario for future applications of cystine-functionalized 
SPIONs as immune-compatible ultrasound and MRI contrast agents.  
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Magnetic nanoparticles have attracted much interest among scientists and the general public 1 
as advanced nanomaterials for several types of applications, as well as for drug and gene 
delivery or/and imaging agents 2, 3. Superparamagnetic iron oxide nanoparticles (SPIONs) have 
been investigated for biomedical applications such as tissue repair, immunoassays, 
detoxification of biological fluids, hyperthermia, drug delivery, probes, in vitro cell separation 
and to produce antibiotic-resistant biofilms. They are thus them important candidate materials 
for new perspectives in nanomedicine 4.  
Since 2005 SPIONs were introduced as tracers for tomographic magnetic particle imaging 
modality 5.  One of the major aims of scientists in improving diagnostic technologies is to create 
better contrast agents and superior imaging systems, however every system has its weaknesses 
6.  
SPIONs are excellent materials for multimodal imaging 7. One interesting modality is the use 
of MRI and ultrasonography (US) at the same time. US is fundamental in everyday clinical 
practice and many researchers are now using new nanomaterials to improve this imaging 
methodology which is very economical and safe 8-10. Further innovations in the development 
of diagnostic tools that possess the advantages of MRI and US dual-modality properties are still 
needed, i.e. the US-triggered release of therapeutic agents to tumor cells for the battle against 
cancer 11-13.  
In order to achieve efficient imaging applications and loading capacity of SPIONs, one of the 
main challenges is to obtain nanoparticles with good hydrophilic surface coating 14-15, 16. To 
achieve this goal the functionalization is of fundamental importance for the good 
biocompatibility and safety of SPIONs. Thus, the first concern is to reduce both SPIONs’ 
instability in biological media and the concentration necessary for efficient functionalization.  
At the same time this would minimize toxic effects and costs, while maintaining a high-
resolution contrast. In a previous work, we reported a new method to increase the stability of 
SPIONs in biological media through the surface coating of SPIONs with cystine 17. Cystine 
acts as a precursor for proteins, antioxidant glutathione (GSH) biosynthesis, as well as 
maintaining physiological redox conditions inside/outside the cell 18. We found that this new 
type of functionalization improved SPIONs’ hydrophilicity and water stability  17, 19. In this 
Chapter 4 | Results 
 
Dr. Marco Orecchioni. Titolo “Biomedical applications of different nanomaterials: 
Characterization and interaction with the immune system”  
Tesi di dottorato in Life Sciences and Biotechnologies, Università degli Studi di Sassari. 
  
183 
work the echogenic properties of Cy-SPIONs were assessed in vitro in degassed water and ex 
vivo in human blood and in silico in a synthetic microvasculature network chip. We show how 
Cy-SPIONs could be used in US as novel intravenous contrast agents. However, an extensive 
and molecular assessment of the potential impact of SPIONs on immune cells is still lacking. 
Toxicity and immune compatibility are still major blocks to the use of nanomaterials in 
medicine 20-24. Thus, all the applications cited above normally require intravenous 
administration and the first cells that come in contact with foreign substances are blood immune 
cells. It is therefore necessary to analyze the possible impact of SPIONs on immune cells also 
using a molecular approach such as gene expression analysis. Jin R et al. 15 highlighted the 
importance of immunological studies especially for the potential use of SPIONs in future pre-
clinical testing, considering also that any difference in nanoparticle-conjugated moiety can lead 
to a different toxicological and immune impact. Most studies that have analyzed the effect of 
SPIONs on immune cells, have only considered one type of immune cell population, such as 
monocytes or macrophages 27-31. Instead in this study we used total PBMCs for our analysis, 
which include many different cell populations, such as T cells, B cells, monocytes, Nk cells and 
dendritic cells.  
Our approach better simulates the normal bloodstream behavior with the interaction of different 
types of cells that can modulate each other’s activations against foreign substances, such as 
nanoparticles. The ex vivo analysis also gives a better overview of the real action of Cy-SPIONs 
on immune cells, opening up the way for future pre-clinical application studies. To lay the 
foundation of our cystine functionalized SPIONs (Cy-SPIONs) in imaging, it is also critical to 
assess their contrast properties. We thus decided to start from the safest imaging modality: 
ultrasonography. 
In this paper we focus on Cy-SPIONs, which are easily dispersible in biological media. We 
provide new insights into the biological and immune effects of Cy-SPIONs with a standard and 
molecular range of assays to evaluate the cytotoxicity, cell activation, cytokine release and the 
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Iron pentacarbonyl (Fe(CO)5), oleic acid (C18H34O2), dioctyl ether (C16H34O), trimethylamine  
N-oxide (C3H9NO), ethanol, L-cysteine (C3H7NO2S) and hexane were purchased from Sigma-
Aldrich®. Toluene was distilled from the usual drying agents under nitrogen. All reactions were 
carried out under a nitrogen atmosphere using standard Schlenk techniques. The reaction 
vessels were oven-dried at 130°C prior to use, evacuated (10-2 mmHg) and then filled with 
nitrogen. 
 
Synthesis and characterization of Cy-SPIO nanoparticles  
To obtain monodisperse, highly crystalline and nanometer-size iron oxide nanoparticles, oleate-
coated SPIONs (OA-SPIONs) were prepared by following a thermal decomposition method 32 
and then functionalized with cystine using a ligand exchange reaction, as described in ref. [24]. 
Fe(CO)5 (0,66 mL, 5 mmol) was added to a solution of oleic acid (1.59 mL, 5 mmol) in dyoctyl 
ether (50 mL) at 373 K, under nitrogen atmosphere. The mixture was heated to reflux (559 K) 
for 1 hour. After cooling to room temperature, anhydrous trimethylamine N-oxide (376 mg, 5 
mmol) was added and the mixture heated again (to 413 K for 2 h and then to reflux for 1 h). 
Ethanol was used to precipitate the resultant OA-SPIONs, which were separated by 
centrifugation and dried in vacuo (1.0 ×10−3 Torr).  
Cystine coated SPIONs (Cy-SPION) were prepared by dissolving OA-SPIONs (506.4 mg, iron 
content 30.3% (w/w)) in 80 mL of toluene and adding an excess of L-cysteine (1.485 g, 12.25 
mmol) under nitrogen atmosphere. The resulting brown mixture was heated to reflux (383 K) 
for about 4 h, up to the precipitation of a brown solid to the bottom of the flask that produced a 
colorless solution. The solid was washed with hexane, collected by centrifugation and dried in 
vacuo (1.0 ×10−3 Torr). The solid was then washed with water to remove the free L-cysteine 
and dried with a vacuum pump. During the exchange reaction, the oxidation of cysteine to 
cystine takes place, promoted by Fe2O3 17, until complete replacement of the oleic acid by the 
in situ generated cystine. 
The iron content of SPIONs was determined by the spectrophotometric method 17 19. The 
SPION size and morphology were determined by analyzing TEM images obtained with a 
Philips CM 12 operating at 100 kV. Samples were prepared by placing one drop of a solution 
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of Cy-SPION in water on the specimen grid and allowing the solvent to evaporate. The SPION 
dimensions were analysed with ImageJ. The surface functionalization of Cy-SPIONs was 
characterized by several complementary techniques 17,19.  
 
MRI phantom analysis of Cy-SPION dispersions 
Additional experiments were carried out to investigate the stability of water Cy-SPION 
dispersions and their MRI potentialities . In particular, in vitro 1H NMR relaxation rates 
measurements were performed on aqueous Cy-SPION dispersions containing increasing iron 
concentrations using the 7 Tesla 950-MR scanner GE Healthcare machine.  
Approximately 13 mg of Cy-SPIONs were introduced in a vial and 1mL of deionized water 
were added. After 10 minutes of sonication with a BRANSONIC 220 water bath sonicator, the 
vial was centrifuged for 5 minutes at 3500 rpm to remove nanoparticles in the mixture. The 
solution was then diluted in various ratios in order to obtain Cy-SPION aqueous dispersions at 
various concentrations. NMR glass tubes containing Cy-SPION dispersions with [Fe] equal to 
0.320, 0.213, 0.160 and 0.106 mM were placed in an agar phantom and the proton NMR 
relaxation times, T1 and T2*, were recorded using standard inversion recovery (IR) and spin 
echo (SE) sequences, respectively. 
 
Cell culture maintenance 
Jurkat cells (T cell line) and peripheral blood mononuclear cells (PBMCs) were cultured in 
RPMI 1640 medium containing 1% antibiotic-antimicotic mixture and 10% heat-inactivated 
fetal bovine serum (FBS) (Invitrogen) in an incubator at 37 °C in a 5 % CO2. Human PBMCs 
were obtained from blood samples from healthy male donors (25-50 years old) using a standard 
Ficoll-Paque (GE Healthcare) separation.  All the donors provided written informed consent. 
The study was reviewed and approved by the ethics committee of the University of Sassari 
(Italy). 
 
Cy-SPION viability and activation on immune cells 
For the viability assay, PBMCs were transferred to a 24-well plate and treated for 24 h in 
triplicate with 50, 100, 200 g mL-1 of Cy-SPION or left untreated. Cells were treated with 
EtOH 70% as a positive control and then washed in cold PBS before the staining reaction. After 
incubation, cells were harvested, washed in cold PBS and re-suspended in 1mL of PBS at 1 x 
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106 cells mL-1. Viability was assessed by the LIVE/DEAD® Fixable Dead Cell Stain Kit 
(Invitrogen), which uses an amine-reactive fluorescent dye, cells with compromised 
membranes (late apoptotic and necrotic). The dye reacts with free amines both inside the cell 
and on the cell surface, yielding intense fluorescent staining. In viable cells, the dye reactivity 
is restricted to the cell surface amines, resulting in less intense fluorescence. 
To detect cells undergoing apoptosis and necrosis, Annexin-V FITC and propidium iodide 
staining were used (Invitrogen). Cells were analysed by flow cytometry (FACS Calibur BD-
Bioscience). To identify T cells and specifically CD8+ and CD4+ T cell populations, the 
populations were isolated using specific antibodies: CD3 for the entire T cell gating, CD8 and 
CD4 for Cytotoxic T cells and T helper cells, respectively. To assess the cell activation, specific 
antibodies were used against CD25, CD69 and CD30 cell activation markers. Al the antibodies 
used were purchased from BD Biosciences. Data analysis was performed by flow cytometry 
(FACS Calibur, BD Biosciences) using CellQuest® software (BD Biosciences). 
 
Proliferation assay 
To perform the proliferation assay, the Click-iT EdU Alexa Fluor 488 Flow Cytometry Assay 
Kit (Life Technologies) was used. The experiments were performed according to the 
manufacturer’s instructions. Cells were seeded at the concentration of 1 x 106 cells mL-1 in 96 
multi-well rounded bottom plates. PBMCs were treated with Cy-SPIONs (50, 100, 200 g mL-
1) and phytohemagglutinin 2% (PHA) and interleukin 2 (IL2) 30 u/mL or left untreated. 5-
ethynyl-2-deoxyuridine (EdU) was added in sterile conditions 16 h before the analysis. After 
72 h of incubation, cells were harvested, washed in PBS, fixed with 4% paraformaldehyde, 
washed in PBS + 1% BSA, permeabilized with a saponin-based reagent, and prepared for the 
Cu-assisted EdU-Azide Click-iT reaction. The reaction occurs after adding 500 l of Click-iT 
reaction cocktail (PBS, CuSO4, fluorescent dye azide and reaction buffer additive) to each 
sample. Analyses were performed by flow cytometry (FACS Calibur BD Bioscience) using 
CellQuest® software (BD Biosciences). A total of 50,000–100,000 events were recorded.  
 
Immune cell gene expression analysis 
Total RNA was extracted from Jurkat cells after incubation with SPIONs 200 g mL-1. RNA 
purification was performed with TriZol Reagent (TriZol, Invitrogen, Carlsbad, CA, USA). 
After extraction, cDNA synthesis was performed using a SuperScript® II reverse transcriptase 
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(Invitrogen) following the manufacturer’s instruction. Comparison of the relative expression 
levels of 84 immune response genes was performed with a RT2 Profiler PCR Array (PAHS-
052ZD, Superarray Bioscience Corporation, Frederick, MD), (instrument CFX96 Bio-Rad). 
Data were analyzed by the comparative threshold cycle (CT) method. The relative 
quantification of the gene expression using the 2−ΔΔCt method correlated with the absolute 
gene quantification obtained using a standard curve. Data were analyzed with RT2 profiler PCR 
array data analysis software (http://www.superarray.com/pcrarraydataanalysis.php). Untreated 
cells were compared to Cy-SPIONs treated samples. Experiments were performed in triplicate.  
 
Ultrasound Imaging  
Technos MPX (Esoate) was used for all ultrasonography experiments. The analyses were 
recorded at 14-MHz; the instrument was set in conventional US modality (B mode), depth 31 
mm, gain 170, −1.3 dB, and mechanical index=1. The US signal was calculated using Adobe 
Photoshop CS5 (Adobe Systems). US signal is reported in 8-bit gray scale intensity from 0 to 
255 shades of gray. For US images on degassed water, the areas of interest were selected. A 
comparison of samples was performed on the same areas with 29205 analyzed pixels. 
Experiments were done in triplicate.  
 
Idealized synthetic microvascular network (SMN) and related viability test 
The Synthetic Microvascular Networks or SMNs were purchased from SYN VIVO CFDRC 
Huntsville, Alabama, USA. The SMN is able to perfectly reproduce a trait of the rat 
microvasculature (vessels depth of 100 μm). The chip was developed using a standard 
photolithography process 33. The SMN was used in order to assess the potential impact of Cy-
SPIONs on human primary immune cells in an in vivo like simulation under ultrasonography. 
Tygon tubing was inserted into the inlet/outlet ports of the device, a syringe was loaded onto a 
syringe pump and PBMCs with or without Cy-SPIONs (200 g/mL) injected at rates flow of 
less than 1µl/min. After 24 h of incubation at 37° in 5% of CO2, the device was covered with 
plastic paper and gel for ultrasonography, and sonication with an US probe was then performed 
for 10 minutes. PBMCs with or without Cy-SPIONs were immediately extracted and cell count 
performed with a trypan blue solution (4%, Sigma Aldrich) under inverted microscopy (Nikon 
Instruments Inc.). 
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Results and Discussion 
 
Synthesis and characterization of Cy-SPIONs 
In this work we studied the bio-immune impact and properties in ultrasound imaging of SPIONs 
with a new type of functionalization, using cystine. Cystine has a fundamental biological role 
as a component of antioxidant glutathione (GSH), and also for the maintenance of physiological 
redox conditions inside and outside the cell. The cystine receptor is also present in many cells 
of the body and is responsible for many biological processes 18. 
Our previous studies 17, 19 showed that Cy-SPIONs are stable nanoparticles and very interesting 
for medical applications, since their dispersion in water is quite stable. The preparation of Cy-
SPIONs involves the synthesis of oleate-coated SPIONs (OA-SPION) by a thermal 
decomposition method 34 and the subsequent functionalization by a ligand exchange reaction 
with L-cysteine.  
Using X-ray diffraction, magnetic properties and microscopy analysis (i.e. TEM and AFM), it 
was possible to characterize the chemical structure of both the magnetic core and the surface 
coating of Cy-NPs, as previously reported 19. In particular, the ligand exchange between oleate 
and cysteine was fully clarified, showing that the complete oxidation of cysteine to cystine 
produced an external cystine-shell, which is fundamental for biomedical applications. The 
water stability of Cy-NP dispersion is very important and the water dispersion was confirmed 
to be stable for more than 7-8 h 19. Concerning the chemical-physical properties of these Cy-
NPs, both spectroscopic (FT-IR) and microscopy (AFM and TEM) studies agree with the 
schematic picture reported in Fig. 1A. The average iron oxide core dimension of Cy-SPIONs 
ranges from 3.6 and 3.95 nm, as determined independently by three methods (namely AFM, 
TEM and magnetic curve analysis 17).  
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Fig. 1 Cy-SPION characterization.  (A) Coating around the iron-oxide nanoparticle core. (B) TEM image of 
the nanoparticles showing high monodispersity and average dimension of 3.95 nm. (C) Distribution of diameters 
through analysis of TEM images. 
 
As an example, a TEM image of Cy-SPIONs is shown in Fig. 1B and the corresponding 
dimension distribution is reported in Fig. 1C. According to the analyses of five new TEM 
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images obtained as reported in the previous section, the average diameter of these nanoparticles 
was 3.95 nm (with a standard deviation of 0.41 nm), in agreement with previous investigations 
17, 19.  In our previous work 17, a preliminary study of the 1H NMR relaxation properties at low 
and high magnetic fields indicated the potential of Cy-SPION water dispersions as MRI contrast 
agents. At concentrations lower than 0.5mM, we found that the spin-lattice relaxation rate R1 
(=1/T1) decreases by increasing the value of the field, while the spin-spin relaxation rate R2 
(=1/T2) has the opposite trend. This is interesting for MRI applications, since the efficiency of 
contrast agents for imaging applications is related to the ratio R2/R1.  The possibility of changing 
this ratio by changing the magnetic field strength opens new possibilities of using our Cy-
SPIONs as negative as well as positive contrast agents. To confirm such behavior 17, we report 
new data acquired at 7 Tesla (corresponding to a 1H Larmor frequency of 300 MHz) by an MRI 
machine. By using a phantom, prepared as described in the previous section, we collected 
several MRI images and calculated the relaxation rates, R1 and R2, of four Cy-NP dispersions 
with different iron concentrations (indicated in Fig. 2 as “region of interest”, namely ROI) and 
one sample of pure water (ROI number 5), as a reference.  
 
Fig. 2 Cy-SPION MRI properties.  (A) In vitro relaxivity study at 7 Tesla of the four Cy-SPION dispersions. 
[Fe], relaxation rates R1 and R2, Enhancement contrast ratio (EHC) are reported. (B) Image of the phantom 
prepared with five NMR tubes with different iron contents. Roi number 5 corresponds to water, and is used in 
order to highlight the contrast effect of Cy-NPs. The MRI T2-weighted image was obtained with an echo time of 
100 ms and a repetition time of 2500 ms. 
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The enhancement contrast ratio (EHC) was calculated by using the following equation, in order 





where SIcy-NP and SIwater SI-correspond to the signal intensity evaluated on the MRI image 
for the Cy-SPION dispersions and water reference, respectively. EHC, R1 and R2 of the Cy-
SPIONs water dispersions are reported in Fig. 2A, while a MRI T2-weighted image is shown 
in Fig. 2B. From this investigation we can confirm that Cy-SPIONs are stable in water. In 
addition, the values of EHC and the fact that the ratio R2/R1 is in the range 20-50 for 
concentrations of Cy-SPIONs in the range 0.106-0.320 mM, indicate that these nanoparticles 
act as negative MRI contrast agents. 
In the following sections, these nanoparticles are investigated in order to check, first, their 
biocompatibility and, second, their possible use as ultrasound contrast agents.  
 
Cy-SPION potential in ultrasonography imaging 
The classical application of SPIONs is as contrast agents in MRI. The recent interest in 
multimodal imaging has thus opened up new perspectives, indeed each imaging technique has 
advantages but also intrinsic limitations, in some cases low sensitivity, in others low spatial 
resolutions 35. Many groups have reported the use of SPIONs encapsulated into other particles 
such as microbubbles, vesicles or liposome for a bimodal imaging using MRI and US 36-40. 
Microbubbles are the most commonly used US contrast agents for medical applications, thanks 
to their highly echogenic in vivo properties 41. The presence of SPIO nanoparticles in the bubble 
shell can alter the surface tension of bubbles, boosting the acoustic impedance and enhancing 
the detectable backscatter. Yang F et al., for example, used SPIONs conjugated microbubbles 
improving their capabilities in US imaging and also, thanks to SPIONs, producing a good MRI 
contrast 37. The size of the most common microbubble-based US contrast agent (1–8 μm) 
renders them as merely intravascular flow tracers and the SPIONs encapsulated in 
microbubbles or vesicles reached these dimensions. In contrast, the chemico-physical 
characteristics of SPIONs (i.e., 4 nm in diameter in the present study) make them potentially 
capable of extravasating and reaching a tumor region, which can exhibit a vascular pore size 
up to 780 nm 42. The small size of SPIONs means that they can cross endothelial barriers and, 
as targetable materials, can reach a tumor region, acting at the same time as vehicles for 
therapeutic agents 32.  
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Fig. 3. Ultrasonography of Cy-SPION in water and whole blood.  
(A) Degassed water alone (left side) or with Cy-SPION (50, 100 and 200 μg mL-1) (right side) under ultrasound 
probe sonication in two plate wells (diameter 6.4 mm). (B) Calculation of the ultrasound signal  of Fig. A (water 
and 200 μg mL-1) (analyzed pixels= 29205). The ultrasound signal is reported in 8-bit gray scale intensity from 0 
to 255 shades of gray. Signal intensity was calculated on measurements of three investigations. Degassed water 
was used as a negative control. *p  values= 0,05. (C) Whole blood before and after injection with Cy-SPION (200 
μg mL-1) under ultrasonography (Scale bar 2.5mm). Red arrows highlight the particle signals. (D) Detection of 
Cy-SPION in a fresh whole blood filled vein phantom. A vein phantom was built specifically to assess the 
echogenic properties of Cy-SPION in whole blood from healthy donors. The phantom was constituted of non-
toxic, non-hemolytic, and non-pyrogenic natural rubber medical tubing with no absorption/adesion properties. 
Vein phantom showed a diameter of 0,5 cm. The vein phantom was filled with fresh extracted human whole blood 
(37 °C in heparin). As visible at the lower picture, a solution of Cy-SPION (100 μl at 200 μg/mL) was injected 
with a syringe; particles are clearly visible in the blood showing hyperechogenic spots (Red arrow); ultrasound 
images were recorded at 14.0 MHz in tissue harmonic imaging (THI) modality.  
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To the best of our knowledge few studies have tested the US ability of SPIONs without any 
coating. For example, Mehrmohammadi M. et al. successfully used SPION (Feridex) for 
magneto-motive US imaging. However, they did not find a significant US signal from the free 
SPIONs in a tissue phantom, and they stated that SPIONs are not useful US contrast agents due 
to their weak reflectivity 43. We are aware of the fact that the modification of SPIONs with 
other molecules or particles may change their contrast properties 40. 
In order to investigate our uncoated Cy-SPIONs as potential ultrasound contrast agents, after 
having assessed the uptake and ruled out the possible cytotoxic of our nanoparticles at different 
concentrations, we assessed the echogenic property of Cy-SPIONs in dose responses at 50, 100 
and 200 μg mL-1 in degassed water. To avoid the possible bubble-formation after injection of 
Cy-SPION solution we carefully suspend the Cy-SPIONs in degassed water for all the 
experiments. Fig. 3A shows visible and well-dispersed nanoparticles under ultrasonography. 
The white area visible in the US image suggests the high echogenicity of Cy-SPIONs. 
Interestingly, the US signal of dispersed Cy-SPIONs was three times more intense than same 
degassed plain water used as a negative control (11.0 vs. 43.0, respectively; P < 0.05) (Fig. 3B).  
In view of the results obtained from the experiments in water, we tested the echogenic propriety 
of Cy-SPIONs on whole blood. Intriguingly, the red arrows in the US image (Fig. 3C) indicate 
a visible and strong US signal of Cy-SPION nanoparticles well dispersed in whole blood.  
To confirm these data, we performed an experiment with a phantom vein and human blood to 
simulate the bloodstream conditions (Fig. 3D). The brightness of Cy-SPIONs after injection in 
the phantom vein under ultrasonography was detected (Fig. 3D). These experiments proved 
that Cy-SPIONs were also perfectly visible in a complex fluid such as blood that per se has a 
high background signal compared to water. Our data are not in agreement with the weak 
reflectivity of SPIONs found by Mehrmohammadi M. et al. The higher US signal that we found 
with our uncoated Cy-SPIONs could be due to the different functionalization compared to 
Feridex used by Mehrmohammadi M et al 43. Thanks to the high dispersbility in water of our 
CY-SPIONs, they are able to give a strong US signal.  
 
Uptake and biocompatibility of Cy-SPIONs 
SPIONs uptake has already been reported for different cell lines 44. Here for the first time we 
assessed their ability to cross the membrane as cystine functionalized SPIONs in ex vivo human 
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PBMCs from healthy donors (S. Fig. 1). Cells were incubated for 24 h with Cy-SPIONs at high 
doses (200 μg mL-1) and analyzed by TEM. S. Fig. 1(A) shows a representative image of the 
control samples, where all organelles are clearly visible and correspond to the normal 
functionality of cells. S. Fig. 1(B) shows the presence of a large number of Cy-SPION inside 
the cells in the treated samples.  Due to their phagocytic properties, monocytes were the cell 
population with the highest capacity of uptake (>70% of visible Cy-SPION clusters) compared 
to the other cell types present in PBMC populations (T cells, B cells, natural killers). 
Some toxicology studies with SPIONs lacking in bio-functionalization have highlighted the 
possible toxicity of these nanoparticles 45, 46. 
To check the cell compatibility of Cy-SPIONs, we performed multiparametric flow cytometry 
assays looking at early and late apoptosis, necrosis, cell membrane status and proliferation on 
ex vivo immune cells (Fig. 4). First, we performed a live/dead staining and apoptosis and 
necrosis assay in dose response (50, 100, 200 μg mL-1 of Cy-SPIONs) on cells incubated for 24 
h (Fig. 4A and 4B). Ethanol incubation was used as a positive control. We chose these 
concentrations following the work of Naqvi S et al, where the authors studied the effect of 
SPION concentration (from 25 to 500 μg mL-1) on immune cells, specifically on macrophages 
47. Even at high concentrations of 200 μg mL-1, Cy-SPIONs did not exert any toxicity.  
Data in agreement with Yeh CH et al; the authors pointed out that the Resovist (FDA approved) 
do not give any toxicity in macrophage also at the higher concentration used (200μg/mL)48. 
Recent studies also displayed that there was no toxicity in murine macrophages after overnight 
labeling with Ferumoxides (Feridex, Advanced Magnetics, USA, Endorems, Guerbet, France; 
dextran-coated, hydrodynamic diameter of 120–180 nm) 49. 
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Fig. 4 Viability and proliferation assays on human primary immune cells. PBMCs were incubated with Cy-
SPION at increasing doses  (50μg/mL, 100μg/mL and 200μg/mL) or left untreated (medium). Data were analyzed 
with different stainings on flow cytometry. (A) Percentage of late apoptotic and dead cells was assessed by staining 
with an amine-reactive dye after 24 h of incubation; ethanol was used as a positive control. (B) Necrosis and 
apoptosis were assessed using propidium iodide and Annexin V staining; ethanol was used a positive control. (C) 
Proliferation assay was performed on stimulated cells with phytohemagglutinin 2‰ (PHA) and interleukin 2 (IL2) 
30 u/mL for three days. 5-ethynyl-2´-deoxyuridine (Edu) is incorporated into DNA during active DNA synthesis. 
Edu positive cells are reported.  
 
Differences from the control percentage were not statistically significant, including annexin-V 
staining (as shown in Fig. 4A and 4B). In addition, we assessed whether Cy-SPIONs impact 
cellular proliferation (Fig. 4C) of total PBMCs and through the specific gating of T cells CD4+ 
and CD8+. We focused on the T cell subpopulation since it is the most abundant on PBMCs 
(up to 40%) and is the easiest one to culture ex vivo for a long time, as required for proliferation 
assays.  
Samples were treated with phytohemagglutinin at 2% and 30 /mL of interleukin 2 for three 
days to boost the proliferation in the presence of magnetic particles. Control samples were left 
untreated. A staining with 5-ethynyl-2´-deoxyuridine (Edu) Alexa-Fluor conjugated was 
performed, and Edu was incorporated into DNA during active DNA synthesis. No significant 
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difference in treated samples compared to controls was observed. However, at 200 μg mL-1 we 
found a decrease in proliferation for each cell population.  
These results confirmed the lack of cytotoxicity of Cy-SPIONs. The bio-immune-compatibility 
of Cy-SPIONs found may be related to the physiological functions of cystine as a component 
of glutathione and therefore as protection for the cells from oxidation stress.  
 
Biocompatibility of Cy-SPION under US into idealized synthetic microvascular network 
(SMN). 
Additional biocompatibility experiments were performed using a microfluidic device (SynVivo 
technology), which simulates the micro-vascular system of mice (Fig. 5).  
 
Fig. 5 In silico microvasculature assay and viability under ultrasonography. (A) PBMCs were extracted from 
healthy donors and treated with Cy-SPION 200 μg/mL or left untreated. Cells were incubated in the synthetic 
microvasculature network (SMN) chip for 24 h, ultrasonography was applied for 15 minutes and viability assay 
(trypan blue exclusion test) was performed. (B) Phase image of a 100X zoom in the SMN with Cy-SPION treated 
cell; arrows indicate some of the live primary cells in the flow. (C) Viability after ultrasonography on medium 
control and Cy-SPION treated primary cells (Scale bar 500 μm).  
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We used purified PBMCs treated with the higher concentration (200 μg mL-1) of Cy- SPIONs; 
untreated PBMCs were used as a control. The cells were added to the microfluidic device and 
after 24 h of incubation with Cy-SPIONs were exposed to US for 15 minutes (the time 
necessary for US exams on humans) on top of the microfluidic channel, and then a viability 
assay with a Trypan Blue exclusion test was performed (Fig. 5A). Red arrows highlighted well-
dispersed Cy-SPIONs inside the microchannel (Fig. 5B). No statistically significant difference 
in terms of percentage of dead cells between treated and control samples was found (Fig. 5C). 
We assume that our Cy-SPIONs are perfectly biocompatible also under US, improving their 
future application in in vivo applications. 
Cy-SPION impact in human PBMCs  
The preservation of normal immune functions is fundamental in the use of Cy-SPIONs for 
potential treatment or the future diagnosis of any disease. The analysis of activation reveals the 
functionality of immune cells. We thus investigated the expression of the activation-related 
surface molecules: i) CD69, a member of the C-type lectin superfamily (Leu-23), one of the 
earliest cell surface antigens expressed by immune cells following activation; ii) CD25 (alpha 
chain of the IL-2 receptor), a late activation antigen; and iii) CD30, a cell membrane protein of 
the tumor necrosis factor receptor family. Due to their well-known activation properties, 
concanavalin A (Con A) and lipopolysaccharide (LPS), were used as a positive control. Fig. 
6A shows the percentage of CD25+ cells after incubation with different concentrations of Cy-
SPIONs, highlighting the total comparability of treated samples with controls. We also found 
(Fig. 6A) the same results for the CD69 and CD30 expression markers. The total absence of 
activation after particle incubation is also reported. As stated by Mahmoudi M et al. there is 
little direct evidence on the induction of inflammatory pathways and cytokines by engineered 
SPIONs (both uncoated and coated) in vivo and in vitro 45.  
To fill this gap in the literature we studied the secretion of a wide variety of cytokines after 
incubation with 200 μg mL-1 Cy-SPIONs in cells. In our analysis we examined four primary 
cytokines: TNFα, IL10, IL6 and IL1β (Fig. 6B) as they are among the most important cytokines 
secreted from PBMCs. Multiplex ELISA assay was used for the detection.  
Interestingly, we found a Cy-SPION dose-dependent increase of TNFα, IL10 and IL6 (p-value 
< 0.05). The cytokines found expressed such as IL6 and TNFα are normally secreted by 
monocytes/macrophages and their action is normally directed on the activation of the acute 
inflammation process 50. IL10 is a cytokine mainly secreted by activated macrophages that 
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through a negative feedback directly control and decrease the immune response 51. This action, 
as previously proved by many research groups 52-55, could be the possible consequence of the 
uptake of Cy-SPIONs by monocytes shown in S. Fig. 1. 
 
 
Fig. 6 Activation markers analysis and cytokines secretion assay. PBMCs were treated with Cy-SPION (50, 
100 and 200 μg/mL)  or left untreated (medium) for 24 h. Concanavalin A (ConA, 10 μg/mL) and 
lipopolysaccharides (LPS 2μg/mL) were used as positive controls. (A) CD25, CD69 and CD30 cell surface 
activation markers were analyzed by flow cytometry. (B) Cytokine secretion was assessed by multiplex ELISA, 
values are expressed in pg/mL (*pvalue <0,05). 
 
Thus, studies conducted in vitro on the effect of SPIONs on macrophage functions have 
revealed modifications in cellular behaviors as well as in the modulated cytokine expressions 
56, 57. For instance, Hsiao JK et al. studied the response of clinically-used SPION ferucarbotran 
(Resovist) loading upon macrophage and found that high doses of SPIONs induced the 
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secretion of TNF-α and resulted in cellular activation through the production of nitric oxide 57.  
Also in the study of Yeh CH et al. the cytokine secretion analysis indicated that Resovist could 
elicit the production of pro-inflammatory cytokines such as TNF-α, IL-1β and IL-6, but their 
levels were much lower than those with lipopolysaccharide (LPS) stimulation 48. We found 
similar results with our Cy-SPION compared to other already approved SPIONs for MRI 
imaging evidencing no significant toxicity on immune cells 58, 59.  
The uptake of SPIONs by phagocytic monocytes and macrophages provides a valuable in-vivo 
tool by which imaging techniques can be used to monitor the involvement of macrophages in 
inflammatory processes such as multiple sclerosis, traumatic nerve injury, stroke, brain tumors, 
and vulnerable plaques in carotid artery.  
Our data are in accordance with findings on commercial clinically approved SPIONs to be used 
as SPION-based MRI contrast agents such as Resovist, Feridex and Combidex, which are 
coated with dextran, other carbohydrates or citrate-stabilized particles. SPIONs with other 
functionalizations (polymers, metals, silica) are in the development phase 52.  
To better understand all aspects of Cy-SPIONs interaction with immune cells, an extensive 
genome study with an RT2 Profiler PCR Array testing was performed, studying the expression 
of 84 key genes on immune responses (Fig. 7). For a clear picture of gene expression, we 
focused on a well established T cell line (Jurkat) for two critical reasons: i) it is a good model 
particularly for the adaptive the immune-cell response; ii) T cells are the most abundant 
population in the blood flow, therefore their reactions can give a wide picture on SPIONs 
impact.  
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Fig. 7 Immune gene expression array. T cells were incubated with Cy-SPION (200 μg/mL) for 24 h or left 
untreated. The expression of 84 immune response related genes was evaluated. A) Heatmap Cy-SPION treated 
sample versus control medium. Genes are displayed for fold change variations versus medium control and colored 
by their standardized expression value (red= high expression, green= low expression) (for gene names see S. Fig. 
2). B) Scatter plot. Genes upregulated with fold regulation >4 are shown in red circles. Unaffected  genes are in 
black. C) Modulated genes versus control with a fold change >2.  
 
The heatmap (Fig. 7A) shows 84 genes displayed for fold change variations in comparison to 
the medium control and colored by their standardized expression value (red= high expression; 
green= low expression). The induction of TNF expression found was in perfect agreement with 
the cytokine data. The other genes modulated with a fold change higher than 2 were: B2M, 
MAPK1, TLR2, IRAK1, TYK2, NLRLP3 and HLA-A (S. Fig. 2). The up-regulation of the 
toll-like receptor 2 (TLR2) in T cells led us to hypothesize that Cy-SPIONs come in contact 
with immune cells through a toll-like receptor. This interaction may also be responsible for the 
up-regulation of genes such as MAPK1, TYK2 and IRAK1, which are normally implicated in 
Chapter 4 | Results 
 
Dr. Marco Orecchioni. Titolo “Biomedical applications of different nanomaterials: 
Characterization and interaction with the immune system”  
Tesi di dottorato in Life Sciences and Biotechnologies, Università degli Studi di Sassari. 
  
201 
signal transduction. MAPK/ERK pathways are responsible for many functions such as cell 
growth and proliferations. TYK2 and IRAK1 also encode for kinases that are responsible for 
interferon and IL1 secretion. These data were confirmed in the Scatter Plot (Fig. 7B); all genes 
were shown in accordance to fold regulation. Only two, NLRP3 and HLA-A, were up-regulated 
with a fold regulation greater than 4. Fig. 7C reports the up-regulated genes. The modulated 
genes found are not implicated with a significant modification in cell functionality, indeed the 





To conclude, in this work we give new insight into the use of cystine functionalized SPIONs in 
imaging, not only for MRI but also for ultrasonography due to their echogenic properties in 
water and blood, as shown in the present study. Intriguingly the small size of our Cy-SPIONs 
make them able to cross endothelial barriers and, as targetable materials, to potentially reach a 
tumor region, acting at the same time as vehicles for therapeutic agents. The potentiality of our 
Cy-SPIONs to extravasate and localize in a tumoral region highlight that Cy-SPIONs could be 
successfully exploited for theranostic applications. Moreover our data clearly point out the good 
immune and biocompatibility of Cy-SPION, with absence of activation stimuli on treated 
PBMCs.   
These findings make Cy-SPIONs perfect materials for new in vivo dual mode imaging studies 
where the preferential route of administration is by intravenous injections.  
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S. Fig. 1 TEM images of PBMCs Cy-SPIONs treated. (A) Untreated PBMCs.  Transmission electronic 
microscope captured image of lymphocytes (*) and monocytes (#). Lymphocytes show a slightly indented nucleus, 
with plenty of heterochromatin, scant cytoplasm with few organelles (Golgi complex, mitochondria). The nucleus 
of monocytes, more voluminous than lymphocytes, has less elettrondensa chromatin; the abundant cytoplasm 
shows numerous organelles (Golgi complex, endoplasmic reticulum, mitochondria and numerous electron-
granules). Vesicles are also visible in amorphous content (§). (B) Cy-SPIONs (200 μg/ml) treated PBMCs. 
Lymphocytes (*) and monocytes (#) are clearly visible.  Monocytes present large cytoplasmic protrusions and 
large vacuoles of phagocytosis, containing small electron-clusters, corresponding to aggregates of particles (arrow) 
suggesting the nanoparticles uptake. Cy-SPIONs are also present in the extracellular medium (arrow). Bar scale 
correspond to 1 μm (3000 X). 
 
 
S. Fig. 2 Heat Map description table. Gene names and values as log2 fold change in comparison to the control 
are reported for all genes showed in the Heat Map (Figure 4A). Empty box in terms of values correspond to 
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Chapter 5  
Conclusions  
Based on the experimental evidences herein provided, it is clear that generalization regarding 
the impact of different nanomaterials, especially CBMs, on the immune cells should be avoided 
considering that many parameters crucially involved in their biological behavior are not always 
addressed and fully described. Appropriate functionalization and controlled shape dimensions 
can change the interaction of nanomaterials with the immune system increasing also the 
biocompatibility.  As illustrated before is proved that different nanomaterials, following their 
administration into the body, might cause a response mediated by the immune system. This 
response could be an immune activation as a result of the response of leukocytes or even 
immune suppression due to their ability to induce apoptosis or necrosis in these cells. The 
different studies here presented explicitly demonstrate that the interactions between 
nanomaterials and the immune cells depend on many factors correlated to their 
physicochemical characteristics. A positive impact of nanomaterials on the immune system, 
able to trigger immune suppression and/or immune activation, is a new concept helpful in the 
development of new nanoscale platforms in medicine as proved i.e. for f-CNTs applied to 
counteract the microgravity immune cell dysregulation. These new platforms indeed can be 
investigated as immunotherapy tools, vaccine carriers, adjuvants, and drug delivery systems to 
target pathology or inflammatory and inflammation-associated disorders. In this context, the 
results presented with the help also of high throughput technologies for a deep molecular 
characterization, evidenced how some CBMs and specific type of functionalized NCs could 
enter into these new platforms and revolutionize the current medicine thanks to their intrinsic 
properties. A specific use of a “bad” property was also herein provided. Thus, a specific type 
of graphene called FLG found able to induce specific toxicity on monocytes was applied in a 
“good” way to target and kill monocytoid cancer cells from acute myeloid leukemia and chronic 
myelomonocytic leukemia patients being extremely promising as a new cancer tool. In a similar 
way the application of a new functionalized Cy-SPIONs can give new insights into the use of 
this materials in imaging, not only for MRI but also for ultrasonography, due to their echogenic 
properties in water and blood. Moreover, our data pointed out the good immune-compatibility 
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of Cy-SPION, without no activation stimuli on treated PBMCs resolving the inflammatory 
reactions found with other SPIONs already present in the market such as Feridex and Resovist. 
To conclude, the different results presented in this thesis underline that changing the 
physicochemical characteristics of nanomaterials based on their interaction with the immune 
system is a crucial aspect that need to be always explored for a successful application of 
nanotechnology in medicine. The analyzed and immune characterized nanoplatforms presented 
in this thesis, indeed can be further investigated and applied in therapy or imaging applications 
helping to reach the hoped medical revolution of nanomedicine. 
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